var title_f23_59_24496="Adrenal adenoma MRI";
var content_f23_59_24496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Adrenocortical adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 167px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACnAcUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDDuCPOlzk/MehqD5ey9RjOc0s7sZ5F3ZJY8mtjwXoUniPXLezjUhS2XbsFHU0xHY/CrwUNXuxf6nHiwi5CEZ80jt9P8K97hRIY1jiQJGoAVVGAB9KrabYwabYQWdom2KJQoH8zVhpMA7RuP1pDHlvQH6elIpB6Z55qFyACzvgfWsDXfE1rpcbEMWOAcj1oA6YNnsc+9Ur3ULW1RzdPsUDuK8h1n4k3T20kVvM0TNnDKBjGetcW+v6hKh8+VpFbkhjxTsI9Z1j4k6DasyIs1w4yNqjHf3ridS+Js824afpUans0zbj168YrlYNY2zbksLWTGc/Kef1+tXGlk1hlhjsEiAPWPIxTsAybxRr+oXGySeOAN/BGv+JNXrXSNUvJR9r1Ka3Xpy7ZPX8q3NG8KSQqssh3KAG56ityaBQVGQdo6so5/wA4oAxLTSNPjcLNLNLKO7k/NzWkNEsLuP8A0yJQQuAUZlK/5xVsKHcOMlVz1GAKs2rbHLKw29Pl5/OgDmNS8CzxKJtK1C5VTj5XkP6H865jUJ/EmjXAi+33aYHH7xiMfSvW4xJHIzW7Ha5yVOP0qO8s4b1G8xcOQfvDPb/61IDzWy8V+JZnEa6oxYf38YrRfxxrtoG8y6Sbjq0YA/CtK+0oaeGmt7dRIed+M4rz7UYbi+ui1y2yLOTwAcfTpTA3h8TNbDOElRgDz8gIAq7p/wASLxmD30CFTjJUAY/AV53qKQxOWtI32dNzZ571ShulUHe0ikn1P60gPoHSPE1rqCKVbLtghc960mupJRhBtbGSOx/zzXz1YXzRSh4pirZ444r0Pwz4sMqLbXecjo+aAPR5NyWwmAIXJAKjj865LxxosfifTHRlX7Qg3IQuCfb8f6VrpcsyjbLvTOcHn/63/wCqrMTh5MxgZUcnH+NAHyfqmm3mmzmGdG3K3TLLjBJzxnnoOcD696sccQtVTLSeWMbnbcSynuT3yPqD6dvffij4ai1C2e+s49syKd56cV4LNAC48yNSQRlXHUg9cYxnigYpVDGYwA/nMAQXAHXg5Y4AGAfwz1rp/h2V/wCE98NhiM/2lbcbu/mL2rmW3PKzbg5z0PJbr6/gegxXQ/D2MD4heHF+X5dUtuVwc/vU9O3T9aAPrfxVomoaxr+hNbaje2Om23nSXYtbhojMfk2IcHkfe/DPTNdNSntSfzpAHNJk5oz6VFNKqZzjigB5YjvUckwQctj6mvO/iH46l0SDyrCLzblhxngAeteL6v451idy9xcyBz2DEAflTsB9M6lrBt4WNsqzyDom/BNebax4k+I11OyaVpUVtCejl42YD/gTY/SvIo/HfiDAS2vpFbPB2qf5itbT/EXja8ZUfVZFycAskf8ARaBGvrOreOtMnWTW9Xv9jdVt3C8f8AxivQ/A/wDaeqrHdfa9UjgHa5uJGL/huxTvBXhu+ZEu9bvpbuZhkZxtx7YFeiQRJEoVFAHtQBKmVUAsxI7k0/J9aaxoNIY4n3pMn1P503OKNw9qAFJJHU/nWbqenNexFRd3kOe8M7IR+RrQdh0pjN9KAOTOmXOlxSOup6ncf7Mt07fzNeS+I9a8X6jqUkNleanYwqcArcuoH1YEV7tqdzbwwM08iKgznJrgbzUdEv5HRbqEtkgbXHX8/pTEeLa1rnizRphFP4j1mQn+JNQlIH/j1Zh8aeJFf/kZNcx738uP/Qq9jv8AwLa6pETGxYHpk5GPw+tcnq/wpmWJjbHL9waAOfsPF3ieNTPH4m1Iheiz3btn6gkivTPBHxalmdLXXm+boJ1PB9yK8i1LwfrNhKVEMmBznoDVTTA1nepHfoVQnB7EDvQB9jWGow30Cy206yIw6q2RVkyEfxN+dfOmieKx4c1CJrScyWEh+aMknb617XoGv2WtWizWkyOCOQDyKLDN5pTjIZj+NeIfHvTvE9nEuu+Gtd1qCFTtuba3vZVQejBQ2APWvY2kA6HioLhI7mJ4ZVV4nBUqRkEHqKQHxFD408YxkA+LfEAG8ZB1SZuOeeWyPXHTpUi+OPGJIVvFmuI+cHzNRnAU574bOPwz7V13xm+Hp8L6l9ssI2Ok3D5U4/1bf3Cfzx/iOfMSjCQoMhlOANuCT6f59O1AF/xV8QPGcP2UReLtfj++D5eozLnp1w3PXvRXLeKsCO0UNuAL9M46Lzz/AJ4ooA9uigaa4CKhLOSBj1r6X+HfhW38OaOhCD7XOoaZiOfXb+H864D4NeEXmuf7Yv4j5KH9yrAYJ9fwr2zFNiGHAwOTVe6uLe1XfcOkfueM8Ut7OlpC80jKoUdTXinjXxZNqlwY4FTYuQCM80DOu13xdHJdG2jXchbapXPJ+tcf4si02CxNxdNL50g3Ihzg84649R+lM8HeHru/le4uI2WHHD8gD86TxbYxRuYJZftO0YUu5IQcnAHbnmmI87adyRhTjPAHNSRg7sucbeqmtOW3WIYj5+h61TZGwCN2SOOcCgC5auGj3QrGGQYJ655FdV4d8W6bCnl6lZojg8Tx8D8sVwljdS2UZjy8ilQpZ8Zb1JwAM9+ABQrmYFIhgk5/H0oA9lfXtInCP9uRBwRyOfrUn9raMyohuk34ySXBHoK8TX5AUY8fmBULHa+ccdcigD6AgazuUyLiHA6DeKV4o2wI5Ydw4A3D8q8CjkfcCDg44GameclQCN3+7x+tID3GZo1IVrpMjqoPTtTZ720gQCS5hKjPBbB/zmvENuyPdsUMQcnNNC7laTIGOoxnFMD2S98QaRHGUe6hduBtJBxWU+n6JrMgS2u4VmJJIyAfyzXlLyIE+bcXPfP1qe0mIZcZycd8UAd9f+AZX5h8qVT3D4/z0rmNQ8F3cbtFGuWxyCcitrw34nu7G4EEshkgPByScV2Ml5FOwcEqCMjB4zQB4vd+G7m0bLrjHcHPFRWjvattkbAH8QPIr2ieC2uFZLhSp5wc815b4n8OyWsjTW5bYevfFAG94R1+ZD9luASP4Hzz3ruYboiMM2QO21R0/CvCQLiNRKANy/xdK6jQfFc5RYnuAjDjGAR/nigD0a4vPPbbsYxsNrADqPpXinxE8PvpmovcWtu/kPzjHH+fxr0FtUkkQEu3zfxAgfyqjqSjU7NrSb99wdpx+GKAPGkJAZmAXYSADx9Cf5fhXQeAHL/EDw0cMM6rbbsrgZ81DxxjHzDp647GsvWNNl02+cS7jJnYny9QASODxn39DWl8NCf+E+8Nluc6lbbTt7eYnGc8+vYc0hn2+aaTSv0rlvF/ia30e1ZfMXziCFGe9IDV1TU47VcKQXPbNY8N6ZWDXDDY2ePxrxi98Qa14j1JLTTd5LNyy+ncmvYdG0WKw0iJbs75VT53c5yaYjh/jHNZ2uiF7CKP7U7AZ284I614rBYSXSqzvgnk9zXqXxD1GLWZzawFdkbFWkGMnHGAfTiuatrS3twcIxYDA49famBkRWlvYMBaxB3b/noMmtW1uki5lVUY8+mOatNbhwQ27I7Hg/jVK8s2liVcYI7dc0AddovjjVNPjRYwk8QA+V+uPQGux0/4o6ZKoS8jmt5+6lCw/AivI7UNHEEcksOMjjp/9ao5T5TgupJ7c0WA9iuPilpUTFcTHB4/dnn9KiPxU0tSS8c23GRhOteOz7nXLHAx0znjr/X/ADms1HkMp8wqVHT16UrAe6x/FfSHH+ruPb5OtR3fxStYkDJZTnPTdxmvFXljBJbIGeDVizuPPYo3CgYA3UwPTZPirdSErHpoj4yC8nBH/fNYuqfEfWWBCNbw5BwEBJrjLjCK8rso2dMH61k/2iJxKVcKRnIB/wA/5xQBsah4j1O+dje3Mkqd1J+Wuevr3EheNs98A4qB5WnVyCcd+ea5jxBqLWcTopCsQDnODjv/ACpAep+BvifPo93HaX3+kWxO0Kv3l+g7/SvoLRtVsdXtEubOVJY2GQQc4r8/ItXlMwZiTtO4Hd2x2x19PrivTPh747vPD9/APMZ7d+SgbIxkDPsfr+vWgZ9hXNjb3UTLJGrA9eK8e+Ivw0ll8y80qQ5UZMeOc16d4e1iLWNNhurZt0cihuK1XIkGGAI96BHyRbWuopdPY30Uki9FXGCPzrQ0bXtR8Jau0W544WYMysMkD+nXp9OvFfRupaBaz7pY4YxcAcNtGa8i8T+BLu5tLzUL1kWWIEquSc/pQB6p4N8RWuvWCvFOrSDhgDkg10BTH8TfWvkDwr4lvdA1cT2zFdhyV3cEen86+pfCXiS18R6NFdW7qHI+dM8qfQ0ATa/o9vrmmzWN8C0Mgx7j0Ir5N+IHgq78Ka3Jbz82zZeCbHDKMn8+2P8A9dfYhkKjJHHWuU8ceEbXxbpjR3LSR3MeWgZTgBu31FAHxB4sbMNkMrw0n1/h6/5/pRWh8StJudDvodPvUKzQySA57/d5opDP0ZsrWKztIra3QJFEoVVUAcUXt3FZW7TTsEjUZJJxVgnAJPQVwmpXDeKbt7aEmPToGyz9DI3H1oA5nxpr9xq27yJGisV/h2kGTt6U/wAHeDYDEur623k24+aOInBOO7Z/HiuhSxsbeQXBVZEiGFEnK/gP/rVkateyX8wFxLti42IRwPcDNUITxL4oMy/ZNHU28CcB14Yj2A6CuEuGkkmJkdmmx0bnnp/OtnUg0aMEhLKeQx4xmsP7KVm3M4Ze+KAM25DKwDKNzDqPaokuDGmySIMuByBz9KuTwl5dyghccZOao3gS1C7y249yB+lADJY7dwMDZgZ+c1TlkdHQLwgPcdqnkw0SF8Edjj+lMSQohjkgWVP72Of5UARXkTAJNCRsYZOear7kIClNp7sDwa09PFpcrJFOSmT8orLvU8qZ0I3gH5TnrQAkLiCQncSDwQvy5H+cU97iOb5oo9pHUDoaqEl5Quw8fKQTinlip2xqRnnGaQD7a6Z3ZWUDB+7nrUiz+UGDEgH+HPfHWqW7y0cORn19KbGGmBUZbH8WaALLM3RRuGfyrVsliXZJIhYjBPPSq9rD9nhIABPfIqu90sbtwGOe6imB2rRWr23n2h2EZ6HB/wA+9WPD+oG5k+y3PKA4y2OMVx2kX0kU4Dk7GIrT1l3tvKnhcgHPzYxxQB6G0VsjlTIGVR8ozk1SuDHIxjlJaLptfpj/AArzpdTuHljZZDkHpXY6LI91GN+SQO+DQBm+IdAZ2U2QIQ8si85/SvNvEg/sm43IArJksMEn9B/jXs1zc+XG6ggNj0xmuQ8UeH11q2e4hzHd4OVPBagDD8P6t/aMaKzKWHHB7jtxXUQ7IwJA5Rl5+XpmvLns7nS7oOqskykmRD/Fz6fXmuu0DUEv1BPD4AK46fh19fzoAveKLRtbtCoSESRjhiPmOK4/4cQzwfEDw2l5FEs39pWqsEJPIkToMcD6/X1r0AFEkVyRz1yOnSs6LSQPiB4WvLaEFW1W0LnaCBiZT3B/P8iDSYH0N8RPEq+HNMiZAHubglIkPcjGf5ivnjxVqGp6tqsNsCZbq5cLsU8kk9K97+JemrdyaZdyBWW1Wb5W9Ts/+J/WvKNCvNN0PVrjU7hTdXR+WMAZ2DGD/wDr60ID0fwtpOmeBfDSS38qLOVDTSE9W9B64rifF/jO41iNo4D9msW4C/xv9fauZ8Qa5ea7qZudQLi3Q4hg/hXrzjuazmuimc7SzcDjOB7ZpgX0kieMbAu7svuT+tT25OV4Ocfw8fh/9esmxTzH+dgctwT2qxJI0GOXaPoDnFAGpJ5gHmMi9MkDvWedQU3IDAL2DEYBqSG53KGEnyHqDUsrWlyp2hS2OSOmaAKF7Km8FG5IP4fjVzS401JfIwDLgnkcmsHW1W3AkhfcV5wOgFQaH4iiguFaVgjK2NxJ/p9aALPiCG605mtsCQnOPSqcO46e7oGedQW8tTgtx0GeMn3P5V3uuxadr2iC8sJ4vPRc4B/Q1wk8wtrUuA3mAEEKeTQBj6pfPbTKGDbicE44q3NfNBYxSqoDNx0H8vwpioLuETSLtX1PJqjfxsLfyFfd147UgL8N7LcWjByck9Tjgf571Wt7MLOqxNvB6k8iorVVjtPJI/HPQeldX4U0o3c0SAgbW6gZ70AWU8NO2lvKqknbncPpXhvjJmS8uYX8wsAAOpUY988f1/Svs1tJVNCMUSkARbRnnt/+uvjfxzE0fiW7R1dZA2Djg5BOB6dCaGByB3DBAKqAOQMfjWtpU8qSRAhiJCQGbp9Rj+X1p00arGCj74xkkKSQ3Jx26fhSRAoYlG3AG0HJ6/jxxj/69IZ9Nfs++J/MaXS7mQ5Ayint6gV7wCOvavir4W6jNp/iG1dXUIJg2FIAAwBtP6+g619m2s3mQRsCCCB0pgXR83XNVL6zhvLaW3nQNFICrA9wasxHnHelIAJoA+X/AIgfD278N6nLeW0Zm01z99eqDjg/yrL8IeJrvwpqa3ED7rZ2AkjJ4Ir6snt47iJ4Z0Vo3GCpGRivm74oeHE0HXnhjT/RJ/mjHYe1Aj3jQNdtdd02K7tT8rDnPUVo+bnkDp6CvnH4VeKJNB1s6feOBa3Djg9B7/yr6CaTaysrDy255oA4H4sfCdPiRe2F3A0kUtsrpIYyils7cZz1xg0V1GrXUiXKxxo6Js3+acbWJJG0Yy2RgE5AHzDBPOCgD0nUyRZS7SQxGBjrn2rnL1PKtYLCxUQyMMuUwDjHNW/FFxIWt4rba53bnXPYZz/n2p8FrE8azhMSgY6liaAMW5VPlgiaNSv3tzZPHFY1+Ym/exsZFHXb0/8Ar1uNGsyvKJPnJJ2hfmHvWBrMTR7iqDyjjgk5H5fjQBj3jKwyGYk43biMf54rBuifNA2AHOcjmtRWRWkDoSzAHKkk/l061QuRCYW+YrN12uCCcdqYGVfmeEpIy7oGPVegqvrwjvbKJo9mVxyTzUl9eGKJYGUkPuYDaWHGM/N0B+YYHU846HDIyj2WX4U9BnmgCtHZf8S1TKEV+xbqaZbljEVLJkepqPaRLh8tH0G4k4qSZwzKUADDjA/GgCrcwoAWAXf0yGzms5pHLADOM89/StC7TMe8Pz6HoaoxwTRESSL5cTd89cUAQOiRvknJHBwe9MZwrFixGfXrTrgZZgOnbjrUTKzIflIPoR/n0pAQM6kckMScD5q1dETc4VQvI4BrMVSZFJAz3962dOBWXKjjBz9aANi4jKQ4Kjd/DtrmUXzJXjckOD0IrrJQJI2eJTuHrXGeL5DpNs+pTBjFHtLrH15YAYGR3PrTAtx/JIoRvmz0x/jW5qEiPpMccg+YdDk5rl9Hv4dYsYb+0EixTbseaBuGGIOcE+nrVt5XaRI5CcA8HOcUgNGxtJHKKoywOOTXb6Na+WiuvAHJYdcfhWXpVn5WmrL8vY9eTTrLWvma2EYPOcg8j1pgaurSQiZEj+c55A/xqtldu0Rnd6nntVAPI5eNgfm5z1P6VJZJNIu0sMAfxnnpQBz3jSzElqLqNEUrwfUc9q5OGY2VxDcxYMZOGwDXocii5gnjlIYEH1z0rz25U2rSwyA7CTt/w/lQB3cbpJFDOwJSQckHO0/jWr4ZRW8S6PG4JH2+B1PbiRa5LQbpn0/y2wyjoDya6Pwu7P4u0ReWC3sGCRjA8wcD86APSPjvqNxbWGlWFmSJL15AWHZV25/9CrxxgY9sYJYAfMQOPfPevW/j2wiTRJT95fPA/Hy68gdswvJuXc/zEf0oQEE8uZgpyqDjHrRIVMvy8bjnH+frTJFkZW2fORxznH0oQFgCwyR7cf5/xpAaelKC2Dzg855qWe4hCur/ACnptplkw28gbj1Gckk/5FYviL97l4TtlHU9yKYFy8Z/7MkkgY5XngGq/hi9W9tZbeUkOvTmqOianvhltrlwGxg5PtWRcrd2N6x05lUMcs2e2aQHVhkijO9AwBI4Iz/nmqTafZ3G51j2/kDVBZ2SNWdy0h644GT71cil3xDymDHH1NAENmHsbllglbaTwM8f55q6rmeQ+bjGM8DOP88/nUUNvdXUvliPfJxggGppbSXTyBdDaTwASaAKglVGdOP9njHrVW5Vc7gTkE4zinXTebJlCOuMjtVi1hMg2P8ANkcYOaAKtsiPICfvflXr3w80oRRJJKDz0HT3rgtO05fMCCMHJGFweeK9r8MW4js4uBwPemB0CwKINmBgivjv49aHFYeOppI0OZCGUjPTnt65+tfZkiqyDNfPX7T2io9nBqKKf3QYMQAeMf8A66QHzxdiWO3U/MoAGM4CnOeo74wOR+tQxZlCmQnarhMqGOHOR1z9ajaRLhI5kVyR+7YEjk9vwwVHPp+U9ltZ9s0eUJKhSPlbI655+v16Y4whnQ+FVEWrI6lDvZTxx0yeD3GDivtbwyWOj2zOxYmMH9K+PvCVmJtTiKqQS4OGz14/z+tfYfhaI2+hWcUjvM6RKpkcDc5A6nAAyevAA9BTEaUJPm4OcGrBOM46Go8ASDHWpeoNADRzkYrh/iv4cXX/AA3K8aE3dsC8ZA546iuuhulkvHhA5Wp5ERg8bAEHjmgD42eQm4jeTiaFuT3FfTPhe+XVPD9rNE4ZgqhuckECvBfi9o76D4lmaAYhlPmqTz1rt/gdrwurOWwbJx8ynIH+f8/gAeg63OUaEdeDyfwoqLXknLxKApYZyD+FFMDtdZuLeHWUe5BIZAq7TyOaSa1mTXHumdlsfsgiiRrkriQuS/7oKAchU+YuxGCFVcsXwII31LXh525o1bPJ4P8AnPauu1UARbQAFA78n8KQGdLcxwo6KjFyODj+eawb2Qs227Coeu0nA59+tXppQhMu7AAOGJ/ziuav7x7reVkG5cn7uD70AVrua3GRbR47lSSwP0rK1VfPtcL5e8f89GycUSzzxxyLNG8i85boAOf/AK9VY7uTtvIJ6rjP60wKr/ZZLDawdroHgk5GKi2x7VSMeW54wc5P5+tRXqPAWntSSccBsZ/SqNpq6B/9PgLk91OCKAHzW4ab93lz15NQtHJcXQVgkKg5OT1pZtUVCywRFT2ZjmqImluQwkfJPUmgC0Y7J7oi6vY/LQYCx85P14q3bWza1GYblhbWyD93K2Oa5drFxPvcnAPTPBq1d3bvGkcZZUAxjP8Ah9KAIbiBYpWjFwsmzgMg4bmkkXBLgLj1HeoC2wDefvEZGKBIybQFIXOPakBYtY2eXhcA/wAXStOJBE3ykMOu4ip9PgglTfIwVSBxgVFdmFHHXcOAcUwNCI4QsXTjkYH51yXxPjMvgTVZQM+WIjkdBmaMf1rdWE3KLsXaT1JPFcX8Y7+TTfC9rpqllN/L867Bgxx7WIJPIO4xngfwnntQBD4Gjlt/CunGRHjJDsAVxkF2IP0III9q6ixniS4H2qPeueq9RWB4W1NdQ8KafIbeSAQxrbYJzv8ALULvHqD+hBHate0ePcGZSFPqP/rUgPVLWG3vdKMELFopEKkozKwBGOGXBB9xgj2rIuLDyrsNGrIN3XA5/KsXQtUk066Xy5B5bHBDHI/+tXUXN4JrdXDbd5420wIZLdYpY95ye/btVHVS6XSxwKVjHVuuPxq+rsYVCSOJMHktyazJp5PP8vhj3BHJoAIk8tldcnA554Ncf4wtVW687aVUnt/LPSuwiBbARivPTHA5/wDrVheO4GNoj4JZe4XOKAOe8KXJjLIMEA4yOAfx7cV3ng2cN4r0dGY5+3QcHB/5aL3rzHQVaKaDdtYhQCQu3d/knvXo/hKNx4x0FiBt+3QEY5/jWgD0f9oLd5ehbFycz/8AtOvIk+dsgY2ddo/nXs3x0Xcui57ef2z/AM868ae3ZXZoy2znAPTHP9SaSAjdi2CMLngjPFOtoWZGL/KNpxnn/P8A9epEiV1zEc+ue/vUxSNIxu+YDsATTApXl59nIYrlVx8vB/8A11navI15p7XFiu6UL8wB/wA/rVudo5wUcDYfWubMk+l6liNi1ueMYxgUgOe06LWLyYmeJ4Npycn/ADmutiUxDEz4OP4vSn3dzG2Ht2UE9scD/Oayb++RcKxXOMD/AD/jQMtXDE8Ic4J59R/k1ZsY5pJlW2UyyE7QqY5PbGOKx1uEx8zcYySo/GpPDfi290rXM20SLagB/MJPPXjnHP5/WgD3/wAOaPH4W0ZtX1bH3MuAM7OelZ/jvQ28S6RHrOk4dQm4KONy1w8/xL1LxNK1i9vF9kjGJUUdeenX2qU+M9QW0NnZsbKzVSCqKOfoTnFAjJtLYGLcUUNnBBI4NbGm6e43HywGPpXJXF2wuN8ckiHOc12PgfxAEv47bUFVkkIAc9Qe1MDsPCujGWQPJFtxjjGM16Zp9sIY1AH503TLKKOEOCOehzWgQqAc/rSAbI4VcE1wHxisIr/4e+IJJE3eVp9xKvsVjYj+VdtKvmsAmfc1k+K57DT/AA7qFxrs1vFpUcDC5e4Xcmw/KQV53Zzt24JYnABJxQB8I6NYG6026ltWU3EMgDK2duwjgkj6H8j61oWVptYmVSHIwN3bv9KtfDiWOUXumNLILmYrJBDgncVVy5HYcAdeuKs6taSNI0bO6DkFgeSCMY/z7UhnWfD+9tbTVYmvMGNDndnrX1Z4fvLe+0+KW2YNERwc5zXxnp1sfLIZyEVSSc5xjk9Oc+w5J4A6Cva/g34omtrldMny0D8oSeBTA90jj3OBmhwY+ATSxkNghsg+lWRHkdqAM2G0USNKD855Jqblv96pmXt0/Go2XaOBg+tArHjP7R2mKdItLwIu5HKsw78ZA/Q15P8ADbVptL8Qwz7yFkbD/P1zwc8/z619HfFXS21jwbdxRjcyDzBz6V8sWEZtL4FQflYcHrwaBn1jdWT3aRSoAVIyNwopfBlz/aHh2zlcFm8sZLHv/kUUCNjwnaqku9lk4B2sx/yfz9Kv68Pm/fSrEgHBLcn6cU2SWK0v7II8SCUbSqtuB+uff+VTaraAuzRFixG7Ycsv59qAOEvY5IRKeZAxwOpz0qrZWUs8TMYmC/3ScD8utdPPpl2waaRkSJeirz/9frWbepcwjzuPI/3geR/nFMDmdXs3aEhI3UgEckqDz7/WsH7P5SfuZhuJIPeuku75GZw1xEsfpux0/lWGZYZGkeJ1OMgbhgfhigChbpMDHHdTIZAAHdV2q5xyQOcfTJ+tQ3emRSXIUSRySZAGB257/X+v4yrcxs7PKylh0ReagNxly6OI+DlgN2Tjgcn1/n36UAR6hZRlliVQsq9Tu6//AFqdptjbMrqzgzgdCRirMbG4XzEhBkUAhy5ILZORjHGAF5yc5PTHMxkhWLdMrJP2z0oA5rxLvsIwJACTyABxXHTatdPE2xI1cDjcMjPbIrv9ZB1K0MWF3Y74HFcBNpU8F28c4LL2HlkHnPfv2/KkBo6dI9zbxNcogm2gvsb5C3fGecVr6dp01xIGmVlhH8QwM+3NUbNVjRRIg2p1DjBrQHiGSV4oPKxZoT9xO31/OgCzqYRdkVvuVQMZbGTU8FuvkZZX3HkbhmgLBeS+bA+32bgg1ai8+JPnDZHAcZ5GKYB5FxJbtDagJI3AfHT8azPFHhNdV8NS6Vq2oQJcmRZYJY8yCNweTgMM5Bcc+uewrR1PXF06xaKBzJM45YqciuYhkkum3mRw465GKAImsBpSQWVqgFvCixqMjkDucADJOST3JNTrwdu0hjyTUwcvIm9C6g8nPP8AOrQZIpkYnMRxnnBpAP02ASgrK5Q44b3rodKmfYbWXDo3HXofWsSaNTJmymDuFV3TIyoJIBwOxKt+R9DWjC7gork+YSMbT70wN+4hMdjw8bN12g8j/P8AjWPDcDcFYBpO3ODW81mJLDM6yibBAYLnn0xXLkNFKVeHY+T8xHBoA07eYCQrcFcsDjYKoeJEhudPlG9mKZIA4BFSI5x8oIOOScEf5zTNQ2jSpmnKqzDqo4oA4jR7KGaQS5T92eB9K9F8GQxS+IdFlDD5byHBPfDrx9a4fSYh9oKh0+Zs7ietdv4UKW3ijRIUO/8A02AZH/XQf40Aeg/Hd9kWjfNjPnj68JXj8dxlcOq4z1Br1r49qHbQEYkKTPyPX93XkkVrE0giLMA3fPT/AOvSQDTL9nlRRkFsHrkfj+tR38ciskrZZD124rSmsUhYKfmHqOP1/KpRagReYSCgGdrHjHoc0wMNLYzsG+4vQkH2rM1uxIIQ8qAMFT14rbluY87VbhTgKfu1nX0gI3O5yDn6UAeUXF7LY6lNbiaSNdxwJcYUjvjjjj6HHbNW9QimhxNcXQKddqt7EdcdP8fpjqXtdPlSNGtIiY+EJQYUdgPToPyqrq2iwTRL90NjAI7A8/4UhnHR6s3lm1060BmfOCfmZiSAAFAznJ+pNXdJ0O51COM3yzoDx3VuDxnPOOT1HfrXV6TpNnaqr26IZD146c9PwzW9JKvls9wquFXG1Rt6DHb+dAGLoVlaaRbNBBkliWLM2S3+en0qeW5+dkJzknB7Y+lee315NrHinyTKwhaQgKo2gDB6enfnritS706Lw5Na3pmeeAsFkiOCxPOCPyJ/M0AdfHHI7bDgqDwRyD7iuu+H3hm41TVU81HWCMhy2ODVXwTpUOq6/CFjxbEZYDoMdq920ebR7O6XTLWeIXSgExKw3D3IoEOuNQltJYLK2gYkjBkyMAfzrYt1cgGU7v0qtf2SvMkinBBySOc1Y80Q2vmclVFAFwIyozBQT2FcjqUbeILfUdK8S6RD/ZMy7GSSQMJV65GOVIwCCOQcEcjNbdxrlpbaVLfSyqsUaljk4r5v8e/FG91q9nhs5RFaRn7iNyMc5P8AhQBzOh6JefDzWdduL2AXmd1lbOGUCSLeD5rKpOM7UwC3HzAjoamjvLbWldlQQyjJO0ZIx16/Q/lWDda1cywuly24tjqcgDHP9Kq6S9vExe2kIucf6rOAR9M/rQM3lsvs8jcM5zuLdea39GujbOskIPmADBPBU5B4/IjnjrUfhe2GsMYYebkD7pz6V00HhW5Rh50ecfeAPagR7B8PvES6tYqsihZkGCM5zXagluhwK8T8Dzy6XriworCJuGBOMGva7fMkYK8fSgCNgTUZBJPv61M8jJIABkUSyIXGBzQMrzQiW1kUj5SDXy1c6bbweOLi2mDeSLggKAOeeK+ryqvGxr5v1TTjL8TJ4mRyJJiRgDP1HagR7v4dtYf7PQQqojAGAAOKK0dBs2gswjEDAHH5+lFAHHadPdX8MFxqDyyCOQ4bb8o/QV3N23kqs8qAr/sZI9ulcotv/Z95eWjNvhMhKfNkjPt/hV952t7ONYpC8f3QHwPXn9KAG3viCUymG3h+VgT8vPH41n3eryrA8EMe3AIYkZI9fwpomgglWYcydQgQfoap6lqVpskaSDc2MfM4BHX1oA82129a8mZVSPYrdSgH60T36iygjihJYDB2gAH6064SOe6mILRgnOwLkVmCCaN3UMiqp496YFe682eUMD5S/wB0Luzir+h+TGpEq5Ud8jH5dqoyzOWwEAbPOPWrIUrZBnJXPOABigC814ZpiAUEUZ6AYJ/p6UySebUrve7SOUHyq2FA59gKp2SNcwkqgOPbnNX7WJ45NxQsgGPvUAEMRtrgyu6l2OFJ6LXQ2K2ttos99qVtBJJg4kIBOPQCsC6liYoIYJIyfvMxznp+VWPGkKweFraOAbJZeWJJ54HT8aAOL1G6TUJ5BbRmOMk7mHOR/Ssq41htPhdLWMh488/eJ75AHWvTNG8PwW3gJ7i7tm82T5t4+9jFecX2mpPOYwiyb3DAH+Eggj9eaQE9lJiFZJHcyuxLtuzmuvUTrp+ckwyL8vABFcxcaZFDYjNwhnTJCDnH5fhWX4g+Ib6HbWlrcaf9reRCynzxGUAOBxgk9+SAOOCecMDU1KGRJzJvMshPDH/Co4g5fc2Oevp+VP8ACS6h4j8Jpq16lvDczTOtuIuFkjXC7sEkg7w45x06Vpf2RqlrCTc2LlWH30H9KQEEgfnytuDwec8VHbRPfX8USZZAQSnbr61Zt9Ou5ExYWtzM5+8qxE4/Ku7+HvhgQ38cmuQzWm4jasqECgDgPEPxI0Dw3qk+kT6Rqttd2chhlIiQhsdHUFwdrAgg4GQQRXb6RpMesaZaatALk211BHPHiPaQHUMAcZGQD2JrsPib8JvDXjNbN9XW4ikt/lju7FlSQIckxncrBlycjI4OcYy2fLdS+D3i3wPqL6l8H/EF1IrYEljcMiO+AEAbIEMuC0jfOqbe25uaLgdlFpt5CArM5/hVGGP8/wCfpT7jw60Mcd3dzREvj9wmc/hms3wp8SNWv/F0PhHxr4TOka9Mlw32iNyiHYJWBWJgfkKxsN6O6kgc4PE8r+RqrzSXDuVJBTpnmmAmq2dtGiR2Um+Z+qso+WuV8Q4gtdoYsRyTtrqr+680iVABH2Rjls/nXD+M73zrdY1ASVTjA6mgCv4dhjnJcnnqFC5yf6V2fhWCX/hKNGklIhxewYjxyfnHrXK6PA0OnRzRLmUnkbgOK7DwmfN8QaOZxIsovYMZIx98cUAdn8eyFj0U5AbE+Dj/AK58V5HA2IWeTbvHA4616z8fgWXQxkgYuMkfSOvGVkeCVlGXzj3xSQGlDc7wFl2pxkZPHtRJLmGRXdT6AVn+aEXLNluu3r/nrV2yh85dzqFA5yO/+etMChZx+UGedAY+oB5zWbeoksUm0MqnoP8A9ddDexWyxlXl24z75P8AnFcX4il1OWALo9uJjuwWyOBzk8ke1IBLcwtE0bZMh6Yp87stvslXcDyMVmeFfD2sKWn1SRkVuRHuyQe/P4/4eldNeRiEImBz19aBlPR4XH7xflxyAfSrckRd2JQlDwanKxmDPG7H1qTTH5beNyrnjH6e1Ajlv+EfgtdRN40ZzJx8o3fjj1q1F8LPFGtagJpbY2+jO2Q1w218Y7LjPX1H41rXkxm1S0wWA8wYz25xXunxA8RReFPh/camyiaeOMCGPP33PQUAeQ+INWT4c+HDYwLm/kHyupGeh4H5GvLdI8R6lb6t/aqXDLfliQ5bJz9PT/GrmtWnijxrot14quolNlAu5X54I6447bh0HPfmvN2uZ8ghypAA4GP88igZ9kfDn4lf2zZxW2qKBeE4EiD5Hr0xpVe3+4TkdBXwl4P8QzWOrwSrlVWQbgpJz+Pb/P4/bnhzVbO98LR6mZo4rRIjJLJI4RY1UZYkngAAHJNAj58+LWtX1rrVxZBZIrduShOV+teSPcC3vmVIt5dQcKOSBn8O9egfF/xvpHjHX7a08Kx3N9dPIkEUvl+UkrNjbt3YbOTjkL69K5i30Q213ILq3kjuU+U7wOOemaBmMxe5uS8cLDf94BiABwOemDyOvPykdq07KB1vPMwVHQlevrknnpz09e/WrQtfLnDBQVzyApIH4d607aFsFlh3M3zEhfbk0gN34OoZfHEYbiPPTd1/z79a+jdZsl8oGFAG46CvnHwx4e8Sf2TqereF7j7HqtojTxIbcSmcKCTEqlW+Yjp8vJAHGci54X/aH1G+8Q2EPiqz0y30VyVuZrK2mMkQ2kBwDI2VDYLYBO3dgE4FMR7bomm+ZqKkQ+VtIznua9FiAjiAUfrWToLWF7aRXum3Ftd20ufLubeVZY5MEg7XXIOCCDg9QRV69uFto8seaAFnljhy8jqPrXIXXi6yTU5LeOZSV4PP8q5b4h+IpIRiFsEjPJ6V4idVuG1CW4LuWJyeaAPrbRdTju7J3iyyAmvIfBgbWvilqEpyY43dsE5xzitX4ba/O/g69nlRmMO/aSOvB4qj+z9B9p1jWNRkDEk7QeoyTk4/T1oA93s0PzKO2KKlsiGMnHp/WikM4nVYoLiS6vBNBGV3Y85wpfAPPP8ASsu0v1vtGndJN8iH5sY5/EnPbj6Vq634V1FrRnhMUszZ3Io4H0z79q4TSt+jarLaXySAP1XIBU9s5qhGm0hgtNzxAZHPAH6Y/lWTOI5YslQCeR2rQ1qUKDH5zyAcBAMYI/8A1VjwTCWYJPHlAPxx19fTNAGddfu5BjmQjYOe2MflisW5YI53HJ6ZBPFdHrKRCXEK7Q3IBwc/rxXPyWzSucY2ryV60AQoygZ3Bmx2FTrFI1q6sck8VYhtoXZeAMdQFxir+mqondnCuqjgFeOtAFTw0PK81XVN2DyyZAq20blXlXYvpsHWiyhIuJXHzDpkcCrU8R8rAwATjJ7UAZxUzywxiLdIWzjODXS+N4WuY9MgbLlV+ZRgYOB1rI0e1QatA0rb1DdB2P4Vq+J7sx3sUduoJZcEbjmgCydbWG8gtLbT1vUQfc3kKM/pXFeINGL6p9olsJLG3ccm3fcP516FpOmLYWPmBSjyjczkZyfz60zUY3mj2K8TLnjjH/66APH/ABX4q8OeD9GvraxAu9dl2osMqs3l7gfnkbkADH3c7jxwAdw5/wCEnw4l8X6ne6j4wSdkwzC1YGN5WxjLkYZVGOFGM4HQDDdHP8NNL0XXZtaUBw85mitSFWK3J5ACgDOCTtPYEDqNx9A+HzhNWkjyqBx8uwdaQEsek/YdPttOCKkNsqwwL97agGFXJ5PA6mul0jTjK0azxwh8fffv36mr0Onq19IsmVweGIzitVbLziImYBhwrDjNMCxb6ZHagbiic5OCCTU15NEqCCNPKBxvZgCTUFvZXSO6urDH3Twc/SkS3eZ/n8zg4+dcY/DNIC7bxW1tFsEsjxnk5Gcf4UyW8hiV1tps8ZAz0q4hjECom4EdCWrIuleNn+U7W4wc8/hQBQnkkuP3Kg4yQ2OmDWVqdpapIGiiyVwNpXJ9M9K2wgYHJIwM7fSsnVTG2JMnZGc5J6nNAHM6vFDbRF0Vt7DoOf8APevMfFMX/EwjjiBMznPPJBr1LVb9Rbte3APlou2MYAz1xx17GuJ0KxluLuW/u7VphIfkYPgrn2xTAytTdrSxhCkq+Oa63wA0lzrmju7yBhdxMcngjeK5LXpMXoRuVz949a7/AMCwxLquk7Fxi5iztwcncOv40AdR8eHCjQ1xyxnGf++K8cdUDkoMEnnbXrf7QhZf7AKk5Bn6f9s68qtpEZkB+U5x06UIBJLdZIdynDg8jPNWbLc8OIwxOMden+farMtuqopRAc9+QfrU9kQItowPcCgDBlsftNzt+6F46HH1q9pOkyW3mNIB5eMblNaYjAOUGc/eJHX14qwY3eFiXKAcYz14/lQBkCxkLmRHUx/7Q4IrivEt8bXVEjOBk4//AF13GqagkEASOMB+RnOK818URyfb4p5j0OQecDkdv89aGBt3lyGgTyAyOwyPf8ajSTy4gXcgnjA9agI+0W0bhgD0yR1p0kAZo0Uck547UgHSyTx6zpflKSrSqDg84zjP6V6L8fYJ9T8PaTpMakCd+w6nAA+n3q5jw3Yvf+MtKt0UAROHY4445/pXq/iuwF34r0NARsgLSMD6DFAE+peEoz8Km8MwqsTPZ+SCuPvY5Pfqa+L9d8NX+garLZatC8N1Hgt6DPQg9xmvsLxX42uE1qPS/D1ot5doC0pc4VeOmcj1rkb8+INU1cXOs6RpGpW8f3raRMjv0ySM/XP+AB4r8Jvhnf8AjLVrjZhLO1UNJO4xhjyoAPX+ldHq3ju+0vw7feDfDDJffbmNm11AROZI5MoYoQM72fO3POATjnlev8da/rXiS007wV4K0w6R/aEkkepKI/JSOIBflLjhY2Bfdgbm2hRncVbU+B/gG38I+OGTVEhu9YitjsuVBKR7jhhFuxgYJG7G7GegOKBh8CfgveeFvEEWveIpoDdx2jCGzjLE280mVclgdrYj+XuCXbH3FZvWvEPgTQ9fG+9skEw/5axja3511QQCUkd6k7H1oA8rl+EGhKQVkuAeP460NO+HOg6cCyRvIepMjE11+o3Xlj7rn6Ams2Rp7pkRSVQ9eaBHLz+GbyDWbd9FnWK1LfvVCnp6Zrbvvhh4N1KK8N/4c0+Sa9lFxcTiPZM0ny5KyqQ6Z2gnaQCSxOSzZ620txFEu0DOKsSKSvXFAHy74k+G3i74S6wPEHw0v7zUNMDxGewJMk0v3gRLEgCzICxwRhl38Abd9dF4O+Lh8d6LcSXVitjf2PlCZUl3RzblPzJnleUf5TnA2/McnHs2rnZC7Oc4FeGeNDbxahc3EMEEdzc7RLIiANLtyBuI64HHPShAYfjHWEvS+S27GBXn4jkVThsM56Ac4/zitjVGLyhd5JJya2/h74bPiPxHDEQ32W3Iklb2Hb8f60DPTUtv+Ed+DDtL+7nmhzzwSXPH6Gug+CentpXgU3UyEPcs0pLDBxnA/kaxfG6S+LNfsPDNgCbK2YSXTr0Xtjp1x/OvS9Umg0jw6Y4kAjiiCKi9hjAoEX/ClyLu1lkEgcFuMdutFVfAKx/2RujC/McnB6daKQzpLdwAImk3SqASGxmuS+IGgJfW/wBshhdpoxgmMDOPX8KsahZtYX/9pXz3LxQ5ZXt1yVHX5hnpj+RzW5puoWeq2YktJkmiPBINAHgk149vI8OoAYIIjdOOf0NV4mGx2YsJOeWGQePrXXeP/DkemPJcCISRzE7CRyv41xlndSFGjlZxIOgz8pqhFjylaEyTMq5yOR1NZ8tq4GYhlc4zW1bO87neD8pzg85pJSZX2JycEEEDj6Y6dKAKljbRQQkyFjIRjGSRTNrwybh9xupHJyato3zbZFPPXJ9+adcxx3EqCEg9eMbQfw/CgCxbmGKPejtlhnbjNV2gkkmbaV2Ek4z/AEqzDGoAySjdQA39KpX1wbUMSp8x+FPOeaALWmwFLw+WxbZg5HAFUoJpdT1+MIw2xH04qdVkWzSKDL3M45IYDHA/x/Ok0uzuNM1aOITIJX+8dwP50Ady4Yxxq6y7FHHPy1CkTGcrIqeWeAqZJPU9unWn6BqSXlxJDPKHliJJAHFaUeoML1ljjTy14K4Pp3NIDjPEmnwNbun3eO/Xp0rjNF1T+yNdi83PlKduQBXZeLtTt5NQ8q3ikWY53nA2HgdOc569q5W20KK61HZIzJK/MZPIz2pge3QPE4iuYWGxwOdvFT3AZkdgA0jdCF49a5bwfftFGNE1Qql+g/dsB94dv8+1dXtMIAkLCcc/L1pANs3u7aPmZnc8bNuVH05qOeK8MvmvIxZv4VBwKnn3YQpIxboWB9//AK9OEc7xAyXDLxyBjn9KAKjC3mtJrS9hhmtpkMcsUigrIrDBBB4IIOMHrTZiwkZjvctngnp70XMUtuTMEyByDjJqFrmNYvtUrrbwqMyPK2B0z6+9AEFx8sR8zeqY+YgkflXFXmpLqVxJBExjtYv4s/ewenSneLvEg1MyW9nMV05fvzg53H2/CuF8258wyRSuluv/AC0Yhc/nTA6nULI37xLO67FHyIcfnWpBBHZ2wRRlgOAeMcf/AK6d4Dja4t5NQv8ALQLwJGxjjiub8U+Izdai1po0eVk+X5cFmNAGHrtpZtO9xJfp9oJ5jCZP6V6F8PbbzU064DbAtxEACuM/MO3+e1c34f8AA1zNdxXervGsZ+bywdzHPTPGK9RtYoY7nT4rZVWNbiPoozwRQBz3x9BeXw+isA7C4xk4/wCedeW2kYAG4FWA7fWvUv2hbO6ltNEvbZGZLZphIV/hDBMf+g15XYs0qEpkjqaSA0s7mQLu46ZNTEsWZBkkjkgCmQJswMAEc4qflnIAB9fxpgCu6owZjgDjjOfpVNElnb5mITPCitqOLbEgbbz14J/z1FVTNgjaNvbjrQBk6iotoChXGTkZPOfrXK+ILYvaqwJaXPGO1dXqBe5m/e7QgPpyKz72H7TBlQ4VCVwylTkEjofp17jpxigDmbOBmto4/l3Mf4mAAOfU9KvQwh5o8Ahwe7D8PpV2Oy+UcEqMfngVLZwbWZ9udoxk/wBKAOp+F1iH1+e8dQXRNoYnp9K67xYSt08ykBtpANUvh1a+VZvcY+93x1Fc94p8SmfxEtjAu8Ftv3M5NAGx4UsktY7i5KhpJmJ3EZI9q1YYWWEvGPnOMGnJphihhIkdU+9tXofrV4O6SbNgMfcnigDnfEWlQ4s9YWLbeWrglsZJHQg1qQXi3PiHTNQjVkYIu47DtKsTgbsYzlTkZyMjI5BO9b28E0Ekci5VhjDGvPby6n03U2t4S7QI4KK3p6Z/OgD3RRlVYenWkbAPPWqPhrUotT0uKaIg8YIB6GtX3qRlN4ophtfGfemGyTIIwMelXjErsCQCRS+UpPIIH1oAZHjZgU1s7anCADAGKbIvykdqAOS8TTeXbSc4yOvevn/xNcBriR2PLZwDzXtPxEuxbWUmTgV4BezyXF2QMvPI2EUDqT9KYihaWc97ex21spluZW2gDORXttvaweAPCYigVX1Kfgtj77H19uKzPC+m6b4KsF1PXJF+33AGxW4KcdB6Hpk0/wANtJ468VxyyGQ2cB37SeAB2x70Aeg/DPw4dL0xrm6O+9um8yRyPXpXQ6/px1Kzkt0fyywxuxnFaaqlvAMkKijrXH+IJL7X5xZaO8sdurYlnjbb+GSD+lAzS8C6ZNpNvc2dxIkpQqQwHbmitPwzosWi2HkxlnkbBeR23Mx9zRSA2qxtW8P214Glts2d7j5Z4DtOccZx1HArYYhQSxAA5JNLQBxct5NaldJ8UwpcW842x3S4wxPqOoPPWvMfGuhzaDeblwIHJMUmCePc4x0/rXvl5aw3lvJBcxrJE4wyt3ri7vSxYwSadrkTXmhv9ycsS0HXAYjBwOefbnFNMR5HDevcyBZ2KTD7u3AB/Krv7yNldjsPTKnnp+VHiXw9/Y84bR5H1LSpQWEkXJjwec4/n+NZFtcykKrXLxp0XecrTA25/wB+odHbGcsSf/rfWoPt4gA3MCc8FuT+tUpIb6dyEuIAmOCJAv8AOs65szCxSa+QMR/BIr/oKANS4vY2n8yZ8k/dUt0HHb/P8qLK5k1HUktdNhW6vZcAbfmCDuT2H41zhEEasHldzjnAx/OltvEl9aWzwaYy26nq0agOf+BdR+FAHrmnWVv4bjW3W5TUPEE+D5CAts/Ht1qjr1o1jHHLqG1blvmYr2GenFec+FfEE2jam18SZriTIzI2Sc9eT/Ot/U/EGqz3RvNStcxOMAM25cfSgCHWtZitbuG50JnEq8TDBCtz0Oa6SLxPr+reG5rq00CFUVSr3pmwowBztArl4tfs5UltPsKhJf4w2QD9MVWSC5so5LRJSdOl5KFvlPQ9PyoAp6dqV6lxJLciS43H76gsBXpui6dB4o0lYS5t7pOU5/eDHQ/TmvLG1E2jiEok1vG2VTsDWjca7dXjRPZu9vcL91kfaq/j/wDXoA7/AFbVLTTZrfSvFTSWV3EubbUIUOD2Bbqf5Diuk0XxHa3AWLUbmNpl4jvo8eXKP9oZO0+3HfpXhGrzXV7OG1K7lubkDAZn3YHpVWyu7qyZhEdq55RuVP4UgPp2XE6s1qYn7kxSAhh9M1YsbcM2ZAdxG7a7hsfka8B8OW1lqySzXtrb70xlPtTW5b6bVrrfDWo+G7YSSNps8ToflDXkkjdPQnFAHp2uGBYcyXMEJX5v377VHP69elcDew3WoO1yTNPZxNkS3g8q2UDHIXndyT+VQ3/jjS7KbzNJ0SFroN8slxhmXn06j865yyHiD4h62INVuzDZJy4A8tUUf3R3Oemc0AUb5pNd1MWWlnzUVuTHHhB9Bz/M10dzpWheGo4210tcXIGVgALFiO2B9O/FbSTQ6Kf+Ef8AANobu/5E13IAUj7fM3AJra0TwJbWk327WZW1HVG+9I+din2H59aAOOnXX/GUAEFr/YuioNvLfM45P3R/nmtTQtAtNDAEcZkkPBmbPPb8Py713rWKAgLuAHocAVTmtPk2xtv+bnLHjj8v1oA527hR3UjaobjKmr+nxSJqVioBCeapJ69xUvl7VdQHVR6g/wCc1a0uEi6ib5yPNXqcdDQBueIdNh1XT3trhQyOCMGvBPEfhqXRLx1jibyA3yOe4PHavd9e1CTTntZDbyS2zFlleMZ8vpgkenXms3xFpVtr+lMEZSSMo49aEB4paAEAupGDhv1/WlRPlJUK49Tk49aT7PLYahNZ3BbzYztHbPP/ANcVPGzgsWiD8dTzj8qYEkduygZk3IB65H0pnl5f92v3TnuKtLEZFZm4HbHGMen+e1TqFEZ5bjkUAc7dROXzGp3Dr2pkMO5cuTkDuc/571vfZX2chskcfKGqs1uNuGBBPXjFAGLJCixnHA9RyB7UWNszw+Wibixx07+mKuSfuHbcAYwDhTkc8+45H/681uaBZRwIuoahthgT7ilhz7/zoA2bqRPDnhF3lfZIEwM9S3pXmfhO7jn1Uy39ni4kfcjsTznpivRNT0iTX7iC91PdDp0B3xwHjf7nioNQ083t1b3CxMkFv9wAY6UAUfG3j6x8L2AF0yGcgbI8564HPoMkV5HdfFnWbi7ElmVSHIBUjle46j6Vt/Gbwdfyr/bYjNxCgBKq3K4GBj+X4153oV1AYAY4wd7bVBU5bJAXAx3J4HXkUgPX/BHxc+3XEVlq1uY5ZCAJI8HB9xmur8ZaY2qGGKFcROfml7gGvHvhvbW9n4t8zWwbKFiTmdTxxgDHYcV9PeGDpl7v+xzxTpjqnIoAy/hvpd54cRrSWU3Fi53I5GCh9K9HGCM9j3rC8uTS3ZmVpbI8nC5ZPoO461Y0++huIvP024iu7XJDBGBKn0z/AENAGsBilA5qK2uIZ8+WwJ7qeCPwNTrjHBpDExweaZKp2GpqZI6KmWIAoA8u+JVlJcxrFDFJPcMcRxIPvH3/ADrL8F+AofDqPrHiNo2u1GUTdlYv8T/kV6nOi/NNsSNAMtJLwQPoa8uuJLn4geIWsdHmkbRbVv8ASbwk7GP91PU+/Tv6ZYjivEWl61468RM+n2kk1lGxWHHyomO5J45xXsvw48Ix+EdFKzurXUnzzODwMdhnsK6CytbPRLSCztIzkDCIvLN7/wD16sJYNcMsl+2/ByIlJ2L9f734/kKBlRo5tWcYOyxH5yf/AFq17e3jt41jhVUVRgADFSAADA6UuOKQCiilooAWiiigApGAYEMAQeoNFFAHL3HhJbZ5Z/D12+m3EjbnXYHif2KcY+oIrz3xVo9zBfI2rQWtvJK20S22SkxwOoJJB5oopoRyetXEmj36/YYGiDfwsVZTzWFcarLdHe/lhyMArGKKKYGdcykQ4ErM7D5h2xn/AOtVOOMFTsb8f8/SiikBYELStkYJXtir8M09qHDuyx4OVByM9On1/lRRTApRIonYrht/3eorStLmWJWtXXMjcq2enFFFAFaeycybSVDjk461Xjl2LJGzhyCSSyjIBJOOB0HT6DnPWiigB6JwN/zDOcCkKHcM5I9AaKKQGroes3dkWijePy3GNsqmQH/OajunDzyPJDtkJ3HYflP4dqKKYHQ/DazudQ1hrhEDW9ucuWx69Md67TT9M1TxvfNP5/8AZ+jI20GAhZJR746dMf40UUgPS9E0ay0SxFtp0KxxjqcfMx9Se9XWUMpyMfSiikMr7l3BRnp+XeqV0FLry5IOcZ60UUAUksdzhrksqDkBTz/npTpJ44ry1iXjdKgyO/zDg/pRRTEdJIodcEAjvmsG50yexczaTHlCcvbqQAT6jJABoopDOY+JHhG81nTvtml27/2pEm5Y0dAZOPuZLAZ44yce9cbofh3xd5R+2eGLyCZSM77m1YOPbbMf19aKKdwNu08Ia7PdoJNO+zK33pJJo2VcDuFYn24B6/WpG8Ja1HBC62Du753RrJFlMHvlgORzwT74ooouKxHP4N8QbrYJbIyTff23AHkdPvjIzjJ+7u6H2zHeeC9fSK5ENmspjK7Qlwp87PXbuIxjvu2+2aKKLjsYVx4Q8U2+2ceGrm9kB+WKO5tgBx1O6UDH0zXV+HvCGptanV/Edk8t5HGXi0qOSM7WA4XO7YXPTJbGe/eiilcDX0vS9c1udbnXLJdJsRnbYNKkkrEMQDIyFlAwAcKx68+lbGq6FPNEI7MRxgcDJ6UUUAecw/DnXtY1fUrXxLNcHS4dn2Z45o1jnyMnaBlxt6HcF5PGRzVDwz4O8UfDvX7uPSPDj67pdzECs0NzAjRHc3y/vZEOfXAxyOeoBRQBpaf4V15I9U8Qap4bW+1C9I2aXJLAZYQGwAGLeXjGG+/09+K6jwt4Sv8AR4bg+XawySvu2W+Ag9h+tFFFwI9Ru/HS3y6fZ+H7WW3kQk37XKeXGeflZd4cngdFI+Yc9ceR3fgD4h6fqj6hpmk3BuZZZNz2N5BEQAx5O6QcN1A5OOoB4oooA7Hw7ovjy8SNvE+itKI3wPNuoROBx8wZHYY5PcH5T7Z7eDRdR89FSLVbWNR1Gol1+mC/9KKKLgb1lp0tuDukvJD/ANNLgt/WlvGvoICbHT2ml9HlX+p/rRRQBxE/hfxP4uvSvim4Om6KrZ+x2sg3Tc8biCQB+J/DqO5tdNXSNOhsdEs4YIUG1BnCIPU9yf5nqe9FFAFy0skt9zZaSZ/vyOfmP/1varODRRQAbaMe1FFAC4ooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance images of an adrenocortical adenoma. Left: T1-weighted scan showing a left adrenal mass with low signal intensity similar to that of liver tissue. Right: The low signal intensity of this mass did not change during the T2-weighted scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George P Chrousos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24496=[""].join("\n");
var outline_f23_59_24496=null;
var title_f23_59_24497="Patient information: Charcot-Marie-Tooth disease (The Basics)";
var content_f23_59_24497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Charcot-Marie-Tooth disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/charcot-marie-tooth-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1672042694\">",
"      <span class=\"h1\">",
"       What is Charcot-Marie-Tooth disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Charcot-Marie-Tooth disease (also called CMT) is not a single disease but rather a group of nerve disorders that affect movement and sensation in the arms and legs. These disorders are grouped together because they run in families and have similar symptoms. The different types of CMT are caused by problems in many different genes.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042709\">",
"      <span class=\"h1\">",
"       What are the symptoms of Charcot-Marie-Tooth disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general, people with CMT have weakness and decreased sensation in the lower part of their legs, and they have problems with their feet. Sometimes their hands and wrists are also affected.",
"     </p>",
"     <p>",
"      Symptoms of the most common form, called CMT1, usually start in childhood, and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Weakness of the foot and lower leg muscles &ndash; This weakness often leads to repeated ankle sprains.",
"       </li>",
"       <li>",
"        Foot problems, such as high arches and toes that bend up at the middle joint (called hammertoes)",
"       </li>",
"       <li>",
"        Lower legs that look very narrow at the bottom and wider at the calf (like an upside-down champagne bottle or a stork leg) &ndash; The legs look like this because there is so little muscle near the ankle.",
"       </li>",
"       <li>",
"        Numbness in the foot or being unable to feel where the foot is placed &ndash; This can cause the person to be clumsy and to fall a lot.",
"       </li>",
"       <li>",
"        Abnormal curves in the spine &ndash; The medical terms for these curves are &ldquo;scoliosis&rdquo; and &ldquo;kyphosis.&rdquo; These usually develop later in life than the other symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In other types of CMT, the symptoms might be slightly different. For example, there is usually more loss of sensation with CMT2 than with CMT1.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042724\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you develop weakness or lose feeling in your legs or arms, see a doctor or nurse. If someone in your family has CMT, be sure to mention that during your visit.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042739\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. If you develop symptoms of CMT, your doctor or nurse will ask you questions and do an exam. If he or she is unsure what is causing your symptoms, you might need tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests &ndash; These tests are used to check for the genes that cause CMT.",
"       </li>",
"       <li>",
"        Nerve conduction studies or electromyography &ndash; These tests measure how well electrical signals travel across the nerves that control the arms or legs. They can also show whether the muscles respond to electrical signals from the nerves the way they should.",
"       </li>",
"       <li>",
"        Nerve biopsy &ndash; For a biopsy, a doctor takes a small chunk of nerve to look at under the microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042754\">",
"      <span class=\"h1\">",
"       How is Charcot-Marie-Tooth disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for CMT involves working with an occupational or physical therapist. When you work with a therapist, you learn new ways to do the tasks you need to do, such as walk and climb stairs. You also learn special stretches and exercises that can help you have better control of your arms and legs. If your muscles cramp or get too tense because of your CMT, a therapist can also teach you ways to help those muscles relax.",
"     </p>",
"     <p>",
"      Another thing that helps people with CMT is the use of special shoes, canes, walkers, and other devices. A physical therapist can recommend the most useful devices for each person.",
"     </p>",
"     <p>",
"      People who have foot problems caused by CMT sometimes also need surgery to correct the problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042769\">",
"      <span class=\"h1\">",
"       Is there anything else I should do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Always make sure all your doctors and nurses know you have CMT. There are certain medicines they should not prescribe to you because they can make CMT worse.",
"     </p>",
"     <p>",
"      It might also be a good idea to exercise and to avoid gaining weight. This will help you keep the strength you do have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1672042784\">",
"      <span class=\"h1\">",
"       What if I want to have children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to have children, ask your doctor what the chances are that your baby will have CMT.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?23/59/24497?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83812 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24497=[""].join("\n");
var outline_f23_59_24497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042694\">",
"      What is Charcot-Marie-Tooth disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042709\">",
"      What are the symptoms of Charcot-Marie-Tooth disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042724\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042739\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042754\">",
"      How is Charcot-Marie-Tooth disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042769\">",
"      Is there anything else I should do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1672042784\">",
"      What if I want to have children?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24498="Contrast echo ASD";
var content_f23_59_24498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Demonstration of left-to-right shunt with contrast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 216px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADYAcQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UopQMnA617T8UPhFb+FPhxYaxaLqP9rWckMOspOuIlaaJXDRnaMqrHYTn7xxQB4rRRRQAoOOlJRRQAUoGSBSV1vww8NyeJ/FtpZKgaL5nk+gH/1/agD2r9nv4axLGur61ah7lmDRRyruVRjOSCOuCD9D3zx9HhEhMUa7QB12pgYxj+X4fhVXQ7EWGnW9sqgmNQjYGVyAM8nn/PrV7JQEuBn+7647UAGQwDIkZJbueq+v5dK8v+MPw/s/EWjyeVGsNyuWE4XABC4+YgcDHp9Oma9ObC7UnG/bgnB6n+f5/wCFPZfOBSTDfLt29OvUHt+FAH5w6rYyafeSQyqUwSVyc5XPByOD9e/WqVfQv7THgaLTJU1qxtwIXAjZyx67uueh698cfhn56oAWlJ4A5/Om0UAKcZ46UlFFABRRRQAUUUUAKe3tSUUUAFLRSUAKaSiigAp2Pu4znGeuabRQA7GFJDDPpSkgJtxyDnOabQMZGcgd8c0AOySoAPv1/wA/5NMr2nW/gtBp/wANk8TRarfPN/Y1rq7I1kDCfOxmIOrlty9SSm3GOeuPFxjBznPagAzjBHBozwR2POKBTl2kAE4JOCSOAPWgBykZwgOScA7vypmPXtx1oDlfukjjHHFLt+TJB46/0oAdHEzkqBtZeWLHA7D+de6/s0+Gzf63cahOd8MHIXcHwAwbnI65GR9CT/Dnw6MO8hMByx+VQAATk4xj8egr7M/Z18O/2D4At5LiKRL67ZncO3RcjAx2A/Xr0wKAPU8kQclAwI+UHIUdP8/l7092HHJiKv2GOPf/AD/jUW/bFiRQNvHT8APXr/ntQzIeWJYA4OOPxz2Gef5UASyMyqGUDAY8ZIB685/z+tOAbGCDk89hzjB/z/SosFYgrDkHLZ+nI9+v60DanDMCuPmCjqMdPr60AZ/ifTbbWdIntLqAzKyE+UQOeDxz/Mema+A/FVh/ZuuX9kVZDHOU8sccgnoOeMEY5PH44/QdnJZY/MO5eC2Bk469f5//AFq+FfjJqFjqHxF1ifTPlgWZkyqlfmBw3B5Hf69+c0AcQQSMnJHTNJ9KKkjWIxSmSRlkUDYoXIbnnJzxQBHSUox3oBwDwDn9KAFyBtI59QaQgjGR16UHBJIGPaigAJLEkkknkk0UoC7CSTuyMDHBHOefypKAEpy+w57UlKpAYHr9aAEbGePSikooAnsbqWxvbe7tmVZ4JFljLIGAZTkZUgg8joQRXR3XxB8VXceuR3esz3EWtf8AH9HMqOknzbvlUjCYPI2bcdq5Y4wMHPHPFJQAUUUUAFFFLjjPagAGMcg5+tfW37NHgSTRNEbWdRgZbq+XciMpyseOMqenf6/SvIP2efBCeK/FgudSDjSbApM6k7RNJnCLn6nnHPT1r7Kt1jJjRGWNEwvlrwMdv5fp2xQBKjFfl4xgHAJPGPfpQX2k8Dk8BieP8/8A1umaEbfHyAoI+6G4GOn6n8z6mm7x5gDOCAQWyMg/5/n6dwB7Ei4VVBVFAySQcd/8n+dETAgEsxOANvOR/n/63rTA5dPMDPwOzfz/AB/x4OKYpBkfaSegBH5Ee3+eaAMXx3pNrr3hvUbK8CFJYztb+4w5BHUZ/Dr69K/P69tpLO7mtp1KyxMUYH1FffXj3UZtJ8Danf2zES28TSZ3AHgHnJ49Ov14wM/A1/dSXt3JcTEl5GLEk5ySaAK9FFFABS0lFABSnGeOlJRQAvbrSUtJQAUUUUAFFFFABRRRQAUoxnmkooAWgUlOycEcYPtQB6Pd/F7Wp/D6abHpuj28w0VPD7X8cUhuGslGPLyzlBnuQuc9McY82oooAUY9KAcHI60lOGQeDg0APQ7mwB2OM4Pb6UwjIJz09aVcggryRz0rtPh78P8AV/GlxNDZI0NrAvmTTSZCdAQo9WIIPsOecgUAei/s0+Bo9T1GbxFqtsDaWoMdukoUrM7LjdtIzhfXPJOPU19GDW4YNRjt58xyM21ZAAw+me3f29cDBNDQYINK0i20/TYFga1jWNLZOrcAZ2nnnn9RzzVsWJuoriaQCTzFYIpUZGQdv06Z/D0GKANtLmPfv3KRwp7c9x/L+vJqZG5JKcdByDj3P48fp05rnPDFhKu6W43kEsEVjkoABjn65wPf1OBvqF5CYCnAHTGOR+uD+VAEjSY2ZwIyMt37c0wvtGWOM/Ln0x3x/wDrqORwqbyMMVBzwMnH88/zzxwK8w+Jes65ZQSTW0i2dipQBim4yHeFwRkcEnbgYJPGRnNAFT49fEJ/C+jRwaTMP7Uu3wOOI4wMknPr2x355AAr5CnlMsksjYLO2cjp19+a0dd1e71K9uLi9nlmuZT87SNuBGORj6jP16YxVCWFBbRvHKXlO4yxBCPKAIAye+c/y9aAK+OM0UoIU5Azg5GRSYOM449aAAHGfejjHvQQVJBBBHBBpwRiduxt2N2MdsZz+XNADKXj0P50qkAHIBzxk54oUZIA78UAJSUtC5JAXOTxxQAlFLSgZz1wBzgUANopaKAEooooAKKKUdeuKAErqPh94J1XxzriafpMYEa4a4uZOI4E9WPr6Dv9ASMPSdPuNW1K1sLGMyXVzIsUaAEkknHavvD4a+DrPwN4XtdJs1YzMRNcy8fvJSvJPrjoPYelAFTwf4Q07wRpFvpOkxM8fmFpbnd+8nJH3m4xxjt0/HIv+MNbtvCHh261i5bEMYACFiDI7cBRnv8A5PAzXSyoMybSqjuRx+Pp/wDr9683+NOlSeI/CV5pUWFKbZsnqCMkY9eh6enHAxQBkaT8TPEvi7TbiXwD4Im1G3gl8p5pLxIgr4yQQxyTjnHbqc5GOK8YeNvit4Xg+2694fmsIGBxKx82OM4/vISBk9m+nIrR+A2ny3vwG8a2kGrW2nz3F48Yv5ZmSKAbE+YtgbR15Hr+FbVxZXPgX9n/AMUJf61L4z+3q0XmWkv2iC13DYCX3EhARk+hxgDk0AR+HvifruiWWmah8QNCuNP0rUwGtNQDho33DcucEkZXuwPHPTAHX6f8TNJ1mK8Phi2vtZNqgeY2cJ2x5ztyTgDJGMDPfPGTXlnhW5bx/wDswaxoom87VvDjiZFON3kpl0xyDjb5i5P92tPwaJPAHwP0aDT4i/iTxhMZYh8qnbtyu45+6EAIxyS+OOaAON/aA8UeM47izs9WWOx0y7hEyQwSblkGejHocccdD7jGPDSQQxI5J6jgflX0JrtlNqng7UPEXxVS5u9Ss4vJtYIB5SxbshT8nBJYZz047Y5wf2VvD2k+IPiBeQ69p1tqNvFpzyxw3Kb13eYi5weCfmI59fXFAHi+OtJWr4nijh8S6zFaxCK3ju5lWNOiIJCAPoOBXrHj7wn4dvfgV4a8ZeFtMSyukdbXU9srtucDYThif4wD2+/70AeJUV7J4V8DeH7b4D6/4y8Uws97cMbfR8TuhDg7d20cN82T3GEPTmvHByaAEoopTzQAlFFFABRRRQAUUUo6dqAEooooAWgUdhjOfSkoAU0Z60lL/OgA4wMZz3oGcHAzxzxSUtAARgDPelUAkAnjrSdcCtHRdKvNc1W1sLGMyT3Mnlp12g8ZJODwOp9qALHhjRrvXNbs9PsbNri4nYBQg3YGeWIz0HPcDj6191eE9AtfDug2ul2EEUUUKBPlUIZDnJZvc88+vPHArD+Gnw907wNoaW9tCsmpuv8Apd04Bd3wMqPRRyMD9eTXbIACU3Ftx+XI/H/HmgCMJ57O+1QFwOQAwHTkf5/PmpWQN3A59M5Pv/X/AOtQqhWAB2gEgAduf6Z/WpCNzsMZwQD8ucDHbH0/yKAGxABUKr8rAnPYAf5/X1NDsc7lIHRQdvQ9j+f+HvT0+6rAnDYOGHGP88/5FRvGCUG0nGcZGfbHv/n3oAbdBiHGFYEZIJ4H+f5YPpXmPxX8K3/iLRpI7O9nSGHB+yKv+tPYEHnGccDkgEdWzXp7IdgZ/wAADnj1Pr0z/nFUowWYEjK9VXkHAP8ALPp6+poA+PfjHoM+j6pZ2kejpaW/lgiYR4Ej7eQD0x1OeBjjoteY8FuBx6V9Q/tW2Y/4RjR5cg7LwxAAZPKN+XI6eo7Yr5fJwWwVOOMjj8aAG9sUDHelKnAJB56e9J/D259qAFYljk02ta1ma9t0063tYQ7sCZGJ46c+3/1z1JzS6/oN7ojRi8CGOQsEdG3KSPvD6g8enBwTQBk8ZpVOAR2IxTafGVUtvDH5SBtbGD+X6UAN4x70HjgjBoJo7UAFKTnHSm0UAFFFFABRRRQAtSW0MlzcRQQIXmlYIijqzE4A/Ooq+m/2a/hpeafNF4s10RIjROLOzlUM2HAHmnPCkjgd+54oA7T4HfCyHwPY/b9VEUmv3UQVieDbA/wKexIxnv8AQ4r1ltuWXggHB24yD3H/ANakBKsA3GByPbufxz1/xp4UjAdRt6bMjr6/lx+XagBxAIAjH3Tnp/Q1S1G3gvbWW0uVUrIpDqfmyP8AOKtrlc7OgHyqDkf/AFuP84pkqFowrbN5x7kduPT6en40AeB/FnWtG8D/AA613wgthLDPqrmW3aAbojkqSzsTy3ByMZ6Z7Z8x+GvxA0XQvhL418L6q17Fe6qrG1kgjDISY9u1jkYyVAPsa9p/aE8LafqWjQ3+oSiOG3JG7gEnBP3uwx+XXkYFfH08TRTvHg5BwP6UAei/AXxtYeCvGU82u+Y2i39pLaXapH5mQwyMr3GRz7GvVdK1N/id8aYL7w2/k+GPD9stta7lEf7vbg7VxkZPGOwA6Z4vfsxXXhi88KHTjZWh12CdmnMsaFpQT8pUkHOBkfr0Br2y0021sZhJZW0UDEDmJFQcEnPHUcn8z9KAM/XtFtNW8PahpU0YSK7haMnAA3EdTnjqB7fgK8M/Zd0Wfw/8R/GOn3BilubTT/LJRwQSZE/T36d/SvopnLiVQfuqCAMZye2O/H+eDXw18Z4bWw+JGrRaU8qw7lY5boxAYgY6DP8Aj7AA6nXP2ffiDbrfahPY2bxoHuH8u5UkjknA45rtPgDHLqPw/wDGPgfV3jtd1r/aMM0oBS3RxtZ2+hAbB7DI4xXzumr6ilu8SX94EddjKJ2wV9MZ6fWt/wAP2ZvA0Vjqd4mpXQa2MUUuAYyQdrtxleBx0JGewBAOy+LHiD+3PAXhS30UQ2Wh6SJIVtIpySzhtqzEHklgC2T039TzXj9ezaD8PrvwRq39teJWs5rG1GIvLfducnA47YPbrkgfeOBkfGvR7CC8t9XgmhgvL8eZJZKVJUcYI28eoJwBxx05APL6KXtmkoAKKKKAClpKKAClBxSUvagBKXjHvRSUAKSSMdvSkpaFxuGQSM8gHBNACUUpJI5+tLyFx2PNAAAMnqeOMUmOKUlckhSPTnpSAE5IBIHJ9qAJYonMqLGu+UvtVQN249sDvzX158Bfh3/wiOiDUdTtFi127X5i+GkgjOflBH3c4zxz3z0FeW/sy+EItX1+61u9iL2tjHiGMoG3yMcZOeoH6k44r6nH8LYDbiWxnrzknn35/wAigCZY9u1lQqduCOOP8/5709RnyxtLEHrjuef6U2MHaVfOM8gp0IHPX+X51IBlyGx3CHvjuPr/AIenNAAwA+ZMDGQGJxx39+/+SaXaAoDHPynBI5P5fhRGC4UhtxycNjrj1J/zxSlXCsU3Egcc4zkYx7elABgkgE7WZvmx1/z/AJ9KRw2/nhj8uf8APt/P8aAMSbuVT7wA6Hj1/wA9M9KUKw28YZhzjofr/h6H3oAaOWwoXdnK/LyD39vx+vbFVghVSpGABwTk44/TrVhywXJAcjG0Ef0+nHpx6CosYw2CQBgMeRnPH+R/9agDwT9pt/tOnWEaThYoXYuuOCMYyx/T8fTJr5kn2YwmACcgdcD6/wCf5V9L/tKap5NktnaoDO42zybdxVGBAAYcAdsd9+B1NfNExXzD5YKhScfNk9fUdfrx0oAioHGfT6Uv8I5H+e1IfegC41zHHaxxW8JSbrJMT8zemP7oHI96jnu7m4hCzSvIi4VdxyFHYD0HHA7c471CXYblDcHrjvQwA/hOPUnvigBZI3jxu43dMHIPPtTMe9amj6ZJql1FaxzL5spPlq2cZA5JPQcD9MnA5rpPGvw/vPDdnb3cTm/tZIw0ksS/6psEkH1GMHP54yMgHDnGeOlBOcU92yqLngD9f8/ypjEsxLEknkk96ADAwcnnHFJSnr0xSrjPIOPrigA4PU/kKKSigBKKKuaTYTalfR28EcjknLlELbF7sfYep4oA9A+CHw7PjbXGuL9D/Ylkc3GMgytgkRgjkdsn09yK+0bIJFGiII4441VQFAUKAMAenp0/xrhfAmlaRpOi2K+GAI7AIDMxGGlOMbiw4zznP4nkg13cTK2Y40BwDhiR+eD17f55oAthWZXZ1IP8Q75wOf5fz607najAc7sHjOB05FRxsXOxicgdBwD+B9c/p9Kew2jAGApx04B+n+f60AOAJAz1LdQc9Pr/AJ70Ku4DAXIAGccken+f8akYqoLMQwUEbjyenb/P51Ez7JAQhPykZIxjHrQBxPxO0A67ociuQTb4cZbgYBJye3Tr/gBXyT4q0iDUZNVvtPhMs0GJJnR1WFB1IA4Jb6dR1+Y4r6d+Jni66t9PuLSwsA6zBkFxLIqIW2HAzyG+h7+wr5BjlWK5vLbULue1iACSRwgnzMcYHt356+9AHsH7LGsafFrk2ly26/a5VMiTY+bg9PfA55x6dK+p0UMvDDHOQvPHXPP0/wA8V8f/ALOU2op47lbTbJZrRo2WUtGF2r69TgnjgZ9Oma+wIUUquSQAoAH8/wCv+eKAEkjyjJJgpjG3jjPr9P8A63vXzf8AtRaBoltp0GqiWOPV5XWJY8jdKgzkgdcDP689q+hdbv7bR9Kub6+mWC2t4zI8hXIA5PT14xjv09a+H/i94xh8aeKBfWguRbRRCJPOP3uSdwX+HOfU/wBKAOH9at6Xfy6ZeR3VqxWeP5lbA+VvX+v165qpSUAdn4o+IeteKLZbXVJYxajkxxJtyc5BJ5Oc/wD1+ea2Phl8P28c3NxdXty9vpdupTzON7t2A+mc8/yBI81HJHOPevZvhD4S8SS2sV1FqYsdLuDuERcDzWyOoPX7o4Hrj1FAGX4l+Fl1ABB4ct77UbiEkzSMoVWGP4QevQ/hz3FeY3EMlvPJDPG8cqHayOu1lPoR2r7wsLIG3jjhkDmM5kxjk/X1x3/HAOBXnvxl+FEPiW3Oo6V5FrqsUZkbKhEmHXkgZzxx2/HNAHyZRTmUqxVuo4ptABTlxn5iQMdhnmm0UAFKMZ5JA9qBjPPSgnPWgAo4weeaSlBwc4oAUHa4IJ4OQQcUKQSAxIXPOBk0E5HP6CgEjPT8qAEGMjPSnE5wGJwBx3wP8mkIO3PbpnHWkHpwM8c0AKQOMZP4VYsYknmjhklWESHBkYEgDI64PSqxIzwMVd0qFZ7kgrG7KpYI5ID47ce2fT+hAPo/9n+WPQ5bjRBMt207GZJIkxsXIHzDoc+/Q4UZ5Ne9rwhYqNvIyD/n/PqBXzr+zXb2lxqOp3UzKLhkHlxEFQoDAYIH4dOnA6k19GquDhBnByqD379h6/8A1qAJVQiVOQUGTnbndxjHt/P86eF+cZzzz8y5zjj8P/rcUxVUlU3KCW4G7kHpx+H9e5qcBDlmIU8cZyR/9b1/KgCMggbiT1GDz/n/AD+FScqHVhkkAHtyP8/5NKflIYD1xn0/x68nj9DSKN3IOAflAz/X/PpQBHtBj2NubdgEM3v/APqoKgIGKnj5SOdxHX8en+TT1Q78biSBgknn/Of84ppwoPILA4yD/n/PPpQAyYAICGBA4Zu4H+73/wAjiqF3dJb2zzSOvlYzk5AH1J7cdT6/StBwzH1IOfm/l9P/ANXTNZd5FDc2kkTjduQgfNgdOvt35/LgCgD5X+OfiaPU9VSO23qqKzHkNkdAD6dTwenA6kkeO7S5O3nHHOBXQeNoEsPEuoWqSmVIpSELnkAjIOR6cdfXPUnHP7gSWbGSc5XjH0HSgBmD6UfXninEn5QcjAwM8/l+dNFAD5FIY528cEqcjP8AkU1cd/yp2xQrbmAYdB6/j/n/ABQPwcjJIx6UAdJ4M0u8vtet0s4WZ8klo2HGMgkevfgdcHsDX2JoFlby6AIAEMHlbSudwOVwc545/kd3cCuS+DugaZZ+D7SZLdfts0Cs5kUBgSozx3GQfrwOMEn0OxtoYrULAhxy27AOBjj8/wD657UAfHnxi8NWvh3xfcLpccY0+Uh0RSflP8Qx1AyfoOnUGuCIxkHrmvsD4weGdL1bRoZLq2jadHLbxwRjGQT1A6dOe3Uk18k3kIhvJAigRo5A5yO/Gcc9D/8AqoArAZ4GCSKQD1OKXb8oIzzntxSE8nnP1oAUEAcqp+uaKcJpFUKruoHYGigCOu4+HfjlfCVlq1q+nQXK38YUykYkXHbPpzn64zkcVw9FAH1V8EdeRNIh+xyxPau5aaP7rwPtyBnoe598k9wB7raqsikwAFGUlNuOfp74z06dPWvifw/4msLXw9btaFbLVrQfOgbYt2RnBPbp6/xc9cV7v8B/GF34simV5Yx9nQiSJcnBI+UAHtxnI6njqc0Ae3RnCq3TKjk4G0Y4/wA/04oyoCZAJc5UIOlRSgoV3gMucZxkr/tYpYySQpARs/Lt528cdf8AP40ASNJ91iC3PBGCOnHTpXmfxP8AiVoHhmC3hv5DLPM4zHEwZlA6k4OfX/8AWcV0/iPUILTUIIbicIXbJTHOD347cf8A6sZr5R/aMmsZvGKvprQOpQmRkUbsn+8R1PB9/XqKAOl/aA8ReGtX8J6MdDvzPdtNvVA2SI9uCWH1Hp1Bx0rw+3SK51WCNWYpI6qS/Uk9e/r3/H2qo7NLJuY5Y4GTxXUfDbQ9Q1rxbpsen6e96sdxG8oCgqF3fxE8Doev17UAfXfwb8HWfhTw0nlRYu7qTzbiQDG/sBg9h0AGAPrmvQyGiSNyRtY4bjjvjPrz1qvahY7aGJUKRoAMKvQAYAIPP4fmaxPGes32l6Re/wBl27XF75JZEH8Tdvxz3/HoKAPBf2l/iLZ36J4b0icXG183pX7qsrH93659fy65NfOnGDyc/SrOpyzT6jdTXalLmSV2lUggqxPI5565681VoAKKKKAJEjJlVOuW2jBxmvr74eaDaR2Nu1xK899HEISpPy7RgHIzycEKfoB6mvj9GZHV0YqynIIOCD617t+z7ompTXX2pZbj7IcF0JO2RQOAPwOOOeo7mgD6H0C60q4gnXSLiJhE7LM0RDHfn5jjrnj/ACADVnX7lI9NlVYxIXDQlB6HhuDz0JHvnHfNWdN0i0sfNaxs4baedzJK8UeNzcZye/t29OBVgxRyRCR0VyAwBK/MmOv/ANb/AOvigD5O8ZfCq7upvN0C0b5Q+I2BXzQCTx6ED19+wyfG5oZYWZJo3jZWKkMCCCOor9DLmyS7gZEOICuAwGccg/5H9ARXj/xg+Edt4gtpr7Qoo49aJyiKAouSTklj3OOM8cn8KAPk+irWpWNzpt7PZ30RhuoHMckbdVYdQaq0AFOQgE5UNweDn0602igApe1JRQAo96KByaKAFJGOgHSm0uM5xSpgMpcEpnkA4JHsaADrgAc+3ehW2hsdTxnNAXIzkAfWkGO9AHu/wj8Q6VpGsafGscUdtNGFnh5MiyHblif4uMggdAfU5H1HBOJVBLhhkksOQff+X/1xzXw98M42vtaSC0glmvm5SLfiMqv3vfODx+OMk4r7K8KXMc2n28RCCSAbWwMYI9F7Dpjt6cA0Ab0ShmZyOckZPUH6/wD6+v0pxyWYZ5HAJ/z/AJ96buBH3mwuRhTnnrwalT5pET7jMQh5J5P09P8APNAAihmG0nB+UEE8HH8+9PJOVKsPQsO/4evJ/pXOeEvFWneKItTXT323Om3slleW7NlomV2VWbgAqwTII47fwmugD8MwLnB9QM8cf5/rigBIOZETJVmdVB24HJwM/wCfpXl1h8bdEu9Sk0SXStW/4SaG8ksl061jWUSyK5UFZOABxuJI4wevFenHaxC7gVU7j83Tp/X/AA9682+Hfgq30v4keNPFkkLQzXl5JbaejqAPKO1nmGefmbKg8cbvWgDsPGOo/wBkaZO7KZQp2Dy1yM544HOM8fkOteA+LPi3eWmmtFbJ+/mUoZd4xglhuHvkZ5wMjsF5988RpO1pLLFDJOiof3W/qcdB78/06nNfKnxgi1S7vLeY+Ho9Mt93EiqF3OSFIfJweR+Q9FJoA8rupTJMZGZpHbJLMTwSSTj8/wBc96jyGwDkKeTx784/z2pzR7F3Hld20Hpx/n/PIqNeGZRyOlACEkhdzEgDAHXH+TRnklcr7ClU4ZcgHB7Y/nVq0s571ma3jYgZL7OijGfXPTt36dTQBWIDMMMzcc5Hp/8AWqzZWkl1cJBAu6SQ4Tg5J659gOv0oWNi7KIleR8KEXDbs9wR7jt/jXsnwL8DXE/ilbu9ieJIFWSONlBBbdxnseh5+h9AQD2/4c6E+leFLG0kgEciRpkL1dsYyRnjgkY9AB3NdgsXlsRHuwRzkDA4/wDrZ/8ArDFSWdufKQbsFgCTjAPsB1x9eevcmpCd77gqgRnB3dsnj+v+RQBga3pgv9PkjdRIzqB82cAjkdOQOevv6nFea6j8NNLXTLkzQ+ZfSr5QlaMHIIYAKBwDwOf9kAYANeyPGJHd+SykbQvYEdCfpzn198VDNbRty0cbYPGRwT05H1/w9TQB8YfEHwLceF2tbuASNYSoDvKEMjgdD04yCc+nOBwK4YxPwFViTzjH4fz4r7v1bw9Z6uzrfwLcx/feFwCsnPf155z9D0Ar5r+MXw9tdBuZr7Q1llsWA8xEXC2vXrznHQe3fJYEAHkB69APpRUsilmIJJ2/LnIOce/+eKKAIaKKKACu6+DXiC68P+N7KS3ZvKuD5Mq7CwZTx25HXqPWuFr0b4TeH9afUotYtdMmubBRIgdD1cDOOOQfcc46elAH2bpWsxX8YMQkOxSSMHPpgZ9Py+orUEpJLFlGTn5u/wAvr7D+fvXNeHrpCkKmGRC6gMGHIPGQccZ9vwGOat+Kr2bT9Eu7u2t/tUkMZcRqcE4BPDdz1/mOaAJdQ03Tr2Rp5kxIFK7lYg8Dr/8Ar+nTNfIfj+bw9/wnOrQeX5N1DMxjuZN3luNoIG3tznBx3J54FWtQ+NniW61UxW0flwMfLW2UkMxPTOP4s4/l3Oc/xB8M/iFreq3Got4M1KGSdyzqsfBY8k8nuc89Pp0oA80nZWlcqQELEgAY/T/69en/AAk+Ky+BbKe0m0uO5hklEoZDhgduDnPXkZ+vtxXG6f4K8Sah4kfw/a6LeHWkQyNZyJ5ciqBkkhsdsfXIqjrPh/V9FllTV9MvLMxSmFzNCyqHGcrnGCeD0oA+uPh38a9G8V6mmny28tlcuT5S/fyP6Y68dvfNdf4+8O6z4h0p7fRdRXTZ3HL7c9uOQcjkZ47j0zXxD4FnltvGWiS2+7zVvItu1tp+8Bwe1foZb/OAzgZHygYyV9iO309ePWgD8/fH/g/VfBmttYa28Elw48wSwyeYr5PXPr3/ABrmcHGccV9ofFy98A6RdQ3XinTrS+v5B+78xCXPXr2Hfr9fSvn/AMb/ABC0vWDbWOmeH7S20yIl2woV3yPbjAwOPw65JAPMoIZZ5RHBG8kh6Iikk9+BVm50u+tbmO3uLO4jncArG0bBjk46Y9f8Otd94U+IWm+HLVks9At/tUww9yGw6+wzxjofc9egrsPhn43stU8TNJr+nRTXMhURuFLsFI9Owx9PfJbNAHJ/DL4Q654uvo5Li3ks9ORlaR5FKl1J6L9cHn2NfZeh6LY6HpFrZaVbJFaQAIiID9M+p5/MnJ5NWtPeGS0zGm2JcAL2Ttj/AD9O2asAgn+Ltg7upAx+HXvQBGIlDMcYOMMSf8jr/KoniEh+VlAAG5uexz+Prz/PFTlcNhzkjlQM5+v446U/aC+1lB4yctxx70AV3jwGGxQQCeOMc/5H+HJqtIoCHGS+0jgfiD+Y/Pr2rQ6MSceo5OM9OR9AKrv8g+6B6du/Pt+H9BQB87fGT4U6h4ju7jWtO+zi+Vf9Tgo1wATwB039u3bPJzXzVcW8ltcSQXKvHNGxR0ZSGVh1BB9+K+7PiF4hh0zS7hbZvMvI03eWuWkRcddo56dfQeua+MfGltM3iG8aWNlnLeZId24MG5DZ9eenbtwKAOdYgsSAACeg6CkpSMHB7enNJ2oAOw4H1pKWigBTgYAwfcU2inIu9sZUcE5Y4HAoASjtQBk1ZspWt5JGRI3YqY8uu4Lu4yO2fTNAEAb5duMjOaQDJHvxgdas3cbCSRlQIoO0oBwvtz1x6/TPJqAAhlUtwDk+gzj1oA9D+C2nLfeK18u/itZIFDq0h4k+bG0dDx14/Q4r7E0GyWKWXO7GQpJ53EEj8PTHbGOOa+LvBzQtqlrK8tpD5jrGA7hdoGTkMeQvfJ78nPFfa2gTbtLt1GWUKFBJxnH6g4PIPt1oA1gWCnczDknIPcd89+n6fSquqWR1HTbq0jvbrT2mQr9qtnCyxgnHyHBweo9efWrDyKuA5Gz7u3IyTn/PHt6Co2OWmCktsUlAPpzj1zQB4zoPwcvvB3iJdZ8G+LpFuQWW4g1O13rOhOGVtpwe/wCPp1re8beL5dO1cWFu8owRIDgE7SMjP0GST0AyfSvQ4kdXZjkjj8eOMD19vwHevOPizZ3w0KfUdFh82eNcfKiscHPHuM/p83bFAGdcfEorK8Fo0bOj7cddpx0bPIIyM47EAZ5rrfD3in+1bJJ4l8yRAPMKFTtO3jkZ4yDz3xx8or461fUry4vpriU+XcEYcocMMAccd8dM9Oo+YkV2vww8bX2m3iWyvEkbNkkgbQDx1GBnOMflwAcgH0dP4jml1210+3Bjffsk81dvHXCt/uknjtz1IFdTPY219ZJBdwRywELuRkXg4x6dfp9BxmvBbz4h6OfFWk3N3va6JH3tqhD/AHix4xkHB78NwdtewaB4s0/WIh5DkckFnXGcY7HvyOPUgdSaAPPPF3wK0HUvMmszLZSkEqIcbSx7kH3yc/XpgCuEn+BsNjpN7Leaj9qubfayCJNq7dw3Agc8j+fHOa+g/EmpmPS7xoiwkUfK6R5YH1x+Xt1zwM18u+LfilqV1HcWcQKtFmHzGJYPg4z2PQnk8jvycgAgs/BvhMOUvL26SUyHEO9TsUcAZ45JyOe69gDn23wXa+ErOP7F4fihX7TwzyMJN4HOMn2yeeeSfvEV8nGaa4vHd5pNxG5vNAPTjvx0AGPw6c16/wDASxvJdWFyyEiArPFFsKgg559M9+eccnIAoA9+0jwFoGlKGsdIt42DNyEzvySOQeO+3H4e9dNbWsUbfu41izkHCgZPH+H6DPQVajXYi4DBVQdRtPTuO3H+eaUKAOBuU5+YDrz/AE9OnHHAoAj8kHcpX5SCQX7fX0/z601oxj7pLAYwBzkDGP5f/qqwD8oLHIXn1IwOo/x/H2qONVC8vlQM9CMH0/z+FADWRQHcL97p29+Py/r6VXeMbyCg6A/cOR6Zx2AP+cmrE3UbTlmz35OSfz/z9KhYkbflIBX+HPGR6j/P40AQSMEAMhwQdo2jJJ6A4HbI69OPQVg6zZWUml3RlRHQpiUYyrJ14xznktkc9+pAqe/vINPt3uJ/kVOA5yxU54AHp0H1OPU15r4l+Kun2MEjC2aR1Ij3Jcbhby5IwTgenU/X+7QB4l4x8BSJrcg8NiS807aAsjMAcjgj5iOmPw6dqKq+IPEF/qOrT3qXtxaefhjHC24ZAAyfQ8DI6+vOaKAOFooooAK9h/Z/8XXum6yNLecCwZGYAgkoQynjsASc5PHHqBXj9aGivdw3ySafKUnUbhtfaSO/+PPpnpQB+hUbxh/lMeD7jOenbgc/0B5q3dKZoHV95BQjke3vxyf89K8J+Beu6hMynU7prkzgyHgAxAdFI5xj65+uePeEdTHy3zE7uvUdO3H5fqKAPinx/wCHbjw/8UbaVrO4jsmuophKUKL/AKwbiCRgfMf155Ne+/GDwr4k1r4gWVxovj228PwPGkItJtQaF2cHJZIwfnycD3Ix0rofjBrNlo3gy7fU4RcRSKoVBhiCrqcjPQgZP+Oa+ZP2gPG2l+OfHFpqPhtrhra3tI4FkkjEblwxbgdcDdxnvnFAHonxnv8AWb34+eHdI0G6u01u1ZFgvZLZImiRxkhWx88arvbc3q4r0nxNqNh8SX8d/DRHP2rTLaFrScneHkUKSfYh9qn6muYtviT4Fv8AxqnjQa9Clxp3h02iWl5FIkr3BYnggHdxlcD+8TzXD+GP2jtTh1/T/wC0tG0Gz0t51W7ks7VlkSInDEfMTkA575xigDwgG50vVQX3xXdrNlh0ZHU8jnuCK930v9o/U00/be6dbNdRIERld8ucEEn2/Xtzkked/HL/AIR6X4j6jeeEb+K9029xdM0W4qkrZMi5YDPzZP8AwL8BwkZHIKKx6jJx060AfTLa1Nr/AOzF4x1q/EYuLzUfvMpJx5kWACep7cfjXzOeh/gJI4zxzmvoz4Yah4f1X9nzUPCWpeKtI0S/vLp8fapsFV3o2WU+uMcH+VcVqHwo0Ozu9ESH4h+HtQiv9RSyl8iUKYUK7mkJLEYGMc8ZZe5xQB6r+z9p+ieCPA2j6j4mW2a98XX629qJrdZMRjKohJ5AY556crmvPrfwB/Znxt1Pw5NN9ltI7jzo2DFR5LHcmB14UkZ6jBPNdZ8TvHXhW6+IehaNYaDZ6rZeHd1qC90ohnjaNfkj28BkYKQ3chhxXo+qaZpXi3xB4S8a4IuhC9pJGkqkxnJZd+OSQcjgY+YHjIoA73SrYW1jFCC2IAqqWPYDGAPbH+eavqBkMf8AeIHP5/hUceXjxt2uQDyB/n/PrUqFmUDntzn/AD/n9QBNuZORgjBDdPX/AD+NC8pjsTwB/L86HVv4D345+79O3+fxpvmFiwIbbgDtkn/P+eM0AMeQBSGb5mB5Dd88GqNzOijg54znrj/63H+HSrDrGDh9u0EHAOCT+P8An8cVhaxq0FgRE7jDISEXDNImRkAeoH+HqaAPCfH99ez+Ibx7CeOBtxD3G7cqkHKrgc7SDu49z1wK8J1ySSWRzdkPIpbKxniLnAA/2cj8M465r0r426mp1hINJYfY7iLcfLYZILE7SSM/KRnJ56k8Ba8flIZ2f5iDg5Pc980AK2Q8hDYBBOCd24Z6Zxz6/hUbduR9PT2oIHyhTkkc5GMGkwcEjkCgAoPXrmiigBKcxy5JbdzyfWm0oxnnoOvOKAAnJJOST1zTgxVcBsqeq/l/n8KaMnipEjaT5RtBHOSwHH+fxoA1NCur1LiWWyDNMsTtMxK/6rHzHkdQDkHkj37ZiKJHUO4GcKAAeOf6UxsozJkY6HbyDinbmABb5gPlwT0Hp7UAev8AgLwBINNtdc1B1FuwXbJFMuVHUZJHHQ469M/dGD9O+F9IOnaZFHDdyTpGgEbNgZyTg5HJ65HfB9TivlTwl8SzZaRHpN+rNbJs8l1Cny2HQknHQe2CfQDn37QvFF1qGnifTWtWtlCKGR127mGeG9sHrzg5OCRQB6dAVA7ZyNpGCPoMcdv8O9PI/eSkITuwRgD5v89aqWbbY1YliSo3Dbjn+vX+nvVqLCADHykHjOM56n8PX8/WgCN8JF85zszj2zx9Tz/PHWvHvGnjA6ZdXtlKJAqRtIn7vehz90Y9CykY7kc4C5PrGsXtjpWk3eo6pdQ2en2y5lmlyqJlsAHqck8ADJ5xg5rlfF0Nle20lxJYJdQPCGGyIhjGRkHH3gdpzz9OgNAHzpe6L4Y1Yz6ut7fN5rt9oHlgLnPO0jpkkMc8gZJ5YV5jdp9nvpYRuCxyNs3IckDIIx74AIP09a+ndR0lNM0vUrnSdNjNhGM7ZF+eSU45BH5fjuOQQK+cfExabUZneFYN8jhEUbdvOQcfTjHtgZOaAM6W7lnlMzuDgl9oyQp698/1+76AV6F4U+KU3hvTEs4NKt5biL5FmldunPJHUEAkeoBI5zkeZSgqWyoDA4GPbv8Aj/8AqqSJlBBBjPcxkcH2+v6/jQB7EnxV1TXvD+rWN68MbtbMu9AflyPuckHkArx0yP4Qa8fLyPIWw4UtnIJIXGTnPrjJ/M10Pgvw8dZ1NbW4QfZpX8vzVXJBxnHB4+nqMcc122rfDNrLW7Sy09ZTCzrFJOWyu4jIw3HpnJAHU8YUEA8/8M6XBeagLa83uruse2FWZgSTg4xyOnucgDkmvsX4a6AbPTI5rm1RJpNrpx8zg85btnjHHHyjHAxVDwB4S0WIrNaxLNc2+Y5ZfLIJII9ep6jPX/gRNenQR7YmRR1GACv6f5/pQAxVxGNxCevOQOex/WnbN7MGx5YCgnPH+fb/AOvTiv7rcBgEBSBkjrz1+lKxwpJbIGGxjjH+e34e9ADAGLMScgZLbup7jn/PPPpTGx5bbmXcByx9fb/Pf1qYjAK84Ygg5/r09/8A61RMFKuoZQwUk+n/ANfP/wBfvQAyRhghslvm2qFyM4wev0x+nbNQzygAsSAADzuyTgZJJPbHP6nim3TFlXGVVH3ZUcn6/n29MVxPjfVLmxjea1uEWZGVGVSDjg/Pnt06ngcnoMUAcj8ctaCaSllCryzuXCbHYb/lw0ZxznkDHo2P4sj5u1B5iglnZmMpG5t/zEY4U+w24yf7oIyBXpPjKR9RmlvtSvhGruX3WshCRy7QyknqAeRgfh8zYHmerxypcS/alxOzbi20fMo6EgcHjB9Ppg5AM/y5JgDFbuVAwMpn3Hf0I/n3oqO7AkkXcVXYoXgYzjvwD+feigCjRRRQAqnDAkAgdj3p0TmORXBIIOeDg/nTKuadffYXd1ghlkZSg81d6jPfaeCfTP60Ae/fA/xjpkn2mCeJF1OcKgRRtULwAcdCR6/j9419LwFAicxuDj7mCOmOlfB/hCG31XVbVIB/ZksJLG5ilIPUdB7ZIz6H6V9r+DESPTIIVuxc4AJfgt0wOBkDge/5ZoA2NQ06y1KAx6hZQXMDEnypUDqc8dD3x/j1r5++Nvw98CWsc93bzrol8XOEiUeWeP7v4dvpxya+jnGYmG4hhu5HBHpj04rx746/DrVfGVpbXWkXUUkttG2LRlz5hPQBuoOBj9OmaAPjWQAOwUhlBwCO9Jmuq8WeB9d8MLCdW0+WBHAPmD5kHGeo68c1zDROIw5V9p5DY4I6dfrxQBHS0lKOtACpnO5QPl55x/LvSHHoc1f0u2E12iM7KsnyK4HOT0x7+g70XdpFFdFDMBHtBDA7+oyP8/j7UAafgPTl1PxBDbuHw3IKAEgjB79vpyenTNfcvg7wrpGjWMM1qnmzSRrvmkOSxAyOe/Uj8PQCvCP2ZvD1hPr9/qCsJI4FCp5qhuMYPP4kZH0HU19Nh0j2ogJAXcB7f5/z2oAlCYTYOR2zz3peBls8dM5/zmoFuEkeSMMpYc4z0HbPvntU+7HIPAHX19v0oAhIIVsjsSeevPH4/wCfpE0zmSIBHwR8+4dMe3bP+eKnjGO+FxxnvzXN+Odeh8P6Ybm4uBGANnABYt2AXvnoB3PpzQBNrOoYspUSVbdPuyThgCmTwR+nP/6q8Z+IvjCC00e5ha7khu0mESvEN8qtnI/4C2OQPoM/NjK8Ua7b+INDuYjeTsZoGmgiDqCy5DOpPZgcNnoM567a8F16VpNQmH71hwN8h8xuOME+2cf/AF80ALr2sz6vfPK5MUBcusPm7gh6kg46nP8AhxgVkMAYl2+pJGBx+PX/AD70+Zy0e55C7scnI69ec/l/XtlhJBwxYYJXp0Hf/PvQA0nczFh8zcjGAPypSqYGHySOgHQ/5/z2qYxvKYgync/G4jA4zx6dMemK3/Cfh/8AtPUBFqa3FtpwYedOqc2w65OR0wRntgjvigDDi065l02e+jUNBbuqSkHlC3QkdcZGM1VYqegA+gr1rU/AeqTRzWsMUgvrSP8A0fyhhNRhyQxUf39vBHJyAOeTXKfELw/YaLHpVzpd99pivojJJG4/ewSLjcr55B56H+WKAOOGM880HGeAcfWkooAe77mJwBwAMADjGPTr70+KTEbIZGVThgAuQT/+omo2IZicY+lISTyaALsccH2RZJZwA04BgVd0gQA7mzjA64A7/gKrSlN7BB8uAAW69ueOlRjHfIpy525GSRz9BQBNExMmTjy0GGYqDgZ/U/8A6uld98Mdfm8OeItPS6kljsmIleJj+7II4c+mASc445PPGPPhuZCWDY4GenHPGfw/SujsZbe20zzUkkF2f3Qd0wq55PXuDg57bs8HAoA+vvDfi06jp1pOkCO91IPKh3BSFJ4YgE9AucLnrjnJrq9Y/td9HuD4bOljVWA8o6kH8hT77Oc9R6d+gxXz18JNfs9Pnt45CjiKAw+UE+aQltuFzz6jAx6dSTXvGmXK3NxBMso2vGXMJAJJP8WfwB/D25APEfAmieLPH/xV1FPiXcyXGn+GJd01ixxbmVsiJEUcbeN2cHKr719F3dulwGdlBkc8tjv6/j6fl3qCysLW0vNQu7W2jiu79lmu5uczMqhVJJPGF4/H1NXH3EnYAOMDI/QfhQByGsaDaW1vEs160STzrFEkhwskr8KvHUnPHYnnjAFeXa58HmE6Qq1tdQLK8gLRlWQkeg6gZ4Xj/vok1W/aW8dDS/GHhTRrGY+Zo10mqXYGMrLkGNSeoITJI7hx14r36awtrmRJLcbopyJFZWwGUrkfUYOPofegD4y+KHg3+wdWRQLcRhGkbyRjA3dCvQ9f6cBcnltI0+C8uhbyukbMV/eOcDAHJJxkA5647c84r7K8ZfDPQfFcltJqcc4MWdpikIJUjGDjrwAfw9M1QtPg34RtFUizaUcPuklYshxkbW/h5578kn2oA828OWGjaRcR2+j2ccl1CBCXJIEjnoQR0bdgY99p6sav6v8A25cki2sJg6SRgOclyRnOW6HowyR1GT8qrn1zSPCGkaVffa7WzCz8AuxLbfTjoD1Ax9B1Nbn7sEMOd5GTkYK9vbtn8PbBAOS+HOnarYaSkd6kaw73b5HyRnB5Pcd8/Xu3HahwN6sSHyCVAOPp/n+VPjA+RVAAIOMg/r68+n86hZV3FsZIOHQHt/n+VAAJlZAd4HOCq9vw9Pf6n2qYHcHCckDB5PHI/wA+v64ykhuVmNxuRoRwVyc9c9frj9T1Aq3cjYoIGctyM988/lnH/wBegCZpt0LDIJBHfj/P+e1VTK6tINo3FTjByOmBx9P8etFtPKUkWVGPqeMNk9cdD0B/Dn1ptxbSJC2x/m2EY6ds9/b+eeeKAM24umcqsQMrqSwjUdT0wfYkH+XXJrlPF2i6lqWnsQ0di7KzsEcSeYgHKbiBzyfr34Az1QaO3j8toSNzBVYHo/IT3/2fUdOck1nXWotqd2I7eRm2gEYUEK4yCCffGR649BQB5Evw/uLvzVVBJbxx7I1D7FliAwWJxncvGPxJ+ZgRnxfC5p5o1uwzSxL5sTyAZuIgSxjYZwzDBGO3C8jLV7u9lIiJNBLsnOWj8s9Cf4M+hPPrznrxVS7tblbaGaEqFZgqIiLw/wB3afY5IwPTGcbqAPI7f4ewOhEOiQSWyn9xkNlUPIBK9eSeTz+GKK9hi0e+lQTDUWtZJRvkiRtqh+5GOueue/bjFFAHwLRRRQAV2un2fg2/0QPcX17YanHC7OhAZZJNw2heMYxn0654AxXFUoJU5FAHtfwi+FT69brq2oXkltZ7A8SqFG8E4556denOf9o19D+G4pdK1C4SyszBZIwX94Qok4AyFHQce3tjnPyV4L+Jup+GLMWcUEU1qA3yHjJPTPsP6nvjHceCfjQ40+W08Su8kjy7w4QFFXbhVC56Zxn8M8A0AfV9vdC5GEUdep6EGrSAYUrwT90gcfT6V554K8a2Or3YsI7mJ7pVLHy2BGMDOT2I5P6+gHoKEfJuHIGAfTH+f8igClq2j2erwJBqdvHdQgsfLnwckjBOeua8Z8X/AAWl1PT003TJI7OwhdngAQADce+OcDnj/wBmOa93zkHODgdQRTUVg6YA2hTyOpPoPagD4v1X4B+NLfUGS0sI7mAudkolUAgnAyPX9PpW74M/Z51e6vJf+EhlWytzEwQKVdi/Yen1PX0wSMfWYA2ZGNpHOMDIx/gKI1IA4A56YxQB4don7Omg21sP7T1G6vLgMOdihOBx8p9+2egA9SdW0+AnhK3LTOt3KzjDRyFSh5yDjt3/AJ+lev5AX0x2H8qi80sxCsAQeRjPXp+gz/nFAGfoGhaboVsttplrBbRrwRGoGeAP8P8A9fNabnA+QdMkkf560oX584HHtSPkkYPHBzn/AD7/AOeKAOfhluYrqdHj/dA5UgYycc//AKv8ci9PLclEaPCMWIIOPl9Pr+P6itBIkXBAJf8Avd+D/KkWMHj+IAcgcHHHGKAMO71k2ocGQSOqbimMjaOoJ74HPrj14x4/4nttQv2urjWgZrfJi89tuIgT8hVSSMZwOvI46Bq92eyhBYCFNrEMy4+8c5J+v+etea/FG0eXTha2tmbpoAF8nYNskTNhTsGBwxx7njjk0AePeH/Ad7rF/bRas15Zws5+dSpjglQk7XJ7MucHpnnkbRXHfF+00aHVbdfCK/6EQ3mBcfLMuAyj+IY4wD+BPNem+Jr2WKKCLxJLcW9vcx+Vc24fc0cowyy57Zxn0B564rzC80C9vLtolgktbO6YglwSyupO0tn5hknGPU8/MSaAOBS1ZmJcDAAbC9wT2P1/ya2vC2gnW9St7IStHJMCI5BjhwOB/Lp9OvA9C8O/CTUdWMIEVwiyAgyOcJDIDyAfc98YyOwHP0Z4L8BaX4ctI2W0X7U2POZtp2SA5yvHy/8A189TQB5r4B+ETW1sv/CQoDaSqVntJFTdBMCDuBHBUkDp+HAIPoFz4e037WBZwI99bRhb23Jwtxb4PUHgkc4Pr9QK7O7d1EjlASgxLHtAMi/Tuf8AD2zXK67LfGZbLRAqTFftFldyEOk4GGeF89Oxwemc9cUAY+o7BDZ6bpuoGGCEh9Iu2AbyXB4gbPOM5HB6cDvXgvx6sNPxYarbRyW2p3k0n2+0fnZKMfMDxw3J469eOBX0laaDYywXvmr5tnqLf8TCGRyTBP8A3ox/B1xx6D615f8AtVpFF4J0KKaIPei+bbPjczRCI8lupJwCc9cZ6YoA+Xj0A49aVSd2VOGz24pxBViSQM9wfUUwDNACuSdpOOnagkgbT2PSkII6gijtigBQSFI7HrQMFTxz9aB1+6Dx059Ov9aVAxOE5Yj8aAFBMZU8EZ3DIB/StzRNTD6nHLezCPMoJY453HDEk5A474/XFYPJUnGRkc+nt/n0qWEv5qAbVY8ZyF/X+v40AevWEq2+sSXsVpBGbvMVssUYwF4RCASeT8oAHOMjPUj1Sw1g2N7ps8kTW2pSSMkyyjG1Vyu0D0LDORx3+6MHz34Z30mjaTplzqFrBcwXDNIgiUFgsfyIAp/22xxjJOBjJNdD4usX1SdVE0krriISxkYJVfMbr/tKPbKdsDIB7LpPiqzubsxRyB8BlV1zkEdR6/xfr68DpBJh05HGAcjIzn2/L6V87aDo9xBp9olpmIyyKZZGmbcr7jL977wzkHn+9/ebjvtP8VyW0tta3RMzmJNzFGY5Yn5Rjo3b9OxNAHU3/gDwjqA1F7zw/ZXU2ou7XNzMhedmfGSHzlcYyMYAxkYrf0myg03TLHT4Gd4bWFLaNpDlgiKFXJ78Bcn+uawtM1Ka8gM0KmMP86ZGOCQc8/nz9T2rYiJXAlO2TJyuO5PPHfrj8e5oA0Hf5gNy4z68df8A63/6hVe4kS2spGZmKLuY5ycD+f8Akd8Vz/iLxVb6LahJHBkcfKqrkkZx0HBPH6dwK8c8SfE7V76/uLG1tCLaQlI5IdxI+bhv9k4w3fg55+UUAewL4mtp5VMbCSJgFVvmOckKOPqcf5JDdB1a8uSXurV41aUiJWJ+6Plyc8dR9MYJ4AzxHw30bUUitp9Qa5ju0KrLC27qjt8oP0JGB2OB1avTre1iILs7HOQGPTqMAEcdu3XHpQBoebGzQoSVJzhcnpjrnrS2wDKWBPy8HPc57/5/TmoPKiQAxgl84A3HB54Hv1z/ACqZTtXbwVUj3OPX+n+TQBJwGVsHAJ756f5706cDf88jBcEcen9Ov1/Wo1lU7mwfl7lvf+X5c/hUiMybmXgZP3m6n/J/zmgCTkNkEjA6DGPb/P8AhVWQ+YdhICjBYEjnPqT34/ycCpkmVmOSwPoM9e+ex54/CqV1eLvCMAJG+4Mjp1J+o/rn0oAbexRhBHMMpgod2DuzwD9Qf5+tYciIvmG3ClmbY7qQCj54J6Dk9fw6DruyQllYSEsCCkhPbPsfTpx0qC106C3iaONSyMu078MWJHLE/wD6+ncCgCnpwluLJfOYB1IV2XAw47jPqD9e/XFaUVqkM8jJxHISWX+HPAP1zx/nJqy0aQptj5YNuLY+93B/XP4/hTXIVQJUwGOCAB34H88fp60AQSxhnyqj6kkZ96Kjur+CCXy55BGQBjeCCwxweBRQB+dNFFFABRRRQAUUUUAeifBzxNbeGNba81K+ENp8qNHsLsRycr6c9+xOeoAP1n4G8caf4mtIJLMyFNgZmfGcEe3oMD6nHXNfBSNtbIAP1Ga9m+C3xBtdG8y01k5tooZDHlMrxHjkj68flyTmgD6+e7REDsyBGOC4+7j2I/yajOqRxorFW2sRyegz7/5Ofc4r568R/Euwhhc6Pc+bKWUM3mgIAY8sRkkZ4wM9x/dGT5to3xZ8R6RdwXM1w9xaCRWMb5w3B5yckdQfU5yetAH1D4k+JOk6QJMBpZECuQCFBBOAFJ4Y8Hjjv0xzlwfFvSJtOhmedIfNQMhLg/Kc8jjt+fTPJFfImv8Ai7V9fvJWv5FVHAVoY02rkZHTrnn+nSuu+F3hmfVpBN9qmge3EdzGix7hKwbJyCOmOcjjqeeKAPqnwRrWoeIxcyXVu1taxMBHvTBkHTO09BjGffjjmuzwAxJySMd+Py7Vxng3QbvTrK3E1y5wWwjrj6AL/CMduevcE12Sk7m25badpBxwfb8P84oAVyQyjO1iTg4yOKRTlRtYN/e79+/+f0FIr7plAGW25J9P8Ov61IVXachVHqKAGnAHyn7zAbh/U0qZ3YYYIz1AH41Sm3RPnaxQHGQOce3qO/r/ACpbOaNFVATu6fNwc5wBj+goAuMcHjg9QR16VkXljJJepISBbKpRk28kMRjj2P8Ah0zWkZB5zIRljgkDkMP89/r9KftypUHnoD7Hp9aAOJv/AApa3t0q3QhuZNnkSmRN4C5JRz9D39geQBWqnhbTpI3OpWttdTtGsEkjx53BPuP9RW/FGqA7gpYfKSecjPGfTp+B9KeWCDuSMLn/ABxQBXgtYoYtibACcE9s9vxz+nsKguY3gZZRk24/dzKvAxjIYH2/lVp2QKC+PlYZ559Rjt14/OobiTEyyKGZ4s7kXkOjc59/X/A4oArag/kRiTKs0fziMYzLHnsO+PQf41jsbeK8JgCC2vcG1bOQky5I+h5PPpz6CrUxlimktIwslywaazLJ8pU9U+vUcY9OKpzxf6TJEwkFjertaUEf6NLnPA7Akde2Oe1AEsG66upLm5iCtCDBfWhIbfnBDj6dsfQd68P/AGqoruHQtC87bJY/apGtpoznaCmdjH17j1H0r6EsIyVVnybiJdjsRxKvI/E//q6nNeJftagt4P8ADyni2bUXYKoG7mM9+nr/AJFAHys6AcKwYDuB6/5//VTTjLFsbs9B0/SnOQRnaMcgY7/5zTACeMdOelACgbzgN0GRuOPfH86TsM4xmk5NLkBSpX5s9fSgBUJUnAXnj5gO4xSDp2qW1ERkJnDFApOF7nHT2+vOPQ1v22h2l8trHYyt9o8iNZVkYAvcyPhUQdSoBUnGSOT6CgDnF5IC7ck9/wD6/FXtOleOdbh1jkCgsA+MFsEDPv8A/r966dPBd695LCrAkagNKRcDc8iA+YeOAFwfXOccjNPTwlcaqs2oWEW2zaK5vY4lxvW3gOM56ZbPp2JHHFAGnpF7pOtT2lrc3Bs0ijhgQuMbEjBaQgZ/ixjAOc8c7iavHUoovD876FrVyGt7VppMpkySvKQqgHn7gHTtycqvPNQeBdVSwkuLyynVikEcKIp3edM2Iwwx6EcDnkdycULuz1TT9Ge1ezws8jSO8XJxESp3Y6KCr+xK8HA5AOutPEevG0ilnnnijKTXfmK23cEARXyPmBHPYkZB5yMdN4C8T79dCSLJHawM2ZGPzOY0/wBnucDg+u0ZG6vH7Oy1K7WSO1WaXcqxYO47gzb1C9+xbke/UiptKnvIHlnZJSZoZG3guN5Y7Q2QP73Hv93g5NAH0r/wmFyrmHTSPto8kbVbBClWORjPGc/gN3QAVHofjvULn/kIxymLKRNOTtLcn+H14yAOcnj5jivNfDMuuX2tNdJYrDJJLOzxtG0bbViyee5OM46E9cADPTXyvp0z2jFJopDbsfvYDFGJwvX+LPHIzg/Mc0Ab2oWupa/faNLbH7RZS5E28eZwZSOFyP7oGc46gcDn1DTPDFjbqge0iklVmUyEks3XnJ9OefUZ64FeaQam+kaNp9/Zxbbe4tBvilycbZNgwg5B/hI9cA8AtXr2j6nFqdrHc28yyxSSSKME/NgZOCegAxyfr0xQBcliIfCDcyH06f5/mcdTUcjThhlQvI75znI/nj+vSrCsTuUt028nuP8AJ/WopWKhmLOF45x07/Tsf/1CgCMqfLkR5R8oXoTng44/x/xFTAGKORiGbG4AHqp6gf5+nTNQPdIsixKwBL7Qx5Gcbh+hzx/9asrUdVWC1mkibzNsQuFBY/wNtYY6nnj9PWgC9NqMMU8IEqbVUSEs3qcDOfzyewz0qxbXAmcxjh43MfJJzxwePY4P/wBevNI/ERNwBrMccEEV20KkSh/OjlHmQvke4P4pnoAD0Fhr0babDI0mbqVGiC78M00bHBOPUc+vOPvGgDr5Ll2LmMliuSpU9SDyAO5/+v2FRQxs025zuVRlNp6Ajn/9f0PtXGz+O7HDLAGaUoJ9mOdpO119CQQR2yRjjBrXsvEUTJcRbWk+z/vFcnaJYGOQy598/lk4yKAOidgnlvKzmIK3G7ccHue/Hb06dc0wXScxMwIzt3D5hg9wRwOeh78+lY0V/I7XCujNbRsEdzjG1gcN68Z59MgHk5p8VyLYSmYmaeD93MnDExn7rAD6Y/DHQE0AbMrBFKysDIi4kLHpkdcn+f41EHj3NDgMypnbsz8nTP8Anvx3rPvJboEylgi2hBfcMmeI8k+2AM/qeMVBDPJ532dIiWgxLHI6bVeMgjaMHORnoMnBHrQBdIiQkTB5CSSrb25HbtRU0aeXGmWd1YBlIcKQPQ/TpRQB+ddFFFABS0laeix3FxqEUNqoXz/3T/LkFRgt1PoMnBHp3oAoTwy28rRTxvFKv3kdSpH1BpqgHOTjjIrr/E13pesaPb3sc6nXbm4uLm983jZGMLEgboTgHgAk9TisG0a1k02ZLzKurIsLqmSoLZcnkE8dM8demc0AUhbz/ZzP5MnkbvLMm35Q2M4z64GcUyON3+4pOTtHufSvWNNuPBF3YaZZwXctrL5l3cO0seWWQ7VhBJ4PGTjvxkjHPq2g/BXwwksU9vczSz211bqSyhuUTLA44+bIP4diRQB802um3M2nSvbwSb4WcvIqE7VVc4BH48n8OAam0bwnruqvbLYafcss8myKQrtVn2FgMn2GR/8AXr6r8F+CNC0kausUy3Ul3FJ5qFAyANL0AB2kZ4/8d7E13Vt4f063nRbeFYmhmaRdoBAYRkdDxyD1HORz2oA+XPgv8Notd1Sa51kFIbKSP5Gyp37jwR36Y4+nXIr6u8O6BY6RpsEFjDF5cabAwx03E9evU1wll4Rg0zxFLLBcR26FbZngVflkYFuTk5OSe3rg9Sa9AshCsJSKTK7pCSPmBwSSPf6+3tmgDUwGdS/3fulSMk/1/wAaVFQMpUk7eCO/+e9RIFALZypK7eozxx/k/wBaWaURQhpCOFLZJ6YGef8APfHQZoAnd1Vgcqd2SCPp3qrcahDbhmmc/JtBbAwN3HXpXN634pTSl8+dALQyxIW5yVfjIHpkj8OvUV5pf/Ea0vLFoGYB/wDSLSeJo8lpo/mUBehPA6np8vPJoA9jv7ws4gj3gvuiLE42sOc5/wA9fpXP6j4j03SyDdXO6a4jFwAgyRtID4Hf6de3XNfP2qeMfFurWz3EGqNbRtbJqyrH8pdo8qyq2MEY6n2J6AV5fq+vapdSJ52os21jOsiOVKCTBYDGcYz0HIDEdzQB9rxeL9KJke2uEZLV4zI7HgxOcB/pnv09eMGt+PW7A28k3noY42COeQFz0OOuOeh/qDXyp8IoY3htZda1bda6jL/Y1xHM4YxBxuRkHpxj0zzyBivoPwxLaTaZbrNsOx/7OnZhgtIM7GYdcn5Tn3yPvYAB2iT7wu3LLvKNjoOTgn8qha7jPm5BBjYJLyQEB6E+n17fjXLv4htoYvstywhl+0tp0yjkxy87Tn3x3/kCK5+/8WX1kYrnVYWh0pC9jq0qkF43JHkuQOowevGPve1AHoZmjhaUuihozsuCePlPAJHToev/AOupoiEd0jfMsC7kIH34z79/8n0rzS8j8RzyrOSIJ7b/AEe5Hl8zW8n+rk2jjcvoO3A716FpdpNbWNrbSSiSW2ACS45ZM9D2zjrjjjIoAmks1KNHEV3bvNhYrwp/uj29v/r1IIlZ3Z/kyMupIO3nGfrn/JFWBGiApCdrPucEc4J6nHvVe4kiSXzyB5T4jf5eh6D8eo/XtQBGquq7WIMsXIyByvsPx/zmvD/2tpc+DvD0cY8xZr93BAPBWMjgjgdeh7jjIzXuznEofYrSoCy4HLDp1r55/a0MsmheH5LKbdaSXMpMa8FZAnOPwzn/APXkA+ZCmdoH3jluRjj/ADmkeOQtypyTgDGP0pHY7jz6qAcHA/l+P40j8k87vegAC8EtnGMjHP8AnmgKAMsSDnGKTI24/Hp3pWCDcNxYg8EDg0ADuWfcfYDPoOlTWsksTtdRuUkjIKyAncHzkEEd+Cc+3rioBg56DjvU1lK8U6lDwpEhXON23n+lAHU+H5LmwW5vDEXcj7IhkJc/aZfvHGcbguc9DwB1ya9o8JafFZaUNJM0bS6hcQaJBcQAACJAWuHGeCNwxu+pPAXPiul+KWsrnT/7QtUlhtbiXUGjI/4+JnQbGfnBAOPoCR3NdXo/xGiis7S3MGZ7PTLiG3YBiJb24k3M7DoCASoPsOoGKAPa21Cytbq0uHlUw/6Tqsm/IURouyFgG+6MjA9fZmzXNX+i6Brt89mt2VuI7KCyCCXD+bcyB3GB1O04x0+gBNeaeKtc0+/Waa2v54Xt4bXRLdXBXzYlBM7MDkr8xHqc5PfjE8MeKbe18U2+rajLdTyRXb3Tkk4ZVjIjGAeoIxjoBxnGaAPbNM0XR/D9ndanb4Lpd3ckLBuRFDGycOcnHbLdOT3Wq3hy20+2fTYzFALa5h061LK+4EsxYqF98DI9gOeTXD67rsVp4eiSC5EdzHo4YyF2LyNdTh2G4cEhT1wOVyM4ArB0W7v38TC08M3DpaPdbbad84UQx43A+uOR3G7jljQB9L6RdWEt4LuDA8xbt2eY87dwQkdscD3+qitZLSwkv0MUNuGWWMEnoSsWQMcnofr35JGPmnw/e+KLyzjs49ssCWfmuTlvlec4bH8ZzkYBAIx0Ar3DQrny9ZuAZ5kP9qCL5gQPktx0HXGOeOc5brgUAbGs6Rp9zo+54Vf7PaOIgrHAw+D8o5J5/oM81q2l7FFIlrZCLbHM6gRsG2Fk3Yz36Z/EnoAK8g+KXieLTtC0hYHdln0+5XzUJIDrKAOnQZ/TK9STWn8MPF667pRvryNIJ4tXiQqjk5DoApY9yeeTgHAJ4UZAPYluz8rFishgRwpbIGDg9O3Xnr+NLeTJlwZWUh2jbODyw+UAdDnj0/Q1nWjpcWsABdCYZkdmG1l2se/uec9x15Iwy+Uq8l08kkyI9vcbV6cgA/L09OO/A7ZoA4fxd4sl0dttqUmufIhvtnODtJD59Pw6cnqVriJ/G5TU7MrAseJ5bO4W4bcsMM4GxsDkkE9PQBThsmuk8ez6Vp0Vq1wbiYR3VxpszJjeolXerKe3OOegIycgCvnrxBq8mqNDIIJIGFqkczbm+eWPIMgyPlONuQPcZ5JAB6DJrzyTPLqeo2guLi0e1VwwJWWCQhfoSF4YgDJz0Ay638QXl9dXNzY3R09Et11iJWlXcGAxKM854LYB55yeSMeXPCv2e4uJrmLzF2OkaFS8gY/OQfbBGP5gVEk0MF07W8k6W6MI2bozRMTnoDg4xz+PcCgD3zS59F8P6jf/AGu9Wa3t3W4gDvy9rOMPx0OCRwD7dNxrXsfEsUWpQ7zA9lpk7WUgjkBL20nIkIPOAT29C3K7a+eL2S9kS3tJi37ktHHIBzsbkfL2AGOAeM46k1r6PpmspZXV0ts4RmGnXMkgDtFkjB2nGAOMH154AAoA+oT4gt7dLX7SAqWzfZLyJTuBjcfupRjnuPftyTWlYoZY5/tSonllrK42cSeTn925I9sZPrwOAa8E8LyalrF5FBe30cn7xtNubiNS2NoxEzOOSehGeAck/MQK9z8K2N81s39peWt3GGsLtXUZZYwAknHBJPOBxzt45NAEPijXdL0ZpYr/AFm2ivrMbmt5ZVWSeAjqM8HGCc+2cdAZvCXibS9RuP7L0jVYL6a2/fW7QxPseIrnaXI27guc4PTGcMcVoz+GtGupbe41fTLHUdQ03Eby3dsrsV6hueM47+o54FbMfk2dtDZw+TFHbjMESKEQxgcBQOn8/rnNAFyN2Vf3BjMZ5APUex460VUW4acebaEPC/zDIGR6j257dulFAH510UUUAKCQQQcEd6UsSMEnGc4zTaKAClIwByOaSigB0bNG6uvDKQQcZ5r1bwt8SNQ06+ttR1e6M8c63cnlxSBT5pQLHkdFwemcn5s88Y8pZslto2qTnaD0o2tgkDIAySOcUAe5+FvjLHY6aLFdIVQWgh89FAXAfJynIyRkjntj1r0/Rvipba9qssWnsIGH2iYl2ByoUlM8+gyD6c8gYr5m0OxhvIrXTIUWSW61OOLzGBBZMcjaDnGT/hg16fb+EtF0+w0W9t5LTzpNO1O783cP3oRiinBOMD5vy46cgDNc8RR6vLq9pbzrJLLa2UcNzCWYq7Pwu3OQfmxxzj6nHrXwytNYsYTZatewzx2slxbqUDEnCllYnPcjPtjjgGvj1LuRL63khWKJlEYHlsQOMcnBznucc556819LfCjxFJfXSW0+oMt62tSpIsh3EhoxzkDoT2PT25JAPcIbo/YIJFPymGOQk8jggdevJPUeue+KkubrLqjofnuWi3kYOHU449cgj3x9RWV4bma80PTSUZ0NrLzz8zKxxnPPbPP16kVo3hj/AH8ssgzEsFznkdtvPtnj/wCvk0AfPnxw1i+fSNOhib7PbzwyhlkXB3wuCp46HuOnXd6CvFvtVqiTKlpdO8skNzbBdwXqVfIGM5JKgj6cHNe7fF/QGa4vLi3uXhng15LSNGwRtuFGTzweec9+rfw14BeXc9ndyW10qO1tE+nhu+3kZwfTPtjvzzQBVv8AWrqe1t7MSn7Ja7xbqTzGrnLL75PP16Yqpp0Ec97HFdSNFDnDuEL7B9Bz1I496qk9hxxj61o6Rp8up3gtrOGWW5dWeJIQWOQM4x6DBoA6bRVt2jitrTTriSa/jNjNK+Tsug25WXPQ8Kce3Xg52/A58T+I/EIjuNSnt01QMftMxYJ9ohHykkfx5wMnn5s9cU7RNH8ZazcJeWYkt3vom1m0xHlZpITtbZ6E459uDkAmu21DS5dIdbX7Qfst9DD4ksDuIAuYjumjyepxk5PHQ8gLQB6D4Y0ZTcQySKJW1q3WG4BVsRXsTFWbcfoR68BeuTXcS6Fa3kso1EK8V7F5F4SOHkXpIV6Z55z1zz0FUNEuLC+tgdEdootUgGq2ZDEZmO0vg926f/X5resNWs9SSB4JIyNSUvGrHaQ6HBGD3HOR7emKAObstI8cqyfate8PWyRA2cjQ6ZJJLJGDhWw7YyARx6e5rqtJs7nTrBLK91KXUZ4CWSeVArsnXawHBx6/4Co47zH2W6kWQKxa2uVZSPKYH7xB5HUY9jVbUdQe2W6RSs2paa3mGEZ3zQ5GSfw/l6A0AbLTq7GPojjIc87W7qe4/wDr1WvXRI2kkj3xuPJnUdE7En2/njHasjVNWQSR2qkLZ38SzWF1uOEmA3bCRyM8EYyTz7CvP/GXxl0HR7GF7hIrjUZmksdS0uJiHgdeS3Ybd3HXPbs2AD0C+8QWWjyz2eo3cFtPbRm5tpZnC/aIlGWwSeSAf5E54r5T+OfjrTvFOssvh2S4GmB0uGimj2AXBUq5Cn1G0H/d79a5bx1441bxn9lTVrsz29lvW0RlVWjVm6EjqcCuUZ96EMEyWznGCPb0x/kUAIIyVOFbd1AA7YyT+A/nUqzDakfloFVy5GPvHjgn0A6fU+tRuwaYnGcnoTx+f/6qWN9ypGCEHJJPIz60ALEI/PVpdzQZ+baNpxzx6A+nUVG2MehPbHQdqFjZs7RnAJOOwHNNwM8HAP6UAKFJUtj5Rxn3q5plrFeXUMEtzHarI2Glf7qADOT7VUCZU8/MCOMUhIJOBj05oAmitpZpUjtkeUyEhFA5fHt6+1L5cmUlkRzvPmfd4ZQeT9M5Gfr6U+CfZbzsR85QRIQ+3bnqdo65Ax+Prirs18s8D+WVhlMcVosYOQUxljk9PmA79D+NAGUWYhQ25lXkgnjk/p2pMY4OCOCcc4FPuxi5kG4PhiMgk5xxnJ5/Ooj7UAOV3AYBiMgZ9wO1aeh63d6Ldx3VplZVjkjVjk/eGD1479sfnzWXyp7cVPaSiJZxt3NJGUHOOpFAHVeHfGN5pdnJZR423EcEO8cAKku7v6jgn0GOnNd3ZfEaS1kimmljM6+ILi8kizvzGYiFO49gTnP4ntXk0UYNrdtPuSdDFH8wzjkevIxjtz2HGaSGaOO/jPkjIcsQ7Z3DHBBHQ8k56ZwemBQB0ni/xHNq2j6AZx+8gjuMnI2uGk4GAeOOCPTHJya6r4c6ktto2pEXscAt7ywuCSy8qHOf95gATg56Y5Uc+VXU80ttZpKwxGhWPIGQuc9euOvH17k1qaNJEbXVRMNoEQlQhsBmEi4yB1wCcYwMjsM5APrqw1Rpb6zhiyIE1u5tCwYAYaDcox3BLdT0znuALFzqMAS2sxcoBPpk21ABu3wuAFC9+MjHUYx615hpbpZaheEzFbWy8Q2dyskrBcJIgXcQerYOQfU5+8VFaV3fQWlvbFWy1rrd3pz7gMKJ4ztLAcnkjgevY7jQBU+KGvWt1pOok+bHI1rYaxaEMrM0h35Y4+7wAeM/3ugArwLWfMS+mt3mMiqS8YQAAbsHgjt2/wDrk13E6yeIm0fTZLyM3PkT6dOz4bcIm3IMnhTz1zjgZ4Azx+qaUIdN0q6id3W8snmcPjCOjMrD9AfXn1OaAMUAllLIzbxjKjGck9PX/Ee1W7WOd7VmiJ8u4/dEkKoYgZ2nJxwcEH8eoFC3UUUTRwhi00cbbpMHa4xk8+vP4YB7mo4ryQCRUlcBpVnC/Kclc8nOcHue3fnigDufAugafe39jb6k8i/2nb3Fr+8JzHdIQwDcjrkDHXt1Oa9PsBZ66ltbTNCYPEGntZS+a6yFL6HIB+XlflAOO+AOi5Pg41h1tbiztyI4Hkju4zkr5Mqj5iMcg9QDk/mamj1K70uV5Iygnk2XttIqjIffnIA6Z59+APu9QD3L4cWFnpL2UFtDLHZ6/HNDOrnzBBe2/wAysHx8oIyRnnDZOcivT7K6J1O3ubyeMQ3rnTbsKMBLhDhWx2zkjB9l55rxXwz4il1WHWtPikt4Ly+jj1nTVQtuNxFncgx0yFJI9y3oK72DUW1yK3MttBDB4nsQyrGpUwahGmXwB6nGAOeMD5iaAO80CD+z7fM8013OZvIvpJTy2R8j49NuOf8AZPYVZv5WihuY2gWa703FxDGWxvjOOnceme2c9cCuD0T4g6dPY6fc+Kbqysbu8kk03U0ll+aKVeA5Xpg88jjpjABrzTxZ8arkLbR6KYGv9Knkt01EszC8t8FRkHByQc8jGRu67aAPoK51VLAo1kQba6QXEYCr8ueCOemCCMdulFfFM3jLXlkIj1a7jQ/MEjlyi55wvoPb8+c0UAcxRRRQAUUUUAFFFFABUiSMkciqeJBhvpkH+YoooAng1C7gnSaGeRJEk81cHgN64/T6Uya7nlihjeRjHCpVFzwASScD3zRRQBAevTFem/BXUILPxhod7das6XA1WFWhYE5jZSruT+IU+vA6ZwUUAfTnw88Qade2tjBBe28jtPfxcvktt3NkHuMDP68jFabXwv4Fa0wy3Olu6lX+80TY5PrjoffHc0UUAcX48sk1Sy1ySWHe82n2msRRsdrM8X3hjpkdSO+PQYryv4naD4c0/VvEc4jghmR7HUbaAS/u3ilI8wBAPTJPOefU4BRQB5rrsujHxRe3GnW5m0pLtZEUZAEJHI9ue3IHAGRXoOi32i+FLKe+tJNmt6DrCTWhaRiGs5wAwHGeFJO4Z9e4FFFAGB4i8S6lYzPYaTqDjTdBvXl09oRh4rebIKh1PK4YDB9fcik07VLjS7u0mvHe6XSJkvIFdt7TWspBkCno3duwByc8YoooA9I0jx1Ha6HqmmeHUkVtLuBrWkxuS5a1dwWj7jgMeBzg8fNkV3fgx4LvVr6EERRa2i6xo7eYMb1XEq+xLYyBxx2xyUUAdDqGqWk89odUuktdJ12I2LDzdvk3kZJ+9wUJ5x09epFedeIPi9p/hiHTt8v9oeKNGnawu4AAUuocnDeYMg4G38Rj1NFFAHh3iL4ma/rNtLYPdGLTFvXvbeGPKtCxcuFVx82ATkdPXrjHFyO8kpZgWlbO5myzMTnJOe/P+TRRQA3JWPGcbhjA78/5/KmnjnA4PSiigBzEEKoPyjPbn60bl3OZPnJzg5PX1oooAlMwELrtDyEKBJz8q+nP4D6DFWVminhnkuQGkKiOFckfNx8xPA4AP4nmiigB15awxvO9q7yW0CrGZl/jkK8/hnI+gHrVB1KEo55Tqp4weBj6/wCFFFACuVwuNq5O4gZ4z0H0H9e9RqM54yByaKKADoRg8+opzQyKWBjfKqGb5TwDjBPtyPzFFFACMjKSCOmOnI5q/ZwEgiSQYRk6NwuST1/Xj1PfiiigDaW2F14sazmeE28t+IizfMo6joOSBnp+A71S022CXkN1dQyy2jyzRho2BaTC9R+fXp9MUUUAZs8a/ZrVvM35ibI6bMMeM/rj396veGNPu9Ql1BLGRYmhsJ55GZtoMarlh+IyMe/pk0UUAempqF4dH8VQSyi6nuNIsLwtGgAPlyxndjrwOSfYnkba0/GRtLZPFRWZpAmqaZqcQKZRVZNpJ9gGxnnhgO5IKKAOf8RrHptzqy2qr5Gla556mJgDHFMm3OfT5V+XkHHdRzx2uKbLUTYXO4fYrqRA8bb1ELAEBT3GMn6Nz1GCigDBbcHkcA7VfZ86Y9cAj6dvwqSCCRMS+UzKsixyZB2DI+XLZ74JHbiiigCWd1t4YY1j33FrKwdt2VK54x3x154xn1NAt1+wsJJomMMo+ReWZD/Ep784GP5YNFFAFvRvEF1pM1vPZzGO6tJ/NhYckg/fBb06dsdT6Vb1bxbqc4ubOKV7fTRfPqENvGSRDKScFT1GAxGPfnnmiigDE1G9uNRvZrm6uDPPOxlcsCAWI/8ArAf/AFhVUn+IDkc4POTRRQA+KIMCfLLc/wAIJA9utFFFAH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four-chamber view (panel A) of a patient with an atrial septal defect shows mild right ventricular (RV) enlargement and the RV and left ventricle (LV) share the cardiac apex. Contrast injection by intravenous injection of agitated saline (panel B) reveals a strong jet of unopacified or washout of contrast by the jet of blood passing from the left (LA) to right atrium (RA) (arrows) consistent with a moderate size left-to-right shunt at atrial level. A scintigraphic shunt study demonstrated a moderate sized atrial defect (&gt;2:1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24498=[""].join("\n");
var outline_f23_59_24498=null;
var title_f23_59_24499="Osteoblastoma sites";
var content_f23_59_24499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skeletal distribution of osteoblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 605px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24499=[""].join("\n");
var outline_f23_59_24499=null;
var title_f23_59_24500="Gifted writing sample 1";
var content_f23_59_24500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Writing sample of gifted child at age 5 years, 0 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    I like to play with Dermot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24500=[""].join("\n");
var outline_f23_59_24500=null;
var title_f23_59_24501="Dorsal hand anatomy";
var content_f23_59_24501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal hand anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The path of dorsal arteries (red) and nerves (green) to the fingers is shown. Each digit is innervated by four digital nerves; the palmar arteries and nerves are not shown in this figure. In order to achieve a complete anesthetic effect, it is necessary to block all four nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24501=[""].join("\n");
var outline_f23_59_24501=null;
var title_f23_59_24502="Vitamin A: Drug information";
var content_f23_59_24502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin A: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/34/11812?source=see_link\">",
"    see \"Vitamin A: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/11/26805?source=see_link\">",
"    see \"Vitamin A: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-25 [OTC];",
"     </li>",
"     <li>",
"      A-Natural [OTC];",
"     </li>",
"     <li>",
"      A-Natural-25 [OTC];",
"     </li>",
"     <li>",
"      Aquasol A&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Fat Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for vitamin A",
"     </b>",
"     (presented as retinol activity equivalent [RAE]) (IOM, 2000): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended dietary allowance (RDA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males: 900 mcg/day (3000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females: 700 mcg/day (2330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females &ge;19 years: 770 mcg/day (2560 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactating females &ge;19 years: 1300 mcg/day (4330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Deficiency (manufacturer recommendation):",
"     </b>",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     I.M. route is indicated when oral administration is not feasible or when absorption is insufficient (malabsorption syndrome): 100,000 units/day for 3 days, followed by 50,000 units/day for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Follow-up therapy with an oral therapeutic multivitamin (containing additional vitamin A) is recommended: Oral: 10,000-20,000 units/day for 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      High-dose supplementation in patients at high risk for deficiency  (unlabeled dose)",
"     </b>",
"     (eg, persons living in developing areas of the world where deficiency is a public health problem, especially persons with severe infectious disease or malnutrition): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 200,000 units/dose every 6 months (WHO, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnant females: Maximum 10,000 units daily or 25,000 units once weekly. Administer for a minimum of 12 weeks during pregnancy or until delivery (WHO, 2008; WHO, 2011c)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postpartum females: 200,000 units at delivery or within 8 weeks of delivery (WHO, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of xerophthalmia (unlabeled use):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults (except females of reproductive age): 200,000 units once daily for 2 days; repeat with single dose after 2 weeks (WHO, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females of reproductive age (WHO, 1997; WHO, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With night blindness or Bitot&rsquo;s spots (less severe xerophthalmia): 5000-10,000 units daily (maximum 10,000 units/day) or &le;25,000 units once weekly for &ge;4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe xerophthalmia: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/11/26805?source=see_link\">",
"      see \"Vitamin A: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for vitamin A",
"     </b>",
"     (presented as retinol activity equivalent [RAE]) (IOM, 2000): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adequate intake (AI):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-6 months: 400 mcg/day (1330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-12 months: 500 mcg/day (1670 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recommended dietary allowance (RDA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 300 mcg/day (1000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 400 mcg/day (1330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 600 mcg/day (2000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Males &gt;13 years: 900 mcg/day (3000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Females &gt;13 years: 700 mcg/day (2330 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pregnant females 14-18 years: 750 mcg/day (2500 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lactating females 14-18 years: 1200 mcg/day (4000 units/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Deficiency (manufacturer recommendation):",
"     </b>",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     I.M. route is indicated when oral administration is not feasible or when absorption is insufficient (malabsorption syndrome):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 7500-15,000 units/day for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-8 years: 17,500-35,000 units/day for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;8 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Follow-up therapy with an oral therapeutic multivitamin (containing additional vitamin A) is recommended: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low Birth Weight Infants: Additional vitamin A is recommended; however, no dosage amount has been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &le;8 years: 5000-10,000 units/day for 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;8 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      High-dose supplementation in patients at high risk for deficiency  (unlabeled dose)",
"     </b>",
"     (eg, persons living in developing areas of the world where deficiency is a public health problem, especially persons with severe infectious disease or malnutrition): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;6 months: Not recommended (WHO, 2011a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6-12 months: 100,000 units/dose; repeat every 4-6 months, but do not readminister within 30 days of previous dose (WHO, 1997; WHO, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;1 year: 200,000 units/dose; repeat every 4-6 months, but do not readminister within 30 days of previous dose (WHO, 1997; WHO, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of measles (unlabeled use)",
"     </b>",
"     (WHO, 2004; WHO, 2010): Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Repeat with single dose in 2-4 weeks if severe malnutrition exists or ophthalmic evidence of a vitamin deficiency is present:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;6 months: 50,000 units once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6-11 months: 100,000 units once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;11 months to 5 years: 200,000 units once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of xerophthalmia (unlabeled use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;6 months: 50,000 units once daily for 2 days; repeat with single dose after 2 weeks (WHO,  2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 6-12 months: 100,000 units once daily for 2 days; repeat with single dose after 2 weeks (WHO,  2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;1 year (except females of reproductive age): 200,000 units once daily for 2 days; repeat with single dose after 2 weeks (WHO, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females of reproductive age: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-25: 25,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 10,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Natural: 10,000 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Natural-25: 25,000 units [contains soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquasol A&reg;: 50,000 units/mL (2 mL) [contains polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10,000 units, 15,000 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. administration is contraindicated.",
"     </b>",
"     May be administered orally or I.M.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of vitamin A deficiency; parenteral (I.M.) route is indicated when oral administration is not feasible or when absorption is insufficient (malabsorption syndrome); dietary supplement (OTC)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14315218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of xerophthalmia caused by vitamin A deficiency; supplement to prevent complications in children with measles in certain settings",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aquasol&reg; may be confused with Anusol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Miscellaneous: Allergic reactions (rare), anaphylactic shock (following I.V. administration)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to vitamin A or any component of the formulation; hypervitaminosis A; pregnancy (dose exceeding RDA); intravenous administration of Aquasol A&reg;",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral vitamin A: In low birth weight infants, polysorbates have been associated with thrombocytopenia, renal dysfunction, hepatomegaly, cholestasis, ascites, hypotension, and metabolic acidosis (E-Ferol syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Evaluate other sources of vitamin A while receiving this product; patients receiving &gt;25,000 units/day should be closely monitored for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamins (Fat Soluble). Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May enhance the adverse/toxic effect of Vitamin A.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoid-like Compounds: Vitamin A may enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14315239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive ethanol intake depletes the liver of vitamin A and may enhance vitamin A toxicity (IOM,  2000)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. In humans, the critical period of exposure is the first trimester of pregnancy. Excess vitamin A during pregnancy may cause craniofacial malformations, as well as CNS, heart, and thymus abnormalities. Maternal vitamin A deficiency also causes adverse effects in the fetus, and vitamin A requirements are increased in pregnant women (IOM, 2000). The manufacturer notes that the safety of doses &gt;6000 units/day in pregnant women has not been established and doses greater than the RDA are contraindicated in pregnant women or those who may become pregnant. High doses are used in some areas of the world for supplementation where deficiency is a public health problem (eg, to prevent night blindness); however, single doses &gt;25,000 units should be avoided within 60 days of conception. High-dose supplementation is otherwise not recommended as part of routine antenatal care (WHO, 2011c).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible at normal daily doses (RDA)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14315219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin A requirements are increased in breast-feeding women (IOM, 2000). High-dose supplementation (eg, doses higher than the RDA) is not recommended in otherwise healthy women who receive adequate nutrition (WHO, 2011b)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F14315240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dairy products, fish, and liver are common dietary sources of vitamin A; broccoli, cantaloupe, carrots, peas, spinach, and squash are sources of beta-carotene (which is converted to vitamin A) (IOM, 2000)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vitamin A Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 unit (100): $2.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (100): $3.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25000 unit (100): $5.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Aloe Grande External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000-1500 units/g (120 g): $16.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Gordons-Vite A External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (120 g): $14.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Vita-Ray External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-200000-3000 (15 g): $6.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Aquasol A Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50000 units/mL (2 mL): $189.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitamin A Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8000 unit (90): $2.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (100): $2.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitamin A-Beta Carotene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000-1000 unit (90): $8.49",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F234423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RAE = Retinol activity equivalent; 1 RAE = retinol 1 mcg or dietary beta-carotene 12 mcg; Retinol 1 mcg = vitamin A 3.33 units (IOM, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Normal levels of vitamin A in serum = 80-300 units/100 mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A Grin (MX);",
"     </li>",
"     <li>",
"      A313 (FR);",
"     </li>",
"     <li>",
"      Arovit (AE, BE, BH, BR, CO, CY, EC, EG, IL, IQ, IR, IT, JO, KW, LB, LY, OM, PE, QA, SA, SE, SY, YE);",
"     </li>",
"     <li>",
"      Avibon (FR);",
"     </li>",
"     <li>",
"      Avitan (GR);",
"     </li>",
"     <li>",
"      Avitina (IT);",
"     </li>",
"     <li>",
"      Avitol (AT);",
"     </li>",
"     <li>",
"      Davitamon A (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ro-A-Vit (GH, KE, TZ, UG, ZM);",
"     </li>",
"     <li>",
"      Vitamin A (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin A is a fat soluble vitamin needed for visual adaptation to darkness, maintenance of epithelial cells, immune function and embryonic development.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Vitamin A in dosages",
"     <b>",
"      not",
"     </b>",
"     exceeding physiologic replacement is well absorbed in the small intestine after oral administration; water miscible preparations are absorbed more rapidly than oil preparations; large oral doses, conditions of fat malabsorption, low protein intake, or hepatic or pancreatic disease reduces oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Large amounts concentrate for storage in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted in the small intestine to retinol and further metabolized in the liver; conjugated with glucuronide; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces; urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braitberg G, Curry SC, and Kunkel DB, &ldquo;Liver Pathology in Fatal Vitamin A Toxicity,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):551-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cetaruk EW and Aaron CK, &ldquo;Hazards of Nonprescription Medications,&rdquo;",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 1994, 12(2):483-510.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/8187693/pubmed\" id=\"8187693\" target=\"_blank\">",
"        8187693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Infectious Diseases, &ldquo;Vitamin A in the Treatment of Measles,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(5):1014-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/8474793/pubmed\" id=\"8474793\" target=\"_blank\">",
"        8474793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Francisco A, Chakraborty J, Chowdhury HR, et al, &ldquo;Acute Toxicity of Vitamin A Given With Vaccines in Infancy,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1993, 342(8870):526-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/8102669/pubmed\" id=\"8102669\" target=\"_blank\">",
"        8102669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeMaeyer EM, &ldquo;The WHO Programme of Prevention and Control of Vitamin A Deficiency, Xerophthalmia, and Nutritional Blindness,&rdquo;",
"      <i>",
"       Nutr Health",
"      </i>",
"      , 1986, 4(2):105-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/3090484/pubmed\" id=\"3090484\" target=\"_blank\">",
"        3090484",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hussey GD and Klein M, &ldquo;A Randomized, Controlled Trial of Vitamin A in Children With Severe Measles,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(3):160-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/2194128/pubmed\" id=\"2194128\" target=\"_blank\">",
"        2194128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kowalski TE, Falestiny M, Furth E, et al, &ldquo;Vitamin A Hepatotoxicity: A Cautionary Note Regarding 25,000 IU Supplements,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1994, 97(6):523-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/7985711/pubmed\" id=\"7985711\" target=\"_blank\">",
"        7985711",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LaMantia RS and Andrews CE, &ldquo;Acute Vitamin A Intoxication,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1981, 74(8):1012-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/7268481/pubmed\" id=\"7268481\" target=\"_blank\">",
"        7268481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nesher G and Zuckner J, &ldquo;Rheumatologic Complications of Vitamin A and Retinoids,&rdquo;",
"      <i>",
"       Semin Arthritis Rheum",
"      </i>",
"      , 1995, 24(4):291-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24502/abstract-text/7740309/pubmed\" id=\"7740309\" target=\"_blank\">",
"        7740309",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders TA, &ldquo;Vitamin A and Pregnancy,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 336(8727):1375.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White JM, &ldquo;Vitamin A-Induced Anaemia,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1984, 2(8402):573.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Infants 1&ndash;5 Months of Age,\" Geneva: World Health Organization, 2011a. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_infants_1-5/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Postpartum Women,\" Geneva: World Health Organization, 2011b. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_postpartum/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO Guideline, \"Vitamin A Supplementation in Pregnant Women,\" Geneva: World Health Organization, 2011c. Available at   file://www.who.int/nutrition/publications/micronutrients/guidelines/vas_pregnant/en/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       WHO Model Formulary",
"      </i>",
"      , 2008. Available at file://apps.who.int/medicinedocs/en/m/abstract/Js16879e/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       WHO Model Formulary for Children",
"      </i>",
"      , 2010. Available at file://apps.who.int/medicinedocs/en/m/abstract/Js17151e/",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      WHO/UNICEF/IVACG Task Force,",
"      <i>",
"       Vitamin A Supplements. A Guide to Their Use in the Treatment and Prevention of Vitamin A Deficiency and Xerophthalmia",
"      </i>",
"      , 2nd ed. Geneva: World Health Organization, 1997. Available at file://www.who.int/nutrition/publications/micronutrients/vitamin_a_deficiency/9241545062/en/",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10047 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24502=[""].join("\n");
var outline_f23_59_24502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234440\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234456\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234443\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234451\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234444\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234422\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234408\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234425\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234424\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315218\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234464\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234454\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234428\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234412\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300220\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234417\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315239\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234419\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234431\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234447\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315219\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14315240\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324099\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234423\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539954\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234411\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234427\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10047|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/34/11812?source=related_link\">",
"      Vitamin A: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/11/26805?source=related_link\">",
"      Vitamin A: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24503="Doxepin (systemic): Pediatric drug information";
var content_f23_59_24503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxepin (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=see_link\">",
"    see \"Doxepin (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=see_link\">",
"    see \"Doxepin (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8082208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10570484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Silenor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Doxepin&reg;;",
"     </li>",
"     <li>",
"      Doxepine;",
"     </li>",
"     <li>",
"      Novo-Doxepin;",
"     </li>",
"     <li>",
"      Silenor&reg;;",
"     </li>",
"     <li>",
"      Sinequan&reg;;",
"     </li>",
"     <li>",
"      Zonalon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10808946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic (Tertiary Amine)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10809042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=see_link\">",
"      see \"Doxepin (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"     <b>",
"      Depression and/or anxiety:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 7-11 years: Limited data available; efficacy results variable; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and have not recommended them for use (Dopheide, 2006; USPTF, 2009; Wagner, 2005); some centers have used the following doses: 1-3 mg/kg/day in single or divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in adolescents and have not recommended them for use (Dopheide, 2006; USPTF, 2009; Wagner, 2005); Initial: 25-75 mg/day at bedtime or in 2-3 divided doses; begin at the low end of range and gradually titrate; select patients may respond to 25-50 mg/day; maximum single dose: 150 mg; maximum daily dose: 300 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Depression and/or anxiety:",
"     </b>",
"     Oral: Initial: 25-150 mg/day at bedtime or in 2-3 divided doses; may gradually increase up to 300 mg/day; single dose should not exceed 150 mg; select patients may respond to 25-50 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Insomnia (Silenor&reg;):",
"     </b>",
"     Oral: 3-6 mg once daily 30 minutes prior to bedtime; maximum dose: 6 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]: 10 mg/mL (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silenor&reg;: 3 mg, 6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8082214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Silenor&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206668.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM206668.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Antidepressant medications:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089129.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10810027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depression/anxiety: Administer with food to decrease GI upset; oral concentrate should be diluted in water, milk, or juice (orange, grapefruit, tomato, prune, or pineapple; but not grape juice) prior to administration (use 120 mL for adults); do not mix with carbonated beverages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insomnia (Silenor&reg;): Administer within 30 minutes prior to bedtime; do not take within 3 hours of a meal;",
"     <b>",
"      Note:",
"     </b>",
"     Not taking Silenor&reg; within 3 hours of a meal will give a faster onset and help minimize the risk for next day effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10809032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10808993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of various forms of depression and anxiety disorders associated with psychoneurosis, alcoholism, organic disease, and manic-depressive disorders (FDA approved in ages &ge;12 years and adults); treatment of insomnia with difficulty of sleep maintenance (Silanor&reg;: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxepin may be confused with digoxin, doxapram, doxazosin, Doxidan&reg;, doxycycline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SINEquan&reg; may be confused with saquinavir, SEROquel&reg;, Singulair&reg;, Zonegran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal [Finland] may be confused with Doxil brand name for doxorubicin (liposomal) [U.S.,  Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Doxal brand name for doxepin [Finland] but also brand name for pyridoxine/thiamine [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8082277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing, hyper-/hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, chills, confusion, disorientation, dizziness, drowsiness, fatigue, hallucinations, headache, seizure, somnolence/sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, photosensitivity, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Blood sugar increased/decreased, breast enlargement, galactorrhea, gynecomastia, libido increased/decreased, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, aphthous stomatitis, constipation, diarrhea, gastroenteritis, indigestion, nausea, trouble with gums, unpleasant taste, vomiting, weight gain, xerostomia; lower esophageal sphincter tone decrease may cause GE reflux",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, purpura, thrombocytopenia, purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extrapyramidal symptoms, numbness, paresthesia, tardive dyskinesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, nasopharyngitis/upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, diaphoresis (excessive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, anemia, arthralgia, atrioventricular block, back pain, blepharospasm, chest pain, complex sleep-related behavior (sleep-driving, cooking or eating food, making phone calls), diplopia, dyspepsia, gingival recession, hematochezia, hyperbilirubinemia, hypermagnesemia, hypersensitivity, hypoacusis, infection, lacrimation decreased, lip blister, motion sickness, myalgia, palpitations, peripheral edema, tympanic membrane perforation, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10808994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to doxepin, any component, or drugs from similar chemical class; narrow-angle glaucoma; urinary retention; use of MAO inhibitors within 14 days",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10809015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment; higher doxepin concentrations may occur. May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is moderate relative to other antidepressants. Use with caution in patients with respiratory compromise or sleep apnea; use is generally not recommended in patients with severe sleep apnea. Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation. Use with caution in patients with renal impairment. May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10808995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder (MDD)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years of age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that are abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. Risk of suicidal behavior may be increased regardless of doxepin dose; antidepressant doses of doxepin are 10- to 100-fold higher than doses for insomnia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid abrupt discontinuation; discontinuation symptoms (including headache, nausea, and malaise) may occur if therapy is abruptly discontinued or dose is reduced; taper the dose to minimize risks of discontinuation symptoms. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). May worsen psychosis or precipitate mania or hypomania in patients with bipolar disease; monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder. Doxepin is not FDA approved for the treatment of bipolar depression. May increase the risks associated with electroconvulsive therapy. Discontinue therapy, when possible, prior to elective surgery (do not discontinue abruptly).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Doxepin causes a high degree of sedation (relative to other antidepressants); may result in impaired performance of tasks requiring alertness. Patients who take doxepin for insomnia should confine their activities to those necessary to prepare for bed after taking the dose; a residual pharmacologic effect may also occur the next day. Hazardous, sleep-related activities, such as sleep-driving (driving while not fully awake), cooking or eating food, and making phone calls while asleep have also been noted; an increased risk of these type of events has been reported with the use of hypnotic agents taken in greater than recommended dosages, as well as with concomitant ethanol or CNS depressant use; amnesia may also occur; discontinue treatment in patients who report any sleep-related episodes. Use with caution in patients receiving other CNS depressants; effects with other sedative drugs or ethanol may be potentiated. Failure of sleep disturbance to resolve after 7-10 days, exacerbation of insomnia, or emergence of new cognitive or behavioral abnormalities may indicate psychiatric or medical illness.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10809031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral solution is physically incompatible with carbonated beverages and grape juice; diets rich in fiber may decrease drug effects. A high-fat meal increases the bioavailability of Silenor&reg;  and delays the peak plasma concentration by ~3 hours.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10827783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal body weight and fetal structural abnormalities were observed in animal reproduction studies at doses greater than the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10810030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, mental status, weight, liver enzymes, and CBC with differential. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10810891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Utility of serum concentration monitoring is controversial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxepin plus desmethyldoxepin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Proposed therapeutic concentration: 110-250 ng/mL (394-895 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Toxic concentration: &gt;500 ng/mL (&gt;1790 nmol/L) (toxicities may be seen at lower concentrations in some patients)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10809035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane; antagonizes the histamine (H",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor for sleep maintenance effect",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10809036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Sedation: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effects: Antidepressant: Usually  &gt;2 weeks; anxiolytic: May occur sooner",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10809038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely throughout body tissues; V",
"     <sub>",
"      d",
"     </sub>",
"     : ~12,000 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 80% to 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic primarily via CYP2C19 and 2D6 to metabolites, including N-desmethyldoxepin (active); N-desmethyldoxepin undergoes glucuronide conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Doxepin: ~15 hours; N-desmethyldoxepin: 31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: Fasting: Silanor&reg;: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (mainly excreted as glucuronide conjugates; &lt;3% as unchanged drug or N-desmethyldoxepin)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10810924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=see_link\">",
"      see \"Doxepin (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of doxepin. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician for feelings of increased depression, agitation, irritability, or thoughts of suicide. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol and the herbal medicine St John's wort; limit caffeine; may increase appetite; do not discontinue abruptly. When used to treat insomnia, may cause hazardous sleep-related activities (ie, driving, preparing and eating foods, and making phone calls while not fully awake); after taking a dose, limit activities to those necessary to prepare for bed; residual pharmacologic effect may be present the next day. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14080782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For treatment of insomnia, use beyond 3 months has not been evaluated.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(11):1503-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24503/abstract-text/18049300/pubmed\" id=\"18049300\" target=\"_blank\">",
"        18049300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24503/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, \"A Practical Approach to Children Failing in School,\"",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24503/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      US Preventive Services Task Force (USPTF), \"Screening and Treatment for Major Depressive Disorder in Children and Adolescents: US Preventive Services Task Force Recommendation Statement,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(4):1223-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24503/abstract-text/19336383/pubmed\" id=\"19336383\" target=\"_blank\">",
"        19336383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/59/24503/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15971 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24503=[""].join("\n");
var outline_f23_59_24503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082208\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10570484\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10808946\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809042\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082350\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082264\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082214\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10810027\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809032\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10808993\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082213\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082277\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10808994\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809015\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10808995\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082279\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082280\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809031\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10827783\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082269\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10810030\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10810891\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809035\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809036\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10809038\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10810924\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14080782\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15971\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15971|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/32/44551?source=related_link\">",
"      Doxepin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/8/40069?source=related_link\">",
"      Doxepin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/8/14470?source=related_link\">",
"      Doxepin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/23/20852?source=related_link\">",
"      Doxepin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/54/14181?source=related_link\">",
"      Doxepin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24504="Breast biopsy";
var content_f23_59_24504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Laura J Esserman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Bonnie N Joe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24504/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/59/24504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with a suspicious mammographic abnormality or palpable breast mass, the obligatory diagnostic technique is biopsy. Surgical biopsy should not be utilized as a diagnostic tool unless percutaneous palpation-guided or image-guided biopsy is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/1\">",
"     1",
"    </a>",
"    ]. A preoperative histologic diagnosis of invasive carcinoma may allow the surgeon to plan a single operation to treat the cancer, including sentinel lymph node (SLN) biopsy or full axillary dissection, depending upon the clinical circumstances. Excision of more extensive areas of DCIS may also be optimally planned if the diagnosis has been established by percutaneous core needle biopsy (CNB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FINE NEEDLE ASPIRATION BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation-guided percutaneous fine needle aspiration (FNA) biopsy has been used for years to evaluate a palpable breast mass. FNA biopsy is performed with a 10 or 20 ml syringe and a 23 to 27 gauge needle. While keeping negative pressure on the syringe, the needle is passed back and forth within the mass while rotating the wrist so that the needle is twisting. The specimen is then expelled into CytoLyte solution for evaluation by a cytopathologist. Pathologists may also prepare smears for quick stain to assess adequacy of the sampled material.",
"   </p>",
"   <p>",
"    Another technique for performing FNA biopsy is the French technique, in which the plunger is removed from the syringe and the needle and syringe (without the plunger) is passed back and forth through the mass. The needle is removed from the breast and the plunger is then replaced and used to expel the specimen.",
"   </p>",
"   <p>",
"    The main disadvantages of FNA cytology are the inability to distinguish between in situ and invasive cancer, and the significant rate of nondiagnostic samples and false negative results in inexperienced hands [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of inadequate or nondiagnostic cytologic samples for palpable abnormalities averages 4 to 13 percent, but may be as high as 36 percent for nonpalpable abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For nonpalpable lesions, the false-negative rate for image-guided FNA in experienced hands is between 0 and 32 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/5-7\">",
"       5-7",
"      </a>",
"      ] and may be caused by inaccurate lesion localization, small size, deflection of the needle by a firm mass, or a combination of these factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When performed by experienced operators, FNA has a sensitivity of 98 percent and a specificity of 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/8\">",
"     8",
"    </a>",
"    ]; rates are much lower in the hands of clinicians who lack specific training. As a result, in institutions with less experienced cytopathologists, the initial diagnostic procedure of choice should be core needle biopsy (CNB) rather than FNA. However, for those institutions with excellent cytopathology, FNA may be the superior biopsy technique for some cases. When a lesion is palpable, FNA can be rapidly performed as a non-image guided procedure. When biopsy results are non-concordant, image guided biopsy should be pursued.",
"   </p>",
"   <p>",
"    Proper lesion selection for FNA may play a role in the diagnostic yield. A greater amount of material can be aspirated from cellular lesions such as infiltrating ductal carcinoma and metastatic lymph nodes, compared with less cellular lesions such as hyalinized fibroadenomas, fibrotic lesions, or infiltrating lobular cancers. CNB is more likely to provide a definitive diagnosis for less cellular lesions.",
"   </p>",
"   <p>",
"    While a positive FNA for carcinoma can confirm the diagnosis of a suspicious lesion, careful correlation with imaging is needed. Certain lesions (eg, fat necrosis, fibroadenomas) can show significant atypia on FNA. Further biopsy may be needed if the FNA of a suspicious lesion is read as negative.",
"   </p>",
"   <p>",
"    FNA can also be used to diagnosis a simple breast cyst. The fluid within a simple cyst can be clear, yellow, grey, green, blue, milk white, or bloody [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/9\">",
"     9",
"    </a>",
"    ]. Nonbloody fluid can be discarded unless there is a clinical or radiographic suspicion of an associated malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/9-16\">",
"     9-16",
"    </a>",
"    ]. Bloody fluid must be submitted for a cytologic evaluation as this indicates a lesion other than a simple cyst. The only exception is that of a traumatic aspirate, which is best judged by the individual performing the FNA. If there is any uncertainty, submit for cytologic analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"     \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound (US)-guided FNA of palpable lesions increases the level of confidence that needle placement has been accurate. In addition, it may be more prudent to perform an FNA rather than a CNB of a lesion in a patient with coagulation abnormalities. In axillary lymph nodes, it is less painful and may be safer.",
"   </p>",
"   <p>",
"    A major advantage of FNA is that it can be easily and quickly performed at the time of a diagnostic study, with potential for an immediate preliminary interpretation. For a patient with a suspicious lesion, FNA can be performed rapidly and immediate results obtained in some centers, expediting early discussion about diagnosis and treatment. Many of the clinical trials of neoadjuvant therapy available to women with stage II or III disease require a tissue core for research studies as well as histologic diagnosis. Once a decision has been made to pursue this approach, cores for diagnosis and research can then be obtained, avoiding the need to perform more than one large CNB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STEREOTACTIC BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stereotactic table allows mammographic guidance for core biopsy. Stereotactic biopsies can be done with the patient upright or prone, depending on the machine. For a prone stereotactic biopsy, the patient is prone on the table and her breast hangs through an opening in the table. A mammography unit is attached beneath the table allowing the radiologist to perform the procedure. While the majority of mammographic lesions can be biopsied via the stereotactic technique, certain situations will preclude stereotactic biopsy including lesions close to the nipple or chest wall, very faint calcifications and a small breast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CORE NEEDLE BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to FNA, CNB offers a more definitive histologic diagnosis, avoids inadequate samples and may permit the distinction between invasive versus in situ cancer. In most centers, stereotactic CNB has replaced wire localization and excision as the most common initial biopsy method for nonpalpable mammographic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ]. CNB is safe, even in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    anticoagulation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Hematomas requiring treatment and infections are much less common with CNB than surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, a CNB before surgical management of a cancer allows for multidisciplinary planning and appropriate clinical trial enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of US to guide CNBs of nonpalpable lesions is faster and better tolerated by some patients than the stereotactic technique. The use of US requires that the lesion can be well visualized by ultrasound and confidence that the ultrasound finding and mammographic finding represent the same thing. With US-guided core needle biopsy, passage of the needle through the lesion can be directly visualized and confirmed; as a result, fewer samples (usually three to five) are needed to provide diagnostic material. If the lesion is better visualized mammographically and is difficult to reproduce reliably on US, then stereotactic guidance is the preferred method.",
"   </p>",
"   <p>",
"    For patients with microcalcifications, stereotactically-guided CNB is the standard approach, since these lesions cannot usually be visualized by US. Calcifications can be targeted sonographically if they can be visualized within a mass on US.",
"   </p>",
"   <p>",
"    US-guided CNB may also be appropriate for palpable lesions. For example, a palpable abnormality does not always correspond to the true lesion, but instead may represent tissue anterior to the lesion. Image guidance can also be useful to successfully biopsy lesions that are small, deep or mobile, and those that are only vaguely palpable that may no longer be palpable after the administration of local anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Vacuum-assisted biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of the vacuum-assisted directional biopsy device can permit the removal of a greater tissue volume than non vacuum-assisted CNB. A vacuum-assisted CNB (VAB) can remove mammographic abnormalities of up to 1 cm in diameter using an 11 gauge device [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The accuracy of this approach was shown in a series of 942 consecutive breast CNBs performed at one institution (342 without image guidance, 241 with US guidance, and 369 using a stereotactic VAB) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/23\">",
"     23",
"    </a>",
"    ]. The false-negative rate with 11 gauge VAB was 3 percent, compared to 13, 5, and 22 percent for non-image guided, surgeon-performed US-guided, and 14 gauge VAB respectively. Others report false negative rates as low as 0.45 percent with 11 gauge VAB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 8 gauge VAB device yields a greater volume of tissue (245 to 310 mg of tissue per core) with the same size incision as the 11 gauge device (which yields 83 to 116 mg of tissue per core). Approximately 1 gram of tissue can be obtained in just four cores with more preservation of tissue architecture, while 10 core samples would be needed for the same yield using the 11 gauge device. From a diagnostic standpoint, increasing the volume of tissue in each core may be more important than increasing the number of core samples [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clip placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;If possible, a clip should be placed in the region of the breast lesion at the time of a biopsy, as this is useful in several clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement of a clip following US-guided CNB is important for documentation and for providing mammographic as well as sonographic correlation of lesion location [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the lesion is very small and might be completely removed by the CNB, a small clip should be deployed at the biopsy site for future identification of the tumor site. Pre- and postprocedure 90-degree lateral and craniocaudal mammograms should be performed to ensure that the correct lesion has been biopsied and to determine the relationship of the clip to the lesion that was visualized prebiopsy. If residual abnormalities are not seen on the postprocedure mammogram, the area where the lesion had been can be localized using the clip as a reference point.",
"      <br/>",
"      <br/>",
"      Clip migration following biopsy has been reported and the distance from the original biopsy cavity can be measured [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/32\">",
"       32",
"      </a>",
"      ]. If sufficiently far away from the biopsy cavity, then an addendum should be made to the report documenting that the clip should NOT be used to localize the lesion before surgery.",
"     </li>",
"     <li>",
"      For patients with locally advanced breast cancer, the tumor site is commonly marked with a clip prior to administration of neoadjuvant therapy, in order to localize the site of the original tumor bed, in case the patient has a clinical and radiographic complete response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Different shapes or types of clips can be utilized if more than one lesion is biopsied in order to differentiate the various sites. This becomes especially important in the event that surgery is required for one of the lesions. If only one type of clip is available, then one clip can be placed in one site, two in another, etc [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One potential disadvantage of CNB is the risk of seeding the needle tract with tumor cells, although this is mainly theoretical. In patients undergoing breast conserving therapy, whole breast irradiation would likely eliminate any tumor cells. The shortest path to the lesion should be chosen with some consideration of surgical planning so that the biopsy tract will be included in the surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some lesions are not suitable for stereotactic CNB. Areas of architectural distortion and large regions of granular calcification may contain sparse tumor and ultimately require excision. CNB can be helpful if the results reveal DCIS or an infiltrating (invasive) carcinoma. Very posterior lesions or those located close to the skin surface may be difficult to biopsy, and excisional biopsy is a better option. Other patients are not amenable to stereotactic core biopsy because of breast size or the inability to tolerate compression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Management of discordant findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;All benign CNB diagnoses require good radiologic-pathologic correlation. Nonconcordant findings (ie, a histologically benign lesion that does not correlate with the mammographic abnormality) should prompt further evaluation and will often require excisional biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management of benign or atypical lesions on core biopsy results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with benign, concordant lesions can be returned to routine screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the core biopsy shows any abnormality such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), papilloma, complex sclerosing adenosis or radial scar a wire localization breast biopsy should be performed to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/10,34-37\">",
"     10,34-37",
"    </a>",
"    ]. Although these are benign entities, they are often associated with a malignancy and excisional biopsy leads to a diagnosis of malignancy in up to 50 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of benign breast disease\", section on 'Atypical hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     WIRE LOCALIZATION BREAST BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with nonpalpable microcalcifications, wire localization and excision must be tailored to each case by the radiologist and the surgeon. The goal of the procedure may be to obtain a histologic diagnosis, to perform complete excision of high-suspicion lesions, to excise CNB-proven tumors, or to remove residual suspicious calcifications following excision of malignant calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wire localization performed using US guidance is faster and better tolerated than is mammographic localization. US-guided wire localization can be accomplished if there is a residual lesion visualized sonographically, or if there is an accurately placed clip (within the last 6 to 12 weeks) with accompanying echogenic material which is visible on US.",
"   </p>",
"   <p>",
"    For patients found to have DCIS, complete excision of the entire lesion with appropriate margins is required for successful breast conserving therapy. The achievement of negative margins is a significant factor for reducing local recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"     \"Microinvasive breast carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of stereotactic CNB prior to planned excision of malignant microcalcifications has decreased the incidence of finding positive margins at the time of excision [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/39\">",
"     39",
"    </a>",
"    ]. This is due to the fact that the surgeon who is aware of the malignant nature of a lesion prior to excision may use a more aggressive surgical approach to obtaining clear resection margins. Nevertheless, 20 percent of cases still have a positive histologic margin of excision [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/18\">",
"     18",
"    </a>",
"    ]. Whole specimen mammography and pathologic assessment of tumor margins are the most common methods to ensure clear margins, but neither is completely reliable.",
"   </p>",
"   <p>",
"    Whole specimen mammography is obligatory for clinically occult lesions excised under mammographic localization and is also recommended for palpable lesions that are associated with microcalcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/40\">",
"     40",
"    </a>",
"    ]. All specimens should be oriented by the surgeon. Specimen radiography is essential to confirm the accurate removal of the mammographic abnormality and to guide the pathologist to the appropriate area for sectioning and microscopic study. Visualization of the clip",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    foreign body material accompanying the clip helps the pathologist and the surgeon identify the prior biopsy site.",
"   </p>",
"   <p>",
"    Specimen radiography can also show whether the lesion has been transected or is in close proximity to the edge of the specimen. In such cases, additional tissue may need to be removed to increase the likelihood of negative margins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/41\">",
"     41",
"    </a>",
"    ]. The best opportunity to achieve clear margins is at the time of the original surgical excision. Some centers and surgeons use digital imaging devices in the operating rooms (eg, Faxitrons) to provide an immediate picture of the specimen and improve the ability of the surgeon to see the lesion in relation to the margin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Postoperative mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative mammography, performed three to five weeks following excision of a cancerous lesion, complements specimen mammography and histologic margin assessment. It is recommended by the American College of Radiology and the American College of Surgeons, especially in the setting of calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual suspicious calcifications may be identified in up to 24 percent of patients, the majority of which represent residual DCIS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. These should be removed, if possible. In one report, failure to do so was associated with significant higher locoregional failure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/43\">",
"     43",
"    </a>",
"    ]. It is far better to identify residual calcifications prior to radiation therapy than afterward, when identification of residual disease may be interpreted as new disease and therefore prompt a mastectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MRI-GUIDED BREAST BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients will have nonpalpable, mammographically occult lesions which are seen only on MRI. A proportion can be identified in on subsequent, targeted \"second-look\" US [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/46\">",
"     46",
"    </a>",
"    ], and may then be biopsied under US guidance. Ultrasound correlate findings have a high likelihood of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. For the remaining lesions, targeting requires MRI guidance.",
"   </p>",
"   <p>",
"    MRI-guided interventions are not available at all institutions, and they can be more difficult, time consuming and expensive than other biopsy methods although technologic advances have improved biopsy efficiency. MRI does not allow real-time monitoring of needle advancement and biopsy. Instead, the MRI table brings the patient out of the MR bore for needle placement and sends the patient back into the MR bore for imaging to verify needle placement at each step of the biopsy process. On average, an MR biopsy can be expected to last from 30 minutes to an hour.",
"   </p>",
"   <p>",
"    In most institutions, MRI-guided CNB has been replaced by MRI-guided vacuum-assisted biopsy (VAB), which avoids tissue shift through the use of continuous suction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/50-55\">",
"     50-55",
"    </a>",
"    ]. Imaging-histologic correlation is essential after MRI-guided VAB [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/56\">",
"     56",
"    </a>",
"    ]. Some discordant cases will be found to represent false-negative MRI findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/50\">",
"     50",
"    </a>",
"    ]. Imaging follow up after benign concordant biopsies is recommended to detect false-negative biopsies such as when a presumed ultrasound correlate is inaccurate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI-guided wire localization and surgical excision may be indicated if a suspicious lesion is not accessible to MRI-guided VAB or if core biopsy results are discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SKIN PUNCH BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small skin biopsy using a punch biopsy device can differentiate between benign and malignant skin changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INCISIONAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a core needle biopsy or skin punch biopsy is non-diagnostic, and the mass is too large to remove without significant cosmetic compromise, incisional biopsy can be performed to confirm diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EXCISIONAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases where the core needle biopsy is non-diagnostic, is not concordant with imaging results, or yields any high risk abnormality such as atypical hyperplasia, radial scar, papilloma or lobular carcinoma in situ, excision of the entire lesion is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/7\">",
"     7",
"    </a>",
"    ]. In some cases, patients will prefer excisional biopsy as they prefer to have the mass excised, even if it is benign.",
"   </p>",
"   <p>",
"    Excisional biopsy of simple cysts, clustered microcysts or cysts with thin septa is not necessary. Excisional biopsies may generate scar tissue inside the breast that hinders the reliability and accuracy of future mammograms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"     \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the absolute indications for a surgical biopsy in the presence of cystic lesions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complex cysts not amenable to core needle biopsy must have a needle localized excisional biopsy for diagnosis.",
"     </li>",
"     <li>",
"      Recurrent cysts in the same location.",
"     </li>",
"     <li>",
"      Aspirated cyst that do not completely resolve.",
"     </li>",
"     <li>",
"      Pathology results from a core biopsy are discordant with imaging, atypical, indeterminate or reveal a malignancy. A metallic marker placed at the time of the diagnostic core biopsy will aid in needle localization of the biopsy area at the time of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/60-62\">",
"       60-62",
"      </a>",
"      ]. An intraoperative specimen radiograph will confirm removal of the entire wire and the metallic marker, providing assurance that adequate sampling was performed.",
"     </li>",
"     <li>",
"      An increase in size or suspicious changes are seen on follow up imaging after a core biopsy with benign results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASSAY FOR HORMONE RECEPTORS AND HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assay for expression of estrogen and progesterone receptors and HER2 is critical for determining the optimal systemic treatment strategy and should be performed on all primary breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Performing these assays on the core biopsy material can facilitate treatment by expediting discussions as to the need for, timing of, and type of adjuvant systemic therapy. However, if the assays are negative, given tumor heterogeneity, they should be repeated at the time of definitive surgery. In up to 15 percent of cases, markers that are negative on a core sample will be positive on the larger definitive specimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     AXILLARY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a suspicious BIRADS 4c or 5 lesion on mammography, ultrasound scanning of the ipsilateral axilla should be performed to evaluate suspicious abnormal axillary nodes. Percutaneous fine needle aspiration (FNA) of a node deemed to be suspicious is an appropriate intervention. Adenocarcinoma cells are relatively easy to distinguish from normal lymphatic cells. If the primary tumor is known to be invasive lobular cancer, cytokeratin stains may be required to distinguish lobular cells from lymphocytes. The diagnosis of invasive lobular cancer and all available clinical information should be shared with the pathologist, as patients are often seen in multiple institutions and the pathologist may not have access to this data.",
"   </p>",
"   <p>",
"    If malignant cells are present in the axillary FNA, then the patient can go on to definitive axillary dissection at the time of the initial cancer surgery, A positive finding means that definitive axillary surgery may be performed at the time of the initial cancer surgery, rather than the two step procedure of sentinel lymph node biopsy followed by axillary dissection in patient's with positive nodes.",
"   </p>",
"   <p>",
"    If the FNA is negative, the axilla still requires surgical evaluation with SLN biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Impact of breast biopsy on later SLN biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;SLN biopsy can be performed in patients who have had a prior breast biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24504/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients who undergo preoperative breast biopsy do not have a higher rate of SLN positivity compared to those who do not have a biopsy, regardless of tumor location. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=see_link\">",
"     \"Sentinel lymph node biopsy in breast cancer: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"       \"Patient information: Breast biopsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with a suspicious mammographic abnormality or palpable breast mass, the obligatory diagnostic technique is biopsy. Surgical biopsy should not be utilized as a diagnostic tool unless percutaneous palpation-guided or image-guided biopsy is not feasible. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fine needle aspiration (FNA) can be easily and quickly performed. For patients with palpable lesions, non-image guided FNA allows the ability to rapidly provide a diagnosis and counsel patients. The accurate interpretation of FNA cytology requires a highly experienced cytopathologist to avoid a high rate of nondiagnostic samples and false negative results. It is generally possible to distinguish between in situ and invasive cancer on FNA cytology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fine needle aspiration biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the clinical trials of neoadjuvant therapy available to women with stage II or III disease require a tissue core for research studies as well as histologic diagnosis. Once a decision has been made to pursue this approach, cores for diagnosis and research can then be obtained, avoiding the need to perform more than one large CNB. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Fine needle aspiration biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared to FNA, core needle biopsy (CNB) offers a more definitive histologic diagnosis, avoids inadequate samples and usually distinguishes between invasive versus in situ cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Core needle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clip should be placed in the region of a CNB as this will provide documentation of concordance with the target lesion on imaging. The clip will also allow subsequent wire localization of the proper area if the lesion requires excision or if the patient is undergoing neoadjuvant therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clip placement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All benign CNB diagnoses require good mammographic-pathologic correlation. Nonconcordant findings should prompt further evaluation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of benign or atypical lesions on core biopsy results'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wire localization breast biopsy is performed to obtain a histologic diagnosis, to perform complete excision of high-suspicion lesions, to excise CNB-proven tumors, or to remove residual suspicious calcifications following excision of malignant calcifications. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Wire localization breast biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whole specimen mammography is obligatory for clinically occult lesions excised under mammographic localization and is also recommended for palpable lesions that are associated with microcalcifications. All specimens should be oriented by the surgeon. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Wire localization breast biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postexcision mammography should be performed three to five weeks following excision of a cancerous lesion to check for residual suspicious calcifications which will require removal. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Wire localization breast biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonpalpable, mammographically occult lesions which are seen only on MRI, biopsy targeting requires MRI guidance. MRI-guided wire localization and surgical excision may be indicated if a suspicious lesion is not accessible to MRI-guided VAB or if core biopsy results are discordant. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'MRI-guided breast biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assay for expression of estrogen and progesterone receptors and HER2 should be performed on the core biopsy or FNA material to facilitate treatment by expediting discussions as to the need for, timing of, and type of adjuvant systemic therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Assay for hormone receptors and HER2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a suspicious lesion on mammography, ultrasound scanning of the ipsilateral axilla can be performed to evaluate suspicious abnormal axillary nodes. Fine needle aspiration (FNA) of any suspicious areas in the axilla can then be performed at the time of percutaneous breast biopsy. This can provide useful staging information and impact on the management of the axilla. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Axillary evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/1\">",
"      Gutwein LG, Ang DN, Liu H, et al. Utilization of minimally invasive breast biopsy for the evaluation of suspicious breast lesions. Am J Surg 2011; 202:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/2\">",
"      Pisano ED, Fajardo LL, Caudry DJ, et al. Fine-needle aspiration biopsy of nonpalpable breast lesions in a multicenter clinical trial: results from the radiologic diagnostic oncology group V. Radiology 2001; 219:785.",
"     </a>",
"    </li>",
"    <li>",
"     Masood S. Fine needle aspiration biopsy of nonpalpable breast lesions. In: Cytopathology Annual 1993, Schmidt W (Ed), Williams and Wilkins, Baltimore 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/4\">",
"      Masood S. Occult breast lesions and aspiration biopsy: a new challenge. Diagn Cytopathol 1993; 9:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/5\">",
"      Hall FM, Storella JM, Silverstone DZ, Wyshak G. Nonpalpable breast lesions: recommendations for biopsy based on suspicion of carcinoma at mammography. Radiology 1988; 167:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/6\">",
"      L&ouml;fgren M, Andersson I, Bondeson L, Lindholm K. X-ray guided fine-needle aspiration for the cytologic diagnosis of nonpalpable breast lesions. Cancer 1988; 61:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/7\">",
"      Svane G, Silfversw&auml;rd C. Stereotaxic needle biopsy of non-palpable breast lesions. Cytologic and histopathologic findings. Acta Radiol Diagn (Stockh) 1983; 24:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/8\">",
"      Ljung BM, Drejet A, Chiampi N, et al. Diagnostic accuracy of fine-needle aspiration biopsy is determined by physician training in sampling technique. Cancer 2001; 93:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/9\">",
"      Mannello F, Tonti GA, Papa S. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies. Breast Cancer Res Treat 2006; 97:115.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/11\">",
"      Louie L, Velez N, Earnest D, Staren ED. Management of nonpalpable ultrasound-indeterminate breast lesions. Surgery 2003; 134:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/12\">",
"      Gordon PB. Image-directed fine needle aspiration biopsy in nonpalpable breast lesions. Clin Lab Med 2005; 25:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/13\">",
"      Morrow M. The evaluation of common breast problems. Am Fam Physician 2000; 61:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/14\">",
"      Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. Lancet 1999; 353:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/15\">",
"      Parish DC, Ghilchik MW, Day JM, et al. Cytokines in human breast cyst fluid. J Steroid Biochem Mol Biol 2007; 104:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/16\">",
"      Tsung JS, Wang TY, Wang SM, Yang PS. Cytological and biochemical studies of breast cyst fluid. Breast 2005; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/17\">",
"      Verkooijen HM, Core Biopsy After Radiological Localisation (COBRA) Study Group. Diagnostic accuracy of stereotactic large-core needle biopsy for nonpalpable breast disease: results of a multicenter prospective study with 95% surgical confirmation. Int J Cancer 2002; 99:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/18\">",
"      Stomper PC, Winston PS, Proulx GM, et al. Mammographic detection and staging of ductal carcinoma in situ: mammographic-pathologic correlation. Semin Breast Dis 2000; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/19\">",
"      Somerville P, Seifert PJ, Destounis SV, et al. Anticoagulation and bleeding risk after core needle biopsy. AJR Am J Roentgenol 2008; 191:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/20\">",
"      Melotti MK, Berg WA. Core needle breast biopsy in patients undergoing anticoagulation therapy: preliminary results. AJR Am J Roentgenol 2000; 174:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/21\">",
"      Bruening W, Fontanarosa J, Tipton K, et al. Systematic review: comparative effectiveness of core-needle and open surgical biopsy to diagnose breast lesions. Ann Intern Med 2010; 152:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/22\">",
"      Liberman L, Ernberg LA, Heerdt A, et al. Palpable breast masses: is there a role for percutaneous imaging-guided core biopsy? AJR Am J Roentgenol 2000; 175:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/23\">",
"      Shah VI, Raju U, Chitale D, et al. False-negative core needle biopsies of the breast: an analysis of clinical, radiologic, and pathologic findings in 27 concecutive cases of missed breast cancer. Cancer 2003; 97:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/24\">",
"      Hoorntje LE, Peeters PH, Mali WP, Borel Rinkes IH. Vacuum-assisted breast biopsy: a critical review. Eur J Cancer 2003; 39:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/25\">",
"      Kettritz U, Rotter K, Schreer I, et al. Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study. Cancer 2004; 100:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/26\">",
"      Jackman RJ, Marzoni FA Jr, Rosenberg J. False-negative diagnoses at stereotactic vacuum-assisted needle breast biopsy: long-term follow-up of 1,280 lesions and review of the literature. AJR Am J Roentgenol 2009; 192:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/27\">",
"      Liberman L, Kaplan JB, Morris EA, et al. To excise or to sample the mammographic target: what is the goal of stereotactic 11-gauge vacuum-assisted breast biopsy? AJR Am J Roentgenol 2002; 179:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/28\">",
"      Pfarl G, Helbich TH, Riedl CC, et al. Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. AJR Am J Roentgenol 2002; 179:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/29\">",
"      Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy. Radiology 1997; 202:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/30\">",
"      Berg WA, Krebs TL, Campassi C, et al. Evaluation of 14- and 11-gauge directional, vacuum-assisted biopsy probes and 14-gauge biopsy guns in a breast parenchymal model. Radiology 1997; 205:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/31\">",
"      Guenin MA. Clip placement during sonographically guided large-core breast biopsy for mammographic-sonographic correlation. AJR Am J Roentgenol 2000; 175:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/32\">",
"      Esserman LE, Cura MA, DaCosta D. Recognizing pitfalls in early and late migration of clip markers after imaging-guided directional vacuum-assisted biopsy. Radiographics 2004; 24:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/33\">",
"      Scott S, Morrow M. Breast cancer. Making the diagnosis. Surg Clin North Am 1999; 79:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/34\">",
"      Chae BJ, Lee A, Song BJ, Jung SS. Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy. World J Surg Oncol 2009; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/35\">",
"      Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when breast core needle biopsies show atypical lobular hyperplasia or lobular carcinoma in situ: a correlative study of 33 patients with review of the literature. Am J Surg Pathol 2005; 29:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/36\">",
"      Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw 2006; 4:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/37\">",
"      Margenthaler JA, Duke D, Monsees BS, et al. Correlation between core biopsy and excisional biopsy in breast high-risk lesions. Am J Surg 2006; 192:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/38\">",
"      Kopans DB, Lindfors K, McCarthy KA, Meyer JE. Spring hookwire breast lesion localizer: use with rigid-compression mammographic systems. Radiology 1985; 157:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/39\">",
"      White RR, Halperin TJ, Olson JA Jr, et al. Impact of core-needle breast biopsy on the surgical management of mammographic abnormalities. Ann Surg 2001; 233:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/40\">",
"      D'Orsi CJ. Management of the breast specimen. Radiology 1995; 194:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/41\">",
"      McCormick JT, Keleher AJ, Tikhomirov VB, et al. Analysis of the use of specimen mammography in breast conservation therapy. Am J Surg 2004; 188:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/42\">",
"      Winchester DP, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998; 48:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/43\">",
"      Lally BE, Haffty BG, Moran MS, et al. Management of suspicious or indeterminate calcifications and impact on local control. Cancer 2005; 103:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/44\">",
"      Aref A, Youssef E, Washington T, et al. The value of postlumpectomy mammogram in the management of breast cancer patients presenting with suspiciouis microcalcifications. Cancer J Sci Am 2000; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/45\">",
"      Waddell BE, Stomper PC, DeFazio JL, et al. Postexcision mammography is indicated after resection of ductal carcinoma-in-situ of the breast. Ann Surg Oncol 2000; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/46\">",
"      LaTrenta LR, Menell JH, Morris EA, et al. Breast lesions detected with MR imaging: utility and histopathologic importance of identification with US. Radiology 2003; 227:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/47\">",
"      Shin JH, Han BK, Choe YH, et al. Targeted ultrasound for MR-detected lesions in breast cancer patients. Korean J Radiol 2007; 8:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/48\">",
"      Linda A, Zuiani C, Londero V, Bazzocchi M. Outcome of initially only MRI detected findings with and without correlate at second look sonography: Distribution according to patient history of breast cancer and lesion size. The Breast 2008; 17:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/49\">",
"      Abe H, Schmidt RA, Shah RN, et al. MR-directed (\"Second-Look\") ultrasound examination for breast lesions detected initially on MRI: MR and sonographic findings. AJR Am J Roentgenol 2010; 194:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/50\">",
"      Han BK, Schnall MD, Orel SG, Rosen M. Outcome of MRI-guided breast biopsy. AJR Am J Roentgenol 2008; 191:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/51\">",
"      Heywang-K&ouml;brunner SH, Sinnatamby R, Lebeau A, et al. Interdisciplinary consensus on the uses and technique of MR-guided vacuum-assisted breast biopsy (VAB): results of a European consensus meeting. Eur J Radiol 2009; 72:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/52\">",
"      Daniel BL, Freeman LJ, Pyzoha JM, et al. An MRI-compatible semiautomated vacuum-assisted breast biopsy system: initial feasibility study. J Magn Reson Imaging 2005; 21:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/53\">",
"      Lehman CD, Deperi ER, Peacock S, et al. Clinical experience with MRI-guided vacuum-assisted breast biopsy. AJR Am J Roentgenol 2005; 184:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/54\">",
"      Liberman L, Bracero N, Morris E, et al. MRI-guided 9-gauge vacuum-assisted breast biopsy: initial clinical experience. AJR Am J Roentgenol 2005; 185:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/55\">",
"      Perlet C, Heywang-Kobrunner SH, Heinig A, et al. Magnetic resonance-guided, vacuum-assisted breast biopsy: results from a European multicenter study of 538 lesions. Cancer 2006; 106:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/56\">",
"      Lee JM, Kaplan JB, Murray MP, et al. Imaging histologic discordance at MRI-guided 9-gauge vacuum-assisted breast biopsy. AJR Am J Roentgenol 2007; 189:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/57\">",
"      Meissnitzer M, Dershaw DD, Lee CH, Morris EA. Targeted ultrasound of the breast in women with abnormal MRI findings for whom biopsy has been recommended. AJR Am J Roentgenol 2009; 193:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/58\">",
"      Wallace AM, Daniel BL, Jeffrey SS, et al. Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization. J Am Coll Surg 2005; 200:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/59\">",
"      Morris EA, Liberman L, Dershaw DD, et al. Preoperative MR imaging-guided needle localization of breast lesions. AJR Am J Roentgenol 2002; 178:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/60\">",
"      Phillips SW, Gabriel H, Comstock CE, Venta LA. Sonographically guided metallic clip placement after core needle biopsy of the breast. AJR Am J Roentgenol 2000; 175:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/61\">",
"      Margolin FR, Jacobs RP, Denny SR, Schrumpf JD. Clip placement after sonographically guided percutaneous breast biopsy. Breast J 2003; 9:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/62\">",
"      Patterson SK, Joe A, Helvie MA. Sonographically-guided metallic marker placement at time of wire localization for intraductal or cystic lesions: a method to verify lesion retrieval. Acad Radiol 2008; 15:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24504/abstract/63\">",
"      Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 796 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24504=[""].join("\n");
var outline_f23_59_24504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FINE NEEDLE ASPIRATION BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STEREOTACTIC BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CORE NEEDLE BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Vacuum-assisted biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clip placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Management of discordant findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management of benign or atypical lesions on core biopsy results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      WIRE LOCALIZATION BREAST BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Postoperative mammography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MRI-GUIDED BREAST BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SKIN PUNCH BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INCISIONAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EXCISIONAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASSAY FOR HORMONE RECEPTORS AND HER2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      AXILLARY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Impact of breast biopsy on later SLN biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=related_link\">",
"      Breast cysts: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=related_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20296?source=related_link\">",
"      Sentinel lymph node biopsy in breast cancer: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24505="Visual development and vision assessment in infants and children";
var content_f23_59_24505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Visual development and vision assessment in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24505/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24505/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24505/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/59/24505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision assessment is an important part of the medical care of children. Severe visual abnormalities (eg, cataracts, strabismus) that are not treated in the first few months or years of life can lead to the development of amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Visual loss also may be an early indication of serious or life-threatening diseases, such as retinoblastoma, lipid storage disorders, or peroxisomal disorders (",
"    <a class=\"graphic graphic_table graphicRef64851 \" href=\"UTD.htm?29/17/29980\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link\">",
"     \"Overview of retinoblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of the visual system and vision assessment in infants and children will be reviewed here. Specific ophthalmologic problems (eg, cataract, glaucoma, strabismus, refractive error, amblyopia, retinoblastoma) are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VISUAL DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The visual system (retina, optic nerves, and visual cortex) is immature at birth. It begins to mature during the first weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/5\">",
"     5",
"    </a>",
"    ]. Myelination of the optic nerves, development of the visual cortex, and growth of the lateral geniculate body occur over the first two years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/6\">",
"     6",
"    </a>",
"    ]. The fovea, the most visually sensitive part of the retina, reaches maturity at approximately four years of age.",
"   </p>",
"   <p>",
"    The period of visual maturation is a critical period during which the visual system is affected by outside influences. Visual stimuli are critical to the development of normal vision. Development of the visual pathways in the central nervous system requires that the brain receive equally clear, focused images from both eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/7\">",
"     7",
"    </a>",
"    ]. Ocular process (eg, refractive error, strabismus, cataract) that interferes with or inhibits the development of the visual pathways may result in amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link\">",
"     \"Refractive errors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of amblyopia\", section on 'Definition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and management of strabismus in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Visual behavior and performance evolve with maturation of the visual system (",
"    <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual fixation can be demonstrated shortly after birth [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/8\">",
"       8",
"      </a>",
"      ]. The visual acuity of a newborn infant is estimated to be approximately",
"      <span class=\"nowrap\">",
"       20/400",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ability to follow an object is detectable in most infants by three months of age.",
"     </li>",
"     <li>",
"      Stereopsis and binocular visual function develop between the ages of three and seven months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Visual acuity reaches the adult level of",
"      <span class=\"nowrap\">",
"       20/20",
"      </span>",
"      by three to five years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF VISION ASSESSMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Objectives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children rarely complain of visual difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"     10",
"    </a>",
"    ]. Vision assessment is an important component of pediatric care. It is performed to detect conditions that affect visual potential; early detection and prompt treatment of these conditions may prevent lifelong visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"     10",
"    </a>",
"    ]. Careful vision assessment also may facilitate detection of neurologic, metabolic, or genetic disorders that have important treatment implications.",
"   </p>",
"   <p>",
"    Ocular and systemic conditions that may be detected through vision assessment in infants and children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cataracts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H11#H11\">",
"       \"Cataract in children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strabismus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amblyopia and amblyopia risk factors (eg, cataracts, strabismus, unequal refractive error). Amblyopia should be suspected when the vision between the two eyes differs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinoblastoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of retinoblastoma\", section on 'Clinical presentation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glaucoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"       \"Overview of glaucoma in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=see_link\">",
"       \"Primary infantile glaucoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurologic, metabolic, or genetic disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"       \"Peroxisomal disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Referral indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for referral to an ophthalmologist or eye care specialist who is appropriately trained and experienced in treating children include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal red reflex (may indicate cataract, glaucoma, retinoblastoma, retinal abnormality, or strabismus, or unequal or high refractive error) (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"       figure 1",
"      </a>",
"      ). Infants with abnormal red reflex should be referred immediately; the referring clinician should communicate directly with the ophthalmologist and confirm that the consultation actually occurred [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link&amp;anchor=H21#H21\">",
"       \"The pediatric physical examination: HEENT\", section on 'Red reflex'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H16#H16\">",
"       \"Approach to the child with leukocoria\", section on 'Referral'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Personal history of prematurity or metabolic or genetic disease with ophthalmologic implications; family history of childhood cataract, retinoblastoma, retinal dysplasia, or glaucoma. Infants with such histories should have a formal ophthalmologic examination in the first weeks or months of life, depending upon the condition. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Abnormal ocular alignment (ie, strabismus).",
"     </li>",
"     <li>",
"      Pupillary asymmetry of &ge;1 mm (suggestive of neurologic condition).",
"     </li>",
"     <li>",
"      Corneal asymmetry (suggestive of glaucoma).",
"     </li>",
"     <li>",
"      Unilateral ptosis or other lesions obstructing the visual axis (eg, eyelid hemangioma), which may cause amblyopia.",
"     </li>",
"     <li>",
"      Asymmetry of vision (eye preference) or visual acuity difference of two lines or more between eyes.",
"     </li>",
"     <li>",
"      Visual acuity worse than",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      in a child three to five years of age or worse than",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      in a child &gt;6 years (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Visual acuity tests'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Nystagmus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Optimal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of vision should be performed in a room with minimal distractions; the door to the examination room should be closed. Other siblings should be reminded to remain silent.",
"   </p>",
"   <p>",
"    Infants and young children are best examined while being held upright in the arms of their caregivers. In children younger than two to three years of age, visual behavior (",
"    <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"     table 2",
"    </a>",
"    ), rather than visual acuity, is assessed. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Visual behavior'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children usually are able to follow directions required for visual acuity testing starting around age three to four years. Patient cooperation is essential to an optimal examination. Accurate assessment of visual acuity can be made in almost all cooperative verbal children. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Visual acuity tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VISUAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of the vision history cannot be overemphasized. Parents often are aware of vision problems in their child before the problem is readily apparent to the clinician. The examiner should ask the parents relevant questions. Suggested questions may include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does your child see well?",
"     </li>",
"     <li>",
"      Do the eyes appear to cross or wander?",
"     </li>",
"     <li>",
"      Have you noticed anything unusual about your child's vision?",
"     </li>",
"     <li>",
"      Does your child hold things close?",
"     </li>",
"     <li>",
"      Does your child squint?",
"     </li>",
"     <li>",
"      Do your child's eyelids droop?",
"     </li>",
"     <li>",
"      Have your child's eyes been injured?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The child's past medical history should be reviewed, because many medical conditions have associated ophthalmologic findings (eg, lipid storage disorders, peroxisomal disorders). Children with a history of prematurity, for example, are at risk for developing amblyopia, high myopia (nearsightedness), and strabismus. Among children with severe visual impairment, 70 percent have additional handicaps; 10 percent have impaired hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The family history should be reviewed for serious childhood eye disease (eg, childhood cataracts, strabismus, amblyopia, glaucoma, retinal problems, nystagmus). Many ophthalmologic conditions are familial; a positive family history increases the likelihood the child may have similar problems. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Referral indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     VISUAL BEHAVIOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children younger than two to three years of age, visual behavior (",
"    <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"     table 2",
"    </a>",
"    ), rather than visual acuity, is assessed. The goal is to determine whether visual behavior is normal for age and whether behavior is similar between the two eyes. Visual behavior can be tested in virtually all children. Newborn infants demonstrate visual fixation if an appropriate target (eg, the human face) is used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of visual behavior begins with the observation of the child's reaction as the examiner enters the room. The child's ability to see the examiner, to visually track the examiner, and to respond to the examiner's smile should be noted. Visual behavior varies with the age of the child (",
"    <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One-month-old infants make eye contact and begin to look at objects that are close to their faces. They appear serious as they fixate.",
"     </li>",
"     <li>",
"      Two-month-old infants begin to display facial expression as they fixate.",
"     </li>",
"     <li>",
"      Three-month-old infants begin to observe their hands while holding them close to their faces.",
"     </li>",
"     <li>",
"      Three- to four-month-old infants begin to watch activity that occurs around them.",
"     </li>",
"     <li>",
"      Six-month-old infants observe their surroundings and recognize favorite people, toys, or foods at a distance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fixation reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quality of the fixation reflex is a good marker of visual function in most preverbal children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"     10",
"    </a>",
"    ]. The choice of target varies depending upon the age of the child. Objects with spatial orientation are essential.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The human face, for which there may be a genetic fixation preference [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/14\">",
"       14",
"      </a>",
"      ], is the ideal target for children younger than three to four months of age.",
"     </li>",
"     <li>",
"      Small, colorful toys or stickers placed on the end of tongue depressors are good targets for infants older than three to four months. More than one target may be necessary for these children because they rapidly lose interest.",
"     </li>",
"     <li>",
"      White light (eg, from a pen light) should be avoided because it lacks spatial orientation.",
"     </li>",
"     <li>",
"      Targets that make noise should be avoided because they provide both visual and auditory cues, and distinguishing which cues the child is using to track the object is difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In testing fixation, the target is moved to and fro while the child remains still. False-positive results may be obtained if the child, rather than the target, is moved. Movement of the child may activate the vestibuloocular reflex, which causes the eyes to move; this reflex is not a measure of visual behavior. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vestibuloocular reflex'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both eyes are assessed together, and then each eye is tested separately by occluding one eye at a time. Accuracy is improved if the fixation test is repeated several times. The eye movements of infants are expected to be somewhat uncoordinated. The ability to follow past midline develops at approximately three to six months of age; vertical eye movements develop around three months.",
"   </p>",
"   <p>",
"    Serious visual disorders may be indicated by asymmetry or abnormality in the fixation reflex. One limitation of the fixation-and-follow test is that it uses the presence of a motor function (eye movement) as a marker of vision. Thus, false-negative results may be obtained if the child has a condition that prevents normal eye movement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=see_link\">",
"     \"Fourth cranial nerve (trochlear nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=see_link&amp;anchor=H3#H3\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation &ndash; Two methods are commonly used to document the fixation reflex: the central-steady-maintained (CSM) method and the fix-and-follow (F + F) method. Both methods provide useful information; the choice of one over the other is a matter of personal preference.",
"      <br/>",
"      <br/>",
"      In the CSM notation, with one eye occluded (the cover test), several characteristics of fixation are noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is the fixation central (",
"      <strong>",
"       C",
"      </strong>",
"      ) or",
"      <span class=\"nowrap\">",
"       eccentric/noncentral",
"      </span>",
"      (NC)?",
"     </li>",
"     <li>",
"      Is the fixation held steadily on the target as it is held still and slowly moved (",
"      <strong>",
"       S",
"      </strong>",
"      ), or not (US)?",
"     </li>",
"     <li>",
"      Is the child able to maintain fixation with the viewing eye when the other eye is uncovered or through a blink (",
"      <strong>",
"       M",
"      </strong>",
"      ), or not (NM)?",
"      <br/>",
"      <br/>",
"      In the F + F notation, whether the child is able to fixate on and follow a target as it is slowly moved through his or her visual space is noted. Each eye is tested separately. Notation also should be made of the child's ability to maintain fixation with the viewing eye when the other eye is uncovered. Determining if an eye is able to maintain fixation after the other eye is covered is only possible with the use of special techniques available to the ophthalmologist, unless the child has strabismus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preferential looking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced preferential looking method uses grating (Teller) cards to test visual acuity and relies upon the preference of children to look at patterns of alternating contrast rather than homogeneous targets. Grating cards typically have one target area with alternating light and dark stripes and another that is homogeneously gray. The examiner, observing through a small hole in the center of the card, notes the direction of the child's gaze as each card is presented. Targets with thinner and thinner stripes are presented until the child no longer has a preference. Visual acuity is estimated by the thinnest target lines that the child is able to detect. Accuracy is improved with test repetition. This technique is used infrequently in the primary care setting.",
"   </p>",
"   <p>",
"    The limitations of the grating test method include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The results are not directly comparable to visual target testing",
"     </li>",
"     <li>",
"      They tend to overestimate vision",
"     </li>",
"     <li>",
"      Accuracy is dependent upon the examiner's skill level",
"     </li>",
"     <li>",
"      Lack of cooperation or visual field deficits affect results",
"     </li>",
"     <li>",
"      It is time consuming",
"     </li>",
"     <li>",
"      It is difficult to assess fixation in children with nystagmus or ocular motility abnormalities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VISUAL ACUITY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accurate assessment of visual acuity can be made in almost all cooperative verbal children. Visual acuity testing with optotypes should be attempted in all children older than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"     10",
"    </a>",
"    ]. It should be repeated periodically throughout childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening tests in children and adolescents\", section on 'Vision screen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Optotype tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optotype recognition tests assess the child's ability to see and recognize an optotype (eg, figure or letter) and to communicate that recognition to the examiner. There are several such tests (",
"    <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Snellen acuity test (the standard letter test) is the gold-standard test and is typically used for children who can identify the letters of the alphabet. Other optotypes are used for children who cannot identify letters. They include pictures (eg, Allen figures, Lea figures), directional optotypes (eg, tumbling E game and Landolt rings), or special charts with a limited number of test letters that the child can learn or identify by matching (eg, HOTV test).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Snellen test &ndash; When using the Snellen chart, the examiner should listen for letters that are consistently misnamed (eg, \"E\" for \"F\"); such misnamings may indicate lack of familiarity with the alphabet rather than an inability to distinguish the letter [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Picture optotypes &ndash; Picture optotype tests can be used to test visual acuity in children who do not know the letters of the alphabet or cannot cooperate for directional optotype tests like the E game (discussed below). Picture optotype tests are available as wall charts or handheld cards (Allen cards).",
"      <br/>",
"      <br/>",
"      Allen cards are one example of a picture optotype test (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ). The child is presented with a single optotype, typically of",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"       table 3",
"      </a>",
"      ) size. The examiner begins at near distance and gradually increases distance until the child can no longer identify the figures. Visual acuity is recorded as the maximum distance (in feet) that the child is able to identify figures over the denominator of the optotype. Thus, for a child who identifies the",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      optotype at 8 feet, vision is recorded as: Allen card vision,",
"      <span class=\"nowrap\">",
"       8/30,",
"      </span>",
"      right eye.",
"      <br/>",
"      <br/>",
"      Some picture charts provide a more accurate assessment of visual acuity than others. As an example, Allen figures are easier to guess than Lea figures (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ) because the component elements of Allen figures have non-uniform shapes and thicknesses.",
"      <br/>",
"      <br/>",
"      The limitations of picture optotype tests are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      They depend upon the child's familiarity with the pictured objects",
"     </li>",
"     <li>",
"      Some children may not be willing to provide a verbal response",
"     </li>",
"     <li>",
"      Cultural and social factors affect results [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Many picture tests cannot test acuity better than",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Picture tests may overestimate visual acuity in children with amblyopia (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Crowding phenomenon'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Directional&nbsp;optotype tests &ndash; Directional optotype tests (eg, the tumbling E game, Landolt rings) (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ) require the child to identify the direction the optotype is facing and to point in the same direction. The tumbling E game is an accurate test of visual acuity.",
"      <br/>",
"      <br/>",
"      However, many children have difficulty comprehending right versus left and coordinating pointing in the correct direction [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/9,18\">",
"       9,18",
"      </a>",
"      ]. These difficulties can be overcome without compromising accuracy by using only three directions, \"up\", \"down\", and \"to the side\", and allowing the child to give the response verbally instead of pointing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/15\">",
"       15",
"      </a>",
"      ]. The chance of the child guessing correctly in three consecutive responses is less than 5 percent, and in four consecutive responses is less than 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/15\">",
"       15",
"      </a>",
"      ]. Landolt rings and other tests that use a directional optotype also can be converted to a three-choice test.",
"     </li>",
"     <li>",
"      Matching tests &ndash; Matching tests (eg, the HOTV chart) (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ) can be used to test the visual acuity of children who are unwilling or unable to communicate verbally. Matching tests are particularly useful for children who are shy or who have a speech impairment.",
"      <br/>",
"      <br/>",
"      The examiner indicates an optotype on the vision chart or card, and the child points to the optotype that matches it on his or her own sample card of the optotypes. The tumbling E, Allen cards, Landolt rings, HOTV, and Lea chart all can be used as matching tests (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision testing performance can be improved by preteaching children how to do the test [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Teaching typically is performed by holding the test targets close to the child or using large optotypes; both of the child's eyes should be used during practice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/9\">",
"     9",
"    </a>",
"    ]. Parents can practice with the child at home before the vision evaluation if they are provided with a copy of the test optotypes and instructions for practicing.",
"   </p>",
"   <p>",
"    Optotype recognition tests are designed to test the vision in each eye individually. Vision should be assessed with and without glasses in children who wear them. If the child is known to have poor vision in one eye, that eye should be tested first to minimize poor performance from loss of attention and to avoid memorization artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Testing artifacts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The standard distance for visual acuity testing in the United States is 20 feet; in other countries it may be 4 meters or 6 meters (",
"    <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"     table 3",
"    </a>",
"    ). However, many children perform better with the test target at 10 feet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/18,19,21\">",
"     18,19,21",
"    </a>",
"    ]. Such testing is acceptable as long as the eye chart is recalibrated for testing at 10 feet. Testing at 10 feet often is preferable in the primary care setting, where the only 20-foot distance may be in an active, noisy hallway full of distractions.",
"   </p>",
"   <p>",
"    Visual acuity testing should be performed efficiently, since the child may quickly lose interest; the child need not identify every optotype on the chart. If the child appears to see normally, the examiner should begin with the row for visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"     table 3",
"    </a>",
"    ) and adjust up or down as needed. The child can identify one figure in a row, and if it is correct, the examiner should go to the next row. If the child misses two figures in a row, the examiner should ask the child to identify all of the figures in the previous row. Visual acuity for the tested eye is the visual acuity of the row above the row in which the child consistently misses two or more figures.",
"   </p>",
"   <p>",
"    The visual acuity often can be determined using only two or three rows of optotypes.",
"   </p>",
"   <p>",
"    It may be easier to keep the child on task if the examiner performs the testing in a game-like manner. Encouragement and positive reinforcement from the parents and the examiner are critical, particularly for the shy child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Crowding phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"crowding phenomenon\" must be considered when examining visual acuity in children who may have amblyopia. The crowding phenomenon is defined by the achievement of better visual acuity when optotypes are presented in isolation than when they are presented in a row with other optotypes.",
"   </p>",
"   <p>",
"    Crowding of multiple visual targets shown to a normal eye has minimal effect on visual acuity. However, crowding of visual targets creates significant distortion in the amblyopic eye and lowers results of visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, using a row of targets provides a more accurate assessment of visual acuity and improved detection of amblyopia.",
"   </p>",
"   <p>",
"    For children who find it easier to understand the vision testing process when optotypes are presented singly, isolated optotypes can be used if there is an adaptation to induce crowding. As an example, contour interaction bars (crowding bars) can be placed around the optotype (",
"    <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/18\">",
"     18",
"    </a>",
"    ]. Crowding can be induced with Allen cards by holding three cards in a row and pointing to the center card for identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child must identify the majority of optotypes of a visual acuity line correctly to be scored with that acuity. When unequal visual acuity is detected, the eye with worse acuity should be retested.",
"   </p>",
"   <p>",
"    Measured visual acuity varies with the age of the child; children younger than four or five years may have acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     20/50",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"     table 3",
"    </a>",
"    ); those who are four to five years should have acuity of at least",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/18\">",
"     18",
"    </a>",
"    ]. The young child's vision should be considered normal if the visual acuity is equal and not severely reduced in the two eyes (ie, better than",
"    <span class=\"nowrap\">",
"     20/50).",
"    </span>",
"    Thus, a three-year-old child who has",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    vision in each eye with the tumbling E test is considered to have normal vision, but a three-year-old child with",
"    <span class=\"nowrap\">",
"     20/70",
"    </span>",
"    vision should undergo further evaluation.",
"   </p>",
"   <p>",
"    Most children have better visual acuity than is recorded, but they are not able to maintain attention for the testing of very small letters. The author of this topic review often tells parents that their child probably has",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    vision, but only a",
"    <span class=\"nowrap\">",
"     20/50",
"    </span>",
"    attention span.",
"   </p>",
"   <p>",
"    Amblyopia should be suspected if acuity differs by more than one row between eyes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Testing artifacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may squint, peek, or memorize the chart in an effort to do a good job, any of which may falsely improve the recorded visual acuity. In addition, in children with amblyopia, visual acuity may falsely appear to improve if optotypes are presented in isolation rather than in a row (the crowding phenomenon, described above). The recorded visual acuity may be falsely low in children who have nystagmus unless efforts are made to compensate for it using techniques that typically are available only to the ophthalmologist. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Vision assessment in children with nystagmus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squinting &ndash; Squinting creates a \"pinhole\" effect, limiting the number of light rays that enter the eye, and thereby minimizes the blur that is present without squinting.",
"     </li>",
"     <li>",
"      Peeking &ndash; Peeking occurs frequently and can be overlooked if the examiner is not careful. The child can peek around a handheld occluder if the examiner turns around to verify the optotype. It is best for the examiner to sit or stand where he or she can see both the child and the chart. The palm of a parent's hand or an eye patch can be used for occlusion if all else fails.",
"     </li>",
"     <li>",
"      Memorization &ndash; Memorization of a row of optotypes is difficult to prevent but is easily overcome by asking the child to read the optotypes in reverse or random order. Computer-generated eye charts provide an unlimited array of letter combinations that can be used to prevent memorization. These systems also facilitate vision testing using a strict protocol that may improve accuracy. However, their cost typically precludes their use in the primary care setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3092026\">",
"    <span class=\"h1\">",
"     PHOTOSCREENING AND AUTOREFRACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photoscreeners use optical images of the red reflex to detect refractive errors (anisometropia, high hypermetropia, high astigmatism), media opacities (eg, cataracts), strabismus, or adnexal deformities (eg, ptosis), each of which is a risk factor for amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Autorefractors use automated retinoscopy or wave-front technology to evaluate refractive error.",
"   </p>",
"   <p>",
"    Photoscreening and autorefraction are alternatives to assessment of visual behavior in children six months to three years of age and to visual acuity screening with vision charts in children three to five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast to assessment of visual behavior and visual acuity testing, photoscreening and autorefraction can be performed with minimal cooperation of the child. These methods may be particularly beneficial in preverbal, preliterate, or developmentally delayed children.",
"   </p>",
"   <p>",
"    In observational studies, vision screening of preschool children with photoscreening or autorefraction has been associated with early detection of risk factors for amblyopia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/25-35\">",
"     25-35",
"    </a>",
"    ]. In some of the studies, earlier detection was associated with improved visual acuity outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/26,28\">",
"     26,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEAR VISION TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Near vision should be performed in children who have the following complaints:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decline in school performance",
"     </li>",
"     <li>",
"      Reading difficulty",
"     </li>",
"     <li>",
"      Eye strain (asthenopia)",
"     </li>",
"     <li>",
"      Headaches",
"     </li>",
"     <li>",
"      Double vision",
"     </li>",
"     <li>",
"      Blepharospasm",
"     </li>",
"     <li>",
"      Blurred or distorted near vision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Near vision testing also should be performed in children with nystagmus. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Vision assessment in children with nystagmus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Near vision testing is performed much the same as is that for distance vision. A near vision testing card is used to present optotypes that are appropriately sized for the testing distance that is printed on the card, typically 14 inches. Near vision is tested with each eye individually. The distance at which the test is performed must be recorded because the testing distance alters the size of the image projected on the retina and, hence, the test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COLOR VISION TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper color discrimination requires the presence of normal cone function. Color deficiency is common, with as many as 8 percent of males and 0.4 percent of females having some level of color deficiency. Most color vision abnormalities in children are congenital in origin. Acquired color vision deficits are much less common and can be caused by optic nerve or retinal disease, among others.",
"   </p>",
"   <p>",
"    Opinion varies on the value of routine color vision testing in otherwise asymptomatic children. Some eye specialists routinely test color vision on new patients who are old enough to cooperate for testing (usually around eight years old), whereas most reserve color vision testing for those who have an indication for color vision testing, such as a family history of color vision deficits, problems with color discrimination, or a disease state that may be associated with a color vision abnormality.",
"   </p>",
"   <p>",
"    Color vision testing can be achieved with a variety of tests. Pseudo-isochromatic plates, such as those available with the Ishihara and the Hardy-Rand-Rittler tests, are commonly used color vision screening tests. More advanced tests, such as the Farnsworth D-15 and Farnsworth-Munsell 100 Hue tests, may be used to better characterize a deficit noted on screening tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VISION ASSESSMENT IN CHILDREN WITH NYSTAGMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nystagmus, a rhythmic to-and-fro movement of the eyes, can be horizontal, vertical, rotary, or a combination of these. Nystagmus may be present all the time (manifest) or only when one eye is covered (latent). Children in whom nystagmus is detected should be referred for ophthalmologic evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=see_link\">",
"     \"Overview of nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vision is usually decreased in children with nystagmus. However, near vision may be better than distance vision. Both near and distance visual acuity testing should be performed in children with nystagmus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Manifest nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifest nystagmus is present all the time. Many children with manifest nystagmus can improve their vision by assuming an abnormal head posture. Nystagmus may be damped when the eyes are directed in a particular field of gaze (eg, up gaze, side gaze, etc), prompting the abnormal head posture. This quiet eye position is called the null zone.",
"   </p>",
"   <p>",
"    Children with manifest nystagmus should have visual acuity tested initially with both eyes open and the head erect, then with both eyes open and the head in the preferred posture. As an example, the results of testing for a child who holds the head to the left would be documented as follows:",
"   </p>",
"   <p>",
"    Vision tested with both eyes open:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      With head straight &ndash;",
"      <span class=\"nowrap\">",
"       20/80",
"      </span>",
"     </li>",
"     <li>",
"      With head turned to left &ndash;",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vision then is tested in each eye separately, and the head posture the patient adopts should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Latent nystagmus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Latent nystagmus is present only when one eye is covered. Children who have latent nystagmus should be tested initially with both eyes open; in this situation, the eyes are quiet and motionless. Abnormal head posture should be noted if present. Vision should then be tested in each eye individually. In the pediatric ophthalmology office, the eye that is not being tested is covered with a +5.00 to +10.00 lens to \"fog\", but not occlude, the vision. Monocular visual acuity can be more accurately assessed because fogging does not induce latent nystagmus. The results of testing are recorded in the medical record as in the following example:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Both eyes open &ndash;",
"      <span class=\"nowrap\">",
"       20/20",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Right eye &ndash;",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      (+5 to +10.00 fogging lens)",
"     </li>",
"     <li>",
"      Left eye &ndash;",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      (+5 to +10.00 fogging lens)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     VISION ASSESSMENT IN CHILDREN WITH SPECIAL NEEDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The population of children with special needs includes children who have known or suspected visual impairment, cerebral palsy, developmental delay, or other neurologic abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H2#H2\">",
"     \"Children with special health care needs\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of vision testing for children with special needs is to determine whether they see and, if so, to estimate the level of vision. This goal is often best met with involvement of the child's parents, teachers, primary care physician, neurologist, ophthalmologist, counselor, physical or occupational therapist, and others who can provide information about the child's visual performance.",
"   </p>",
"   <p>",
"    The examiner should have an understanding of the effects of the child's medical problems on the child's behavior so that testing conditions can be optimized. Some children perform better at certain times of day (ie, when awake or about in the morning); others are on medications that may affect their ability to perform. Visual assessment is feasible in the majority of children with special healthcare needs under the right circumstances (eg, suitably adapted methods, familiar environment, patient and skilled examiner) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/36\">",
"     36",
"    </a>",
"    ]. In a cohort of 240 children attending schools for special needs, 95 percent were able to cooperate with assessment of visual function, and visual acuity could be reliably assessed in 83 percent. Approximately one-half had a refractive error that required correction, and one-half of these required a new prescription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important clinical signs of severe visual impairment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Manifest nystagmus (present all the time), which may result from abnormalities of the eyes, optic nerves, or brain.",
"     </li>",
"     <li>",
"      \"Blindisms\" or behaviors that occur in children with severe visual impairment. Examples include repeated poking of the eyes (oculodigital reflex), repetitive rocking of the head or trunk, and repetitive hand waving.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vision tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some rudimentary tests of vision can be used to assess the visual performance of children with special needs who cannot perform conventional optotype testing and in whom visual behavior is otherwise difficult to assess:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal response to a bright pen light is eye closure or withdrawal; ignoring the light is a cause for concern.",
"     </li>",
"     <li>",
"      Constriction of the pupils to light indicates that the afferent and efferent pupillomotor pathways are intact and increases the likelihood that the child sees. However, the test must be interpreted with caution, because children with cortical blindness may have normal pupillary responses.",
"     </li>",
"     <li>",
"      The threat response is a learned reflex in which the child withdraws when an object (or the examiner's hand) is moved rapidly into the child's visual space. It indicates the presence of at least rudimentary vision and is reliable in children older than six months of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other means of testing the vision of children with special needs include the vestibuloocular reflex and use of optokinetic drums.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Vestibuloocular reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vestibuloocular reflex (VOR) is a normal reflex in people who have an intact neurologic system. The examiner, while holding the child, rotates 360 degrees to stimulate the semicircular canals in the inner ear and cause a temporary nystagmus. The presence of normal vision inhibits VOR nystagmus within three to five seconds after the rotation stops. Nystagmus may continue for 15 to 30 seconds in children who have severe visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Optokinetic drum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optokinetic drums are cylindrical devices with a recurring pattern of white and black stripes of varying thickness. Rotation of the drum in the child's visual space stimulates the development of nystagmus if the child can distinguish the black and white contrast. Gross vision (ie,",
"    <span class=\"nowrap\">",
"     20/400)",
"    </span>",
"    is present if the child responds to the optokinetic drum with thick stripes. Visual acuity can be estimated by using drums with thinner and thinner stripes until the response is no longer detected. False negative tests occur in children who lack interest or who do not have normal ocular motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/38\">",
"     38",
"    </a>",
"    ]. False-positive results, presumably caused by the presence of other vision-related neural pathways, can occur in children who do not have a normal visual cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     VISUAL EVOKED POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The office eye examination is not always sufficient to determine whether a child is able to see. The visual evoked potential (VEP) test is used when other measures do not provide the necessary information. The VEP test uses electrodes that are placed on the child's scalp, over the occipital lobes of the brain, to detect electrical response in the visual cortex in response to visual stimuli.",
"   </p>",
"   <p>",
"    VEP testing is not necessary in routine clinical practice and is generally obtained only in special situations. The visual stimuli are patterned targets (eg, checkerboards) that are presented to the child on a television monitor. Analysis of the electrical patterns that are produced permits estimation of the child's visual acuity. Close agreement between VEP testing and psychophysical testing exists [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24505/abstract/39\">",
"     39",
"    </a>",
"    ]. However, VEP results must be interpreted with caution because variation in laboratory technique can alter the results, and normal flash VEP (VEP using a flash stimulus rather than a patterned target) can occur in the absence of a functioning visual cortex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/58/27553?source=see_link\">",
"       \"Patient information: Crossed eyes and lazy eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual stimuli are critical to the development of normal vision. Any ocular process that significantly interferes with or inhibits the development of the visual pathways may result in amblyopia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Visual development'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link\">",
"       \"Overview of amblyopia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Visual behavior and performance evolve with maturation of the visual system (",
"      <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Visual development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vision assessment is performed to detect conditions that affect visual potential. Indications for referral to an ophthalmologist include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Referral indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormal red reflex",
"     </li>",
"     <li>",
"      History of prematurity",
"     </li>",
"     <li>",
"      Metabolic disease or genetic disease with ophthalmologic implications",
"     </li>",
"     <li>",
"      Family history of childhood cataract, retinoblastoma, retinal dysplasia, or glaucoma",
"     </li>",
"     <li>",
"      Abnormal ocular alignment",
"     </li>",
"     <li>",
"      Pupillary asymmetry of &ge;1 mm",
"     </li>",
"     <li>",
"      Corneal asymmetry",
"     </li>",
"     <li>",
"      Unilateral or bilateral ptosis or other lesions obstructing the visual axis",
"     </li>",
"     <li>",
"      Asymmetry of vision",
"     </li>",
"     <li>",
"      Visual acuity worse than",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef88620 \" href=\"UTD.htm?26/47/27388\">",
"       table 3",
"      </a>",
"      ) in a child three to five years of age or worse than",
"      <span class=\"nowrap\">",
"       20/30",
"      </span>",
"      in a child &gt;6 years",
"     </li>",
"     <li>",
"      Nystagmus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parents often are aware of a vision problem before it is readily apparent to the clinician. It is important to ask the parents specific questions about the child's vision, including whether the child sees well, holds things close, or squints; the eyes appear to cross or wander; the eyelids droop; or the eyes have ever been injured. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Visual history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children younger than two to three years of age, visual behavior (",
"      <a class=\"graphic graphic_table graphicRef73947 \" href=\"UTD.htm?6/12/6348\">",
"       table 2",
"      </a>",
"      ), rather than visual acuity, is assessed. The goal is to determine whether visual behavior is normal for age and whether vision behavior is similar between the two eyes. Visual behavior may be assessed through observation, evaluation of the fixation reflex, and forced preferential looking. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Visual behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visual acuity testing with optotypes (",
"      <a class=\"graphic graphic_figure graphicRef60600 \" href=\"UTD.htm?40/50/41760\">",
"       figure 2",
"      </a>",
"      ) should be attempted in all children older than two to three years. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Visual acuity tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Photoscreening and autorefraction are alternatives to assessment of visual behavior in children six months to three years of age and to visual acuity screening with vision charts in children three to five years of age. (See",
"      <a class=\"local\" href=\"#H3092026\">",
"       'Photoscreening and autorefraction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/1\">",
"      Hyvarinen L. Assessment of visually impaired infants. Ophthalmol Clin North Am 1994; 7:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/2\">",
"      Magramm I. Amblyopia: etiology, detection, and treatment. Pediatr Rev 1992; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/3\">",
"      Bohra LI, Weizer JS, Lee AG, Lewis RA. Vision loss as the presenting sign in juvenile neuronal ceroid lipofuscinosis. J Neuroophthalmol 2000; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/4\">",
"      Traboulsi EI, Maumenee IH. Ophthalmologic manifestations of X-linked childhood adrenoleukodystrophy. Ophthalmology 1987; 94:47.",
"     </a>",
"    </li>",
"    <li>",
"     Hyvarinen L. Vision in Children: Normal and Abnormal, Canadian Deaf-Blind Rubella Association, Meaford, ON 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/6\">",
"      Boothe RG, Dobson V, Teller DY. Postnatal development of vision in human and nonhuman primates. Annu Rev Neurosci 1985; 8:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/7\">",
"      Eye examination and vision screening in infants, children, and young adults. American Academy of Pediatrics Committee on Practice and Ambulatory Medicine, Section on Ophthalmology. Pediatrics 1996; 98:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/8\">",
"      Ling B. Genetic study of sustained fixation and associated behavior in the human infant from birth to six months. J Genet Psychol 1942; 61:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/9\">",
"      Shamis DI. Collecting the \"facts\": Vision assessment techniques: Perils and pitfalls. Am Orthopt J 1996; 46:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/10\">",
"      Committee on Practice and Ambulatory Medicine, Section on Ophthalmology. American Association of Certified Orthoptists, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology. Eye examination in infants, children, and young adults by pediatricians. Pediatrics 2003; 111:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/11\">",
"      Essman SW, Essman TF. Screening for pediatric eye disease. Am Fam Physician 1992; 46:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/12\">",
"      Hartmann EE, Dobson V, Hainline L, et al. Preschool vision screening: summary of a Task Force report. Behalf of the Maternal and Child Health Bureau and the National Eye Institute Task Force on Vision Screening in the Preschool Child. Pediatrics 2000; 106:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/13\">",
"      American Academy of Pediatrics, Section on Ophthalmology, American Association for Pediatric Ophthalmology And Strabismus, et al. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/14\">",
"      Goren CC, Sarty M, Wu PY. Visual following and pattern discrimination of face-like stimuli by newborn infants. Pediatrics 1975; 56:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/15\">",
"      Simons K. Visual acuity norms in young children. Surv Ophthalmol 1983; 28:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/16\">",
"      Quinn GE, Berlin JA, James M. The Teller acuity card procedure. Three testers in a clinical setting. Ophthalmology 1993; 100:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/17\">",
"      Friedman DS, Katz J, Repka MX, et al. Lack of concordance between fixation preference and HOTV optotype visual acuity in preschool children: the Baltimore Pediatric Eye Disease Study. Ophthalmology 2008; 115:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/18\">",
"      Friendly DS. Preschool visual acuity screening tests. Trans Am Ophthalmol Soc 1978; 76:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/19\">",
"      Recommended stardard procedures for the clinical measurement and specification of visual acuity. Report of working group 39. Committee on vision. Assembly of Behavioral and Social Sciences, National Research Council, National Academy of Sciences, Washington, D.C. Adv Ophthalmol 1980; 41:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/20\">",
"      Bachman JA, Bachman WG, Franzel AS, Marcus MC. Preteaching developmentally delayed preschoolers to aid vision screening. Optom Vis Sci 1994; 71:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/21\">",
"      Brant JC, Nowotny M. Testing of visual acuity in young children: an evaluation of some commonly used methods. Dev Med Child Neurol 1976; 18:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/22\">",
"      Morad Y, Werker E, Nemet P. Visual acuity tests using chart, line, and single optotype in healthy and amblyopic children. J AAPOS 1999; 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/23\">",
"      Miller JM, Lessin HR, American Academy of Pediatrics Section on Ophthalmology, et al. Instrument-based pediatric vision screening policy statement. Pediatrics 2012; 130:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/24\">",
"      Donahue SP. Objective vision screening for amblyopia in children: a test that has finally arrived. Ophthalmology 2010; 117:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/25\">",
"      Schmidt P, Maguire M, Dobson V, et al. Comparison of preschool vision screening tests as administered by licensed eye care professionals in the Vision In Preschoolers Study. Ophthalmology 2004; 111:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/26\">",
"      Kirk VG, Clausen MM, Armitage MD, Arnold RW. Preverbal photoscreening for amblyogenic factors and outcomes in amblyopia treatment: early objective screening and visual acuities. Arch Ophthalmol 2008; 126:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/27\">",
"      Arthur BW, Riyaz R, Rodriguez S, Wong J. Field testing of the plusoptiX S04 photoscreener. J AAPOS 2009; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/28\">",
"      Atkinson J, Braddick O, Nardini M, Anker S. Infant hyperopia: detection, distribution, changes and correlates-outcomes from the cambridge infant screening programs. Optom Vis Sci 2007; 84:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/29\">",
"      Rowatt AJ, Donahue SP, Crosby C, et al. Field evaluation of the Welch Allyn SureSight vision screener: incorporating the vision in preschoolers study recommendations. J AAPOS 2007; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/30\">",
"      Salcido AA, Bradley J, Donahue SP. Predictive value of photoscreening and traditional screening of preschool children. J AAPOS 2005; 9:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/31\">",
"      Matta NS, Arnold RW, Singman EL, Silbert DI. Comparison between the plusoptiX and MTI Photoscreeners. Arch Ophthalmol 2009; 127:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/32\">",
"      Teed RG, Bui CM, Morrison DG, et al. Amblyopia therapy in children identified by photoscreening. Ophthalmology 2010; 117:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/33\">",
"      Leman R, Clausen MM, Bates J, et al. A comparison of patched HOTV visual acuity and photoscreening. J Sch Nurs 2006; 22:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/34\">",
"      Guo X, Jia X, Guo L, et al. Comparison of computer-photoscreening with non-cycloplegic retinoscopy for amblyopiogenic risk factors in children. Chin Med J (Engl) 2000; 113:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/35\">",
"      Longmuir SQ, Boese EA, Pfeifer W, et al. Practical community photoscreening in very young children. Pediatrics 2013; 131:e764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/36\">",
"      Das M, Spowart K, Crossley S, Dutton GN. Evidence that children with special needs all require visual assessment. Arch Dis Child 2010; 95:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/37\">",
"      Hoyt CS, Nickel BL, Billson FA. Ophthalmological examination of the infant. Developmental aspects. Surv Ophthalmol 1982; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/38\">",
"      BERLYNE DE. The influence of the albedo and complexity of stimuli on visual fixation in the human infant. Br J Psychol 1958; 49:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24505/abstract/39\">",
"      Sternheim CE, Cavonius CR. Sensitivity of the human ERG and VECP to sinusoidally modulated light. Vision Res 1972; 12:1685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6261 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24505=[""].join("\n");
var outline_f23_59_24505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VISUAL DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF VISION ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Objectives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Referral indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Optimal conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VISUAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      VISUAL BEHAVIOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fixation reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preferential looking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VISUAL ACUITY TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Optotype tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Crowding phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Testing artifacts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3092026\">",
"      PHOTOSCREENING AND AUTOREFRACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEAR VISION TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COLOR VISION TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VISION ASSESSMENT IN CHILDREN WITH NYSTAGMUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Manifest nystagmus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Latent nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      VISION ASSESSMENT IN CHILDREN WITH SPECIAL NEEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vision tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Vestibuloocular reflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Optokinetic drum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      VISUAL EVOKED POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6261\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6261|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32506\" title=\"figure 1\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/50/41760\" title=\"figure 2\">",
"      Optotype recognition tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6261|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/17/29980\" title=\"table 1\">",
"      Ophth findings IEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/12/6348\" title=\"table 2\">",
"      Visual behavior infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/47/27388\" title=\"table 3\">",
"      Snellen visual acuity conversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/44/12999?source=related_link\">",
"      Fourth cranial nerve (trochlear nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27018?source=related_link\">",
"      Overview of retinoblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/58/27553?source=related_link\">",
"      Patient information: Crossed eyes and lazy eye (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24506="Evaluation of the infant with ambiguous genitalia";
var content_f23_59_24506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of the infant with ambiguous genitalia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Christopher P Houk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Lynne L Levitsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/59/24506/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/59/24506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with a congenital discrepancy between external genitalia, gonadal and chromosomal sex are classified as having a disorder of sex development. A 2006 consensus conference suggested that the potentially pejorative terms \"pseudohermaphrodite,\" \"hermaphrodite,\" and \"intersex\" be replaced by the diagnostic category \"disorders of sex development\" (DSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some DSDs present with abnormalities of the external genitalia (ambiguous genitalia). Abnormalities sufficient to prompt evaluation occur in approximately one in 4500 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/2\">",
"     2",
"    </a>",
"    ]. Manifestations may include bilateral cryptorchidism (",
"    <a class=\"graphic graphic_picture graphicRef73353 \" href=\"UTD.htm?24/35/25136\">",
"     picture 1",
"    </a>",
"    ), perineal hypospadias with bifid scrotum (",
"    <a class=\"graphic graphic_picture graphicRef54419 \" href=\"UTD.htm?34/32/35329\">",
"     picture 2",
"    </a>",
"    ), clitoromegaly (",
"    <a class=\"graphic graphic_picture graphicRef64870 graphicRef76693 \" href=\"UTD.htm?15/62/16358\">",
"     picture 3A-B",
"    </a>",
"    ), posterior labial fusion (",
"    <a class=\"graphic graphic_picture graphicRef51835 \" href=\"UTD.htm?17/46/18144\">",
"     picture 4",
"    </a>",
"    ), phenotypic female appearance with a palpable gonad (with or without inguinal hernia) (",
"    <a class=\"graphic graphic_picture graphicRef78743 \" href=\"UTD.htm?18/59/19376\">",
"     picture 5",
"    </a>",
"    ), hypospadias and unilateral nonpalpable gonad (",
"    <a class=\"graphic graphic_picture graphicRef60214 graphicRef70901 \" href=\"UTD.htm?20/52/21318\">",
"     picture 6A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    DSDs also include infants with discordant genitalia and sex chromosomes (",
"    <a class=\"graphic graphic_picture graphicRef74637 \" href=\"UTD.htm?18/11/18609\">",
"     picture 7",
"    </a>",
"    ). Turner syndrome (45,XO) and Klinefelter syndrome (47,XXY) are also DSDs but do not generally present with ambiguous genitalia. 46,XY infants with palpable gonads and simple hypospadias or microphallus, although undervirilized, do not have truly ambiguous genitalia and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"     \"Hypospadias\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The evaluation of the infant with a DSD is presented here. The management of such infants, which is critical and often controversial in the absence of well-defined outcome-based guidelines, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"     \"Management of the infant with ambiguous genitalia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL SEX DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A logical approach to the infant with a disorder of sex development (DSD) requires a basic understanding of normal human sexual differentiation. This process is reviewed here briefly and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link\">",
"     \"Normal sexual differentiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In early fetal development, both XX and XY fetuses have similar reproductive structural anlage; this period is referred to as the sexually indifferent phase of sexual development. This ambisexual state continues until the formation of the bipotential gonad at seven weeks, when fetuses bearing a Y chromosome begin developing testes, thereby becoming sexually distinct from fetuses without a Y chromosome. Normal ovarian development also requires active genetic pathways. Thereafter, gonadal differentiation and function determines the genital phenotype. Multiple genes contribute to normal sexual differentiation; mutations in these genes can lead to various DSDs (",
"    <a class=\"graphic graphic_table graphicRef81145 graphicRef56975 \" href=\"UTD.htm?42/50/43823\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gonads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial, sexually indifferent phase of gonad formation begins at five weeks of gestation with the development of paired gonadal ridges. The process becomes sexually dimorphic after germ cell seeding at six weeks and bipotential gonad formation at seven weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Genes involved in gonadal development",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       SRY",
"      </strong>",
"      &ndash; SRY is a master regulator of male sex determination. Around six weeks gestation, those gonads with a Y-chromosome begin expressing SRY (sex-determining region on the Y chromosome) protein, the transcription factor thought to initiate the downstream molecular events of testis formation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       SOX9",
"      </strong>",
"      &ndash; Shortly after SRY expression, the SOX9 gene, which is required for Sertoli-cell differentiation and type II collagen production, begins to be expressed in the testes. Haploinsufficiency of SOX9 results in campomelic dysplasia, a skeletal dysplasia associated with sex reversal in 75 percent of affected XY individuals. Further evidence for the role of SOX9 in sexual differentiation comes from the observation that SOX9 duplication is the only known autosomal cause of XX sex reversal (XX karyotype with male phenotype).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        SF-1/NR5A1",
"       </strong>",
"      </span>",
"      &ndash; Steroidogenic factor 1 (SF-1), also known as NR5A1 (",
"      <a class=\"external\" href=\"file://omim.org/entry/184757\">",
"       MIM 184757",
"      </a>",
"      ), is a critical gonadal transcription factor with a role in steroidogenesis, fertility, and male sexual differentiation. SF-1 mutations cause agonadism, adrenal hypoplasia with adrenal insufficiency, hypogonadotropic hypogonadism, cryptorchidism, micropenis, and XY sex reversal [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link&amp;anchor=H3#H3\">",
"       \"Unusual causes of adrenal insufficiency\", section on 'Congenital adrenal hypoplasia'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       DHH",
"      </strong>",
"      &ndash; Mutations in the desert hedgehog gene (DHH) can cause gonadal dysgenesis and sex reversal in 46,XY individuals (",
"      <a class=\"external\" href=\"file://omim.org/entry/233420\">",
"       MIM #233420",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/9\">",
"       9",
"      </a>",
"      ]. DHH signaling triggers testicular differentiation by upregulating SF-1. &nbsp;",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        DAX-1/NROB1",
"       </strong>",
"      </span>",
"      &ndash; The dose-sensitive sex-reversal locus on the X chromosome (formerly known as DAX-1 and now referred to as NR0B1,",
"      <a class=\"external\" href=\"file://omim.org/entry/300473\">",
"       MIM 300473",
"      </a>",
"      ) is a gonad-specific transcription factor upregulated in the ovary. Mutations in",
"      <span class=\"nowrap\">",
"       DAX-1/NR0B1",
"      </span>",
"      are responsible for adrenal hypoplasia congenita (AHC), a syndrome of adrenal hypoplasia and hypogonadotropic hypogonadism in 46,XY males without a DSD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       DAX-1/NR0B1",
"      </span>",
"      is said to function as an anti-testis factor in the ovary but is not required for normal testicular function. Therefore,",
"      <span class=\"nowrap\">",
"       DAX-1/NR0B1",
"      </span>",
"      duplication can repress SRY and cause a DSD with a female phenotype in an individual with 46,XY chromosomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link&amp;anchor=H3#H3\">",
"       \"Unusual causes of adrenal insufficiency\", section on 'Congenital adrenal hypoplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       WT-1",
"      </strong>",
"      &ndash; The Wilms tumor (WT-1) gene is a transcription factor involved in both gonadal and renal development. All WT-1 mutations are associated with renal malformation or dysfunction. Three distinct phenotypes are seen with WT-1 mutations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      WAGR syndrome (Wilms tumor, aniridia, genitourinary anomalies, and mental retardation, MIM #194072), caused by a contiguous deletion of the WT-1 gene and the adjoining PAX6 gene.",
"     </li>",
"     <li>",
"      Denys-Drash syndrome (a triad of progressive renal disease, 46XY karyotype with undervirilization, and Wilms tumor, MIM #194080), in which WT-1 mutations disrupt DNA binding ability in the protein [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/10\">",
"       10",
"      </a>",
"      ]. Affected individuals usually have ambiguous genitalia or normal female external genitalia, and streak gonads [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/11\">",
"       11",
"      </a>",
"      ]. Nephrotic syndrome presents within the first two years of life and progresses rapidly to end stage renal failure within a few years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"       \"Congenital and infantile nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Frasier syndrome (46,XY DSD, gonadal dysgenesis, and renal failure,",
"      <a class=\"external\" href=\"file://omim.org/entry/136680\">",
"       MIM #136680",
"      </a>",
"      ), in which there is an altered ratio of the two splice isoforms of the WT-1 protein [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/12\">",
"       12",
"      </a>",
"      ]. Affected individuals have normal female external genitalia but fail to develop secondary sexual characteristics [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients are at risk for gonadoblastoma developing in the dysgenetic gonads. The renal disease is a glomerulonephropathy, gradually progressing from steroid-resistant nephrotic syndrome to renal failure in the second or third decade of life.",
"      <br/>",
"      <br/>",
"      WT-1 mutations in patients with a 46,XX karyotype may cause isolated nephrotic syndrome without abnormalities of genital development, but any offspring with a 46,XY karyotype may be affected by Denys-Drash or Frasier syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wnt-4 and Wnt-7a",
"      </strong>",
"      &ndash; Wnt-4, and Wnt-7a are signaling molecules found in M&uuml;llerian ducts and show XX-specific gonadal expression. In Sertoli and Leydig cells, Wnt-4 overexpression upregulates",
"      <span class=\"nowrap\">",
"       DAX-1/NR0B1",
"      </span>",
"      and this may explain the etiology of human XY sex reversal associated with 1p35-p31 duplication syndromes. Animal models have demonstrated that the Wnt-4 gene suppresses male sexual differentiation and ovarian androgen production [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/13\">",
"       13",
"      </a>",
"      ]. A loss of function mutation in the Wnt-4 gene was reported in a woman with primary amenorrhea (a result of M&uuml;llerian agenesis) and hyperandrogenemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/14\">",
"       14",
"      </a>",
"      ]. No Wnt-7a mutations have been identified in humans to date.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These transcription factors involved in bipotential gonad formation are necessary for developmental processes in other tissues, and their disruption often is associated with nongonadal malformations and diseases. Other transcription factors have been associated with sex reversal in animals or humans. Mutations in the FGFr2 gene lead to partial sex reversal in male mice; human loss of the terminal 10q26 region also has been associated with DSD, but a specific association with mutations in this gene has not been described in humans. Similarly, loss of FGF9, an inducer of FGFr2, leads to sex reversal in male vertebrates but has not yet been reported in humans with DSDs. These genes can induce various skeletal dysplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Translocations or mutations in SRY affect development of the gonads and other reproductive structures but are not generally associated with other anomalies. Defects of other gonad-specific genetic factors, such as",
"    <span class=\"nowrap\">",
"     DAX-1/NR0B1,",
"    </span>",
"    DMRT",
"    <span class=\"nowrap\">",
"     1/2,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     ARX/ATRX",
"    </span>",
"    often lead to syndromic phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Because agonadism eliminates the normal androgen production required for male genital development, autosomal gene defects interfering with testicular formation may appear sex-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Internal genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wolffian (mesonephric) and M&uuml;llerian (paramesonephric) ducts develop in both sexes. In males, at approximately the seventh week of gestation, testicular Sertoli cells begin secreting M&uuml;llerian-inhibiting substance (MIS, also called M&uuml;llerian-inhibiting hormone, and AMH, anti-M&uuml;llerian hormone), which induces M&uuml;llerian duct regression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/19\">",
"     19",
"    </a>",
"    ]. Shortly afterward, Leydig cells begin producing testosterone. Testosterone stabilizes the Wolffian duct and promotes development of the epididymis, vas deferens, and seminal vesicle. In females, the lack of testosterone leads to Wolffian duct regression and, in response to the lack of MIS, permits M&uuml;llerian duct maturation into oviduct, uterus, cervix, and upper vagina, respectively (",
"    <a class=\"graphic graphic_figure graphicRef78289 \" href=\"UTD.htm?2/10/2214\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     External genitalia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The external genitalia become sexually distinct at approximately the ninth week of gestation, after Leydig cells have produced sufficient testosterone to permit peripheral synthesis of DHT (dihydrotestosterone), the potent testosterone metabolite formed by 5-alpha-reductase.",
"   </p>",
"   <p>",
"    Peripheral synthesis of DHT induces posterior fusion of the genital folds and growth of the genital tubercle into a phallic structure (",
"    <a class=\"graphic graphic_figure graphicRef65480 \" href=\"UTD.htm?31/56/32645\">",
"     figure 2",
"    </a>",
"    ). Differentiation and growth of the external genitalia are particularly dependent upon DHT, and 46,XY infants who lack 5-alpha-reductase type 2 are born with normally functioning testes but undervirilized external genitalia.",
"   </p>",
"   <p>",
"    Male external genital morphogenesis is complete by 12 to 16 weeks. After initial embryonal stimulation via placental",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/25/33171?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    , subsequent fetal phallic growth is a result of fetal pituitary luteinizing hormone (LH) stimulation of testicular Leydig cell testosterone production [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By 12 weeks, the non-hormone-dependent separation of vagina and urethra is complete in females (",
"    <a class=\"graphic graphic_figure graphicRef65480 \" href=\"UTD.htm?31/56/32645\">",
"     figure 2",
"    </a>",
"    ). Excess androgen exposure before this separation can cause labial fusion and development of a phallic urethra or urogenital sinus, but later exposure causes only clitoral enlargement and",
"    <span class=\"nowrap\">",
"     masculinization/scrotalization",
"    </span>",
"    of labial folds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Penile length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penile length is measured on its dorsal surface from the pubic ramus to the tip of the penis (excluding any excess foreskin) after stretching the penis to the point of increased resistance. The ruler should be pressed down against the ramus to completely depress the suprapubic fat pad. Penile width (diameter) is measured at the midshaft.",
"   </p>",
"   <p>",
"    In a term infant, at birth, the normal penile length is &ge;2.5 cm, and normal penile diameter is &ge;0.9 cm. These measurements should be adjusted for gestational age (",
"    <a class=\"graphic graphic_figure graphicRef66323 \" href=\"UTD.htm?7/4/7246\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/20\">",
"     20",
"    </a>",
"    ]. Small phallus (micropenis) may be caused by decreased",
"    <span class=\"nowrap\">",
"     testosterone/DHT",
"    </span>",
"    exposure in the second or third trimester and by deficiencies of growth hormone or gonadotropin. Micropenis with accompanying hypospadias is rarely secondary to growth hormone or gonadotropin deficiency. Standards for stretched penile length of premature infants and older children and adults are available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gonads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scrotum, labia majora, and inguinal area should be carefully palpated to identify the presence and position of the gonads. In a 46,XY child, bilateral nonpalpable testes may arise from isolated cryptorchidism, anorchia, or occur in conjunction with persistent M&uuml;llerian duct syndrome. In a 46,XX child, virilizing congenital adrenal hyperplasia (CAH) should be ruled out. This disorder is usually associated with genital ambiguity, and not with microphallus without hypospadias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=see_link\">",
"     \"Undescended testes (cryptorchidism) in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gonads palpable below the inguinal ligament (eg, in the labioscrotal folds) (",
"    <a class=\"graphic graphic_picture graphicRef78743 \" href=\"UTD.htm?18/59/19376\">",
"     picture 5",
"    </a>",
"    ) are usually testes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/21\">",
"     21",
"    </a>",
"    ]. Asymmetry of the gonads or other genitalia may indicate gonadal dysgenesis or development of both gonadal structures namely ovary and testis, termed ovotesticular DSD under the new nomenclature (previously termed \"true hermaphroditism\"). (See",
"    <a class=\"local\" href=\"#H109685527\">",
"     'Ovotesticular DSD'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Urethral opening",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single opening at the base of the phallus (",
"    <a class=\"graphic graphic_picture graphicRef54419 \" href=\"UTD.htm?34/32/35329\">",
"     picture 2",
"    </a>",
"    ) may be either an incompletely fused penile urethra (hypospadias) or a virilized urogenital sinus (eg, internal connection between the vagina and urethra). Accordingly, these findings must be confirmed either by",
"    <span class=\"nowrap\">",
"     cystoscopy/vaginoscopy",
"    </span>",
"    or radiographically, because the physical examination can be misleading. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clitoral size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clitoral width is measured by gently but firmly pressing the shaft of the clitoris between the thumb and forefinger to exclude excess skin and subcutaneous tissue. Normal clitoral width in a neonate ranges from 2 to 6 mm. Mean clitoral length in the newborn infant may vary in different population groups, but lengths of more than 9 mm are unusual in normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The clitoris may appear disproportionately more prominent in preterm infants because clitoral size is fully developed by 27 weeks gestation and because there is less fat in the labia majora [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/24\">",
"     24",
"    </a>",
"    ]. Standards for clitoral size through infancy and adulthood are available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clitoromegaly secondary to androgen exposure in a 46,XX infant can be caused by CAH (",
"    <a class=\"graphic graphic_picture graphicRef64870 \" href=\"UTD.htm?18/52/19266\">",
"     picture 3A",
"    </a>",
"    ), ovotesticular or testicular DSD, maternal androgen exposure, or, rarely, by tumor infiltration of the clitoris (eg, neurofibromatosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have suggested using the clitoral index (length of the clitoris [mm] multiplied by width of the clitoris [mm]) to assess androgen exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As a general rule, this calculation does not contribute much to the clinical assessment and management of infants with a DSD. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Virilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female virilization standards for CAH have been established by Prader based upon the degree of virilization of the urogenital sinus and the external genitalia (",
"    <a class=\"graphic graphic_figure graphicRef73502 graphicRef52525 \" href=\"UTD.htm?13/34/13863\">",
"     figure 4A-B",
"    </a>",
"    ). For assessing the development of external genitalia in 46,XY children with DSD, the Quigley scales have been widely used (",
"    <a class=\"graphic graphic_figure graphicRef50228 \" href=\"UTD.htm?12/59/13247\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/28\">",
"     28",
"    </a>",
"    ]. These standards can be useful in the diagnosis and treatment of children with DSD as a means of objectively documenting genital phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anogenital ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anogenital ratio, which is independent of gestational age and body size, is the distance between the anus and posterior fourchette divided by the distance between the anus and the base of the clitoris [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/29\">",
"     29",
"    </a>",
"    ]. A ratio of &gt;0.5 suggests virilization with some posterior labial fusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25315825\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of a disorder of sex development (DSD) should be considered in infants who have:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilaterally nonpalpable testes (",
"      <a class=\"graphic graphic_picture graphicRef73353 \" href=\"UTD.htm?24/35/25136\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Microphallus (stretched penile length less than 2.5 cm in a full-term infant); microphallus without associated hypospadias is not \"ambiguous,\" but may be a marker of other disorders.",
"     </li>",
"     <li>",
"      Perineal hypospadias with bifid scrotum (",
"      <a class=\"graphic graphic_picture graphicRef54419 \" href=\"UTD.htm?34/32/35329\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Clitoromegaly (clitoral width &gt;6 mm or clitoral length &gt;9 mm) (",
"      <a class=\"graphic graphic_picture graphicRef64870 graphicRef76693 \" href=\"UTD.htm?15/62/16358\">",
"       picture 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Posterior labial fusion (anogenital ratio &gt;0.5) (",
"      <a class=\"graphic graphic_picture graphicRef51835 \" href=\"UTD.htm?17/46/18144\">",
"       picture 4",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Gonads palpable in the labioscrotal folds (",
"      <a class=\"graphic graphic_picture graphicRef78743 \" href=\"UTD.htm?18/59/19376\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hypospadias and unilateral nonpalpable gonad (",
"      <a class=\"graphic graphic_picture graphicRef60214 graphicRef70901 \" href=\"UTD.htm?20/52/21318\">",
"       picture 6A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Discordant genitalia and sex chromosomes (",
"      <a class=\"graphic graphic_picture graphicRef74637 \" href=\"UTD.htm?18/11/18609\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial evaluation should include history, physical examination, karyotype (including FISH with SRY probe),",
"    <span class=\"nowrap\">",
"     pelvic/abdominal",
"    </span>",
"    ultrasonography, and assessment of adrenal and gonadal function, as detailed below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Initial evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to evaluate adrenal function promptly to minimize the risk of adrenal crisis. Tests to evaluate adrenal function include measurement of 17-hydroxyprogesterone, and may require a stimulation test using adrenocorticotropic hormone (ACTH), and sometimes assessment of the urinary steroid excretion pattern by gas",
"    <span class=\"nowrap\">",
"     chromatography/mass",
"    </span>",
"    spectroscopy. In the newborns with common disorders of adrenal steroidogenesis, adrenal steroids are usually sufficiently elevated that an ACTH test is unnecessary.",
"   </p>",
"   <p>",
"    The selection of subsequent tests is dictated by the results of the karyotype and SRY testing (",
"    <a class=\"graphic graphic_algorithm graphicRef70570 \" href=\"UTD.htm?23/3/23615\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef66241 \" href=\"UTD.htm?7/9/7312\">",
"     algorithm 2",
"    </a>",
"    ). Tests to evaluate gonadal function include measurement of serum levels of M&uuml;llerian-inhibiting substance (MIS), gonadotropins, and sex steroids, and hCG stimulation test. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Laboratory tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25315832\">",
"    <span class=\"h2\">",
"     Categorization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The information from the initial evaluation can be used to categorize the infant into one of three categories, as suggested by an international consensus conference [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Virilized XX",
"     </li>",
"     <li>",
"      Undervirilized XY",
"     </li>",
"     <li>",
"      Mixed sex chromosome pattern",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the infant with ambiguous genitalia should include a family history, physical examination, evaluation of the sex chromosomes, and assessment of internal anatomy by ultrasound. Next, adrenal and gonadal steroid secretion should be measured in a specialized pediatric endocrine laboratory using age-specific reference values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history in a child with a disorder of sex development (DSD) should include the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal exposure to androgens (eg, progesterones,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"       danazol",
"      </a>",
"      , testosterone) or endocrine disrupters (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      , aminoglutethimide).",
"     </li>",
"     <li>",
"      Maternal virilization in pregnancy (placental aromatase deficiency, luteoma).",
"     </li>",
"     <li>",
"      Family history of females who are childless or have amenorrhea (androgen insensitivity).",
"     </li>",
"     <li>",
"      Family history of unexplained infant deaths (congenital adrenal hyperplasia).",
"     </li>",
"     <li>",
"      History of consanguinity (or homogeneous population) (recessive disorders, eg, CAH or disorders of androgen biosynthesis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"       \"Diagnosis and treatment of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include careful inspection and palpation of the genitalia. The labioscrotal folds and inguinal region should be palpated for gonads, and the number of urogenital openings documented. Measures of the",
"    <span class=\"nowrap\">",
"     phallus/clitoris",
"    </span>",
"    and anogenital ratio should be done for standardization (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In the infant with ambiguous genitalia, associated nongenital anomalies or dysmorphic features should be documented (",
"    <a class=\"graphic graphic_table graphicRef58766 \" href=\"UTD.htm?35/41/36508\">",
"     table 2",
"    </a>",
"    ). The presence of associated nongenital anomalies usually excludes common forms of CAH. Genital malformation may occur as part of an overall pattern of malformation (eg, chromosomal abnormality such as trisomy 21, trisomy 18, or 13q syndrome), incomplete masculinization (eg, inadequate",
"    <span class=\"nowrap\">",
"     FSH/LH",
"    </span>",
"    production which may lead to microphallus and is sometimes associated with hypospadias, or inadequate production of the cholesterol precursors for steroid hormone synthesis). If gastrointestinal anomalies accompany genital maldevelopment, a disorder of cloacal differentiation should be considered.",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with congenital gonadotropin-releasing hormone deficiency also may have cleft lip or palate and other midline defects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"       \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants with Smith-Lemli-Opitz syndrome (a disorder of cholesterol biosynthesis caused by deficiency of sterol-delta-7-reductase, or DHCR7) may have a variety of phenotypic abnormalities in addition to ambiguous genitalia (",
"      <a class=\"graphic graphic_picture graphicRef55839 \" href=\"UTD.htm?19/7/19583\">",
"       picture 8",
"      </a>",
"      ). These include microcephaly, micrognathia, low-set and posteriorly rotated ears, and syndactyly of the second and third toes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Defects in cholesterol biochemistry'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals with P450 oxidoreductase deficiency, a rare form of congenital adrenal hyperplasia, may have craniofacial and limb abnormalities (also known as Antley-Bixler syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H18#H18\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'P450 oxidoreductase deficiency'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the infant with a DSD should include determination of sex chromosomes and assessment of gonadal and adrenal steroids. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A karyotype is performed, usually using peripheral leukocytes. In some complicated patients, a karyotype of the gonadal tissue obtained when surgery is being done for other reasons may be helpful in identifying mosaicism. Because of the possibility of mosaicism, it is suggested that at least 200 cells be examined. The results of the karyotype permit classification of the infant into one of three diagnostic categories that guide further evaluation, as suggested by a consensus conference [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"       1",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      XX DSD",
"     </li>",
"     <li>",
"      XY DSD",
"     </li>",
"     <li>",
"      Mixed sex chromosome DSD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      17-hydroxyprogesterone should be measured promptly in all infants with nonpalpable gonads presenting with genital ambiguity to exclude congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. This is the most common cause of genital ambiguity and can lead to life-threatening adrenal insufficiency within the first weeks of life. In addition, serum electrolytes should also be measured at the time of presentation, and at least daily until the reported 17-hydroxyprogesterone level makes it clear that salt wasting 21-hydroxylase deficiency is not etiologic. Neonatal screening for this disorder is routinely performed in many countries and all US states. However, any infant presenting with genital ambiguity should have a rapid and extensive evaluation for CAH as described above, without waiting for the results of the newborn screen. Moreover, there is a substantial risk of false-negative results for the neonatal screening for CAH [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Next, evaluation for the SRY gene using fluorescence in situ hybridization (FISH) and SRY-specific probes should be performed, to narrow the diagnostic possibilities. The SRY gene is a critical factor in testicular development and usually coincides with the presence of a Y chromosome. The presence of SRY in an individual with 46XX karyotype indicates SRY translocation; absence of SRY in an individual with a 46XY karyotype suggests SRY deletion.",
"     </li>",
"     <li>",
"      All infants with ambiguous genitalia should also be tested for less common types of CAH by measuring dehydroepiandrosterone [DHEA], 17-hydroxypregnenolone, and 11-desoxycortisol (preferably by liquid chromatography tandem mass spectrometry [LCMSMS]). These tests will detect CAH caused by defects in adrenal and gonadal steroid production, including 11-beta-hydroxylase deficiency and 3-beta-hydroxysteroid dehydrogenase deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=see_link\">",
"       \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      ). Measurement of cortisol and ACTH can be useful in the diagnosis of ACTH deficiency related to defects in SF-1 or other pituitary disorders, although interpretation of these test results can be difficult in stressed or ill infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the near future, easy availability of genome-wide microarray studies (GWAS) will probably permit molecular diagnoses of most children with genetic DSD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography of the abdomen and pelvis is important to determine the presence of gonads, a uterus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a vagina. Retrograde urethrogram may be necessary, although most surgeons find direct visualization by",
"    <span class=\"nowrap\">",
"     cystoscopy/vaginoscopy",
"    </span>",
"    to be the single best method of assessing the urethral and vaginal anatomy. In some complicated cases (particularly those infants with elements of male and female",
"    <span class=\"nowrap\">",
"     gonads/internal",
"    </span>",
"    reproductive structures), laparoscopic visualization with gonadal biopsy, may be required to completely inventory the reproductive structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     46 XX DSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of 46,XX DSD includes congenital adrenal hyperplasia (CAH), gestational hyperandrogenism, testicular DSD, and ovotesticular DSD (",
"    <a class=\"graphic graphic_algorithm graphicRef70570 \" href=\"UTD.htm?23/3/23615\">",
"     algorithm 1",
"    </a>",
"    ). 46,XX DSD with evidence of functioning testicular tissue may be caused by translocation of the SRY (sex determining region of the Y) gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=see_link&amp;anchor=H7#H7\">",
"     \"Normal sexual differentiation\", section on 'Testicular determination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Congenital adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAH is the most common diagnosis in virilized XX infants. Depending on the site of the steroid biosynthetic defect (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 6",
"    </a>",
"    ), patients with CAH may underproduce or overproduce mineralocorticoid, typically leading to abnormalities in serum electrolytes and blood pressure (",
"    <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequent enzymatic defects, 21-alpha-hydroxylase (CYP21A2) and 11-beta-hydroxylase deficiencies, usually can be excluded with basal measurement of serum 17-hydroxyprogesterone (",
"      <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"       table 3",
"      </a>",
"      ). In borderline cases, an",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      or genetic testing may be needed. Affected infants with 21-alpha-hydroxylase deficiency often have salt-wasting, which causes hyponatremia with hyperkalemia and hypotension, and they are at risk for the life-threatening complication of adrenal crisis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=see_link&amp;anchor=H285022333#H285022333\">",
"       \"Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'Additional lab testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In rare individuals, 21-hydroxylase deficiency may be caused by a mutation in P450 oxidoreductase, and has a variable phenotype. Because abnormal electron transport causes combined P450C17 and P450C21 deficiencies, both girls and boys are born with ambiguous genitalia, indicating intrauterine androgen excess in females and androgen deficiency in males [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link&amp;anchor=H18#H18\">",
"       \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\", section on 'P450 oxidoreductase deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because 11-beta-hydroxylase deficiency and 3-beta-hydroxysteroid dehydrogenase deficiency each have their own characteristic serum steroid patterns, ACTH, cortisol, dehydroepiandrosterone (DHEA), 17-hydroxypregnenolone, and 11-desoxycortisol also should be measured (",
"      <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=see_link\">",
"       \"Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Samples should be sent to a specialized laboratory that is capable of properly extracting and quantitating serum steroids in neonates. The best results for steroids are obtained using liquid chromatography tandem mass spectrometry (LCMSMS) methodology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gestational hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;XX virilization, with normal female internal anatomy, can result from exposure to maternal androgen or synthetic progestational agents. Causes include maternal luteoma or theca-lutein cysts, and placental aromatase enzyme deficiency. These disorders are suggested by a history of exogenous progestins or androgen exposure,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal virilization during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31236?source=see_link\">",
"     \"Diagnosis and management of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other uncommon causes of XX virilization include SRY translocation, SOX9 duplication [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/4,5,35-37\">",
"     4,5,35-37",
"    </a>",
"    ], and ovotesticular DSD (previously termed true hermaphroditism) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"     1",
"    </a>",
"    ]. Evaluation for these disorders includes measurement of M&uuml;llerian inhibiting substance (MIS) or inhibin B and the testosterone response to administration of hCG (",
"    <a class=\"graphic graphic_algorithm graphicRef70570 \" href=\"UTD.htm?23/3/23615\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The hCG stimulation test is described below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'hCG stimulation test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    SRY translocation can be diagnosed using a FISH probe for the SRY gene; SOX9 duplication can be confirmed with a SOX9 FISH probe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/36\">",
"     36",
"    </a>",
"    ]. These tests are available for either research or clinical evaluation (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ). Unfortunately, once these uncommon disorders are excluded, most causes of XX virilization remain undefined.",
"   </p>",
"   <p>",
"    46,XX ovotesticular DSD is a rare condition in which a child with an XX chromosome constitution has virilization with mixed ovarian and testicular tissue (either ovotestis, or ovary and testis); this condition has been termed \"true hermaphroditism\" in the past. The specific diagnosis requires histological confirmation of the presence of ovarian follicles and testicular tubules. The development of the internal and external genitalia in these children can be quite variable depending upon androgen production and exposure. The origins of this DSD are still not entirely clear, although it has been associated with a loss-of-function mutation in the RSPO1 gene in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     46 XY DSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic process in undervirilized XY infants who express SRY is more difficult because of the phenotypic variability and the large number of potential causes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/3,42\">",
"     3,42",
"    </a>",
"    ]. XY infants with palpable gonads and simple hypospadias or microphallus, although undervirilized, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"     \"Hypospadias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the information from the initial evaluation, evaluation of undervirilized XY infants should include measurement of serum luteinizing hormone (LH), follicle stimulating hormone (FSH), M&uuml;llerian inhibiting substance (MIS), testosterone (T), and dihydrotestosterone (DHT) (",
"    <a class=\"graphic graphic_algorithm graphicRef66241 \" href=\"UTD.htm?7/9/7312\">",
"     algorithm 2",
"    </a>",
"    ). Gonadotropins and sex steroids should be measured at a postnatal age when they are normally detectable (either in the first 24 hours of life or between two and six months of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Administration of hCG may help to clarify the sex steroid response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Congenital adrenal hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of CAH can cause undervirilization in an XY infant: 17-alpha-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase deficiency, P450 side chain cleavage (scc) deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/45\">",
"     45",
"    </a>",
"    ], and StAR protein deficiency (lipoid hyperplasia) (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"     table 3",
"    </a>",
"    ). These disorders are discussed in detail separately. CAH caused by 21-hydroxylase deficiency is also seen in 46,XY children but does not result in genital ambiguity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H32\">",
"     'Testing for associated adrenal insufficiency'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation for uncommon causes of CAH (eg, StAR protein deficiency, 3-beta-hydroxysteroid dehydrogenase deficiency, and 17-alpha-hydroxylase deficiency) (",
"      <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"       figure 6",
"      </a>",
"      ) requires the measurement of additional adrenal steroid intermediates (17-hydroxypregnenolone, deoxycorticosterone, and dehydroepiandrosterone [DHEA]) (",
"      <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"       table 3",
"      </a>",
"      ). CAH resulting from 3-beta-hydroxysteroid dehydrogenase deficiency usually is associated with a modest elevation in 17-hydroxyprogesterone because of peripheral conversion of its precursor (17-hydroxypregnenolone) in the neonatal liver. Because the 17-hydroxyprogesterone result is readily and more rapidly obtained than the 17-hydroxypregnenolone, modest elevation of 17-hydroxyprogesterone serves as the first clue to this diagnosis in a genotypic male infant [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"       \"Uncommon causes of congenital adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For 17-alpha-hydroxylase deficiency and 3-beta-hydroxysteroid dehydrogenase deficiency, an",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      may be necessary to confirm the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'ACTH stimulation test'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Abnormal testicular activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of MIS or inhibin B, which are markers of Sertoli cell mass, are in the normal male range for age when functional testicular tissue is present, and can serve as useful markers of testicular activity even if testes are not seen with",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because MIS secretion by the testes causes M&uuml;llerian duct regression, decreased MIS secretion or action that occurs early in development is characterized by fully developed M&uuml;llerian duct structures (gonadal dysgenesis or persistent M&uuml;llerian duct syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Defects that occur later in development lead to partial regression of the M&uuml;llerian duct structures (testicular regression syndrome, vanishing testes syndrome or congenital anorchia).",
"   </p>",
"   <p>",
"    Low MIS levels in an individual with a 46,XY karyotype suggest one of the following disorders, each of which is characterized by diminished testicular activity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonadal dysgenesis &ndash; Complete XY gonadal dysgenesis is associated with female external genitalia, intact M&uuml;llerian ducts, and streak gonads [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/49\">",
"       49",
"      </a>",
"      ]. Infants with dysgenetic gonads or both testicular and ovarian tissue may demonstrate disordered gonadal steroid secretion and intact adrenal responses. An hCG stimulation test cannot be used to detect ovarian tissue, because hCG alone will not stimulate an estrogen response from ovarian tissue. 46,XY DSD infants with androgen insensitivity will also show normal testicular responses on hCG stimulation. Inhibin A is secreted by the ovary in the first two months of life. Therefore, measurement of inhibin A may prove useful in assessing the presence of ovarian tissue in infants, but this measure has not yet been validated in children with DSDs.",
"      <br/>",
"      <br/>",
"      Two papers have suggested that administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=see_link\">",
"       human menopausal gonadotropins",
"      </a>",
"      (hMG) to stimulate ovarian function might be used as a test to identify ovarian tissue, measuring either an increase in estrogen levels or ultrasound evidence of follicular development [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. This approach could be used in infants who are older than two or three weeks of age.",
"     </li>",
"     <li>",
"      Testicular regression syndrome &ndash; Loss of testicular function and tissue early in development may result in a female phenotype with atrophic M&uuml;llerian ducts.",
"     </li>",
"     <li>",
"      Vanishing testes syndrome &ndash; Loss of testicular function late in fetal life results in normal male genitalia, absent M&uuml;llerian ducts, and anorchia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link&amp;anchor=H23#H23\">",
"       \"Etiology, diagnosis, and treatment of primary amenorrhea\", section on 'Vanishing testes syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Persistent M&uuml;llerian duct syndrome &ndash; Mutations in the MIS gene with low serum levels of MIS, or in the MIS receptor, with lack of response to MIS in a 46,XY individual cause persistent M&uuml;llerian duct syndrome, with normal external male genitalia and variable testicular descent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes of abnormal testicular activity in XY infants include DAX-1 duplication, which causes male-to-female sex reversal (dose-sensitive sex reversal) through repression of SRY, and SF-1 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]; MIS levels will be low in either of these disorders. Mutations in the MIS cognate type II receptor also can cause persistent M&uuml;llerian duct syndrome with normal external male genitalia and variable testicular descent, but serum levels of MIS are appropriate for age and gender, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Abnormal androgen synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of XY undervirilization in which androgen synthesis is abnormal include 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, 5-alpha-reductase deficiency, LH receptor defects, and gonadal dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. In a patient who has testicular tissue on ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    normal concentrations of MIS, the hCG stimulation test can be performed to distinguish between these disorders and those in which there is an abnormal response to androgen (",
"    <a class=\"graphic graphic_algorithm graphicRef66241 \" href=\"UTD.htm?7/9/7312\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'hCG stimulation test'",
"    </a>",
"    below.) When a defect in testosterone biosynthesis is identified, adrenal function also should be evaluated. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Testing for associated adrenal insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with the following disorders will have an abnormal response to hCG stimulation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      17-beta-hydroxysteroid dehydrogenase type 3 deficiency &ndash; Defects in testosterone biosynthesis usually cause greater impairment in virilization of the external genitalia than of the internal genitalia. The most common hereditary defect in testosterone synthesis is 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, which can be caused by at least 15 different mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/61\">",
"       61",
"      </a>",
"      ]. In this condition, serum testosterone concentrations are often in the lower normal range, whereas serum concentrations of androstenedione, the precursor before the enzymatic block, are elevated several fold (",
"      <a class=\"graphic graphic_figure graphicRef65690 \" href=\"UTD.htm?39/20/40271\">",
"       figure 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. The ratio of testosterone to androstenedione is usually less than 0.8, which distinguishes this disorder from other forms of undervirilization [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Abnormal response to androgen'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      5-alpha-reductase type 2 deficiency &ndash; Steroid 5-alpha-reductase type 2 deficiency is an autosomal recessive disorder in which 46,XY subjects with bilateral testes and normal testosterone formation have impaired external virilization during embryogenesis due to defective conversion of testosterone to dihydrotestosterone (DHT) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/64-66\">",
"       64-66",
"      </a>",
"      ]. In this disorder, the ratio of testosterone:DHT is &gt;10:1 (",
"      <a class=\"graphic graphic_algorithm graphicRef66241 \" href=\"UTD.htm?7/9/7312\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=see_link\">",
"       \"Steroid 5-alpha-reductase 2 deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LH receptor defects &mdash; LH receptor defects, caused by mutations in the LH receptor gene on chromosome 2p21, can cause ambiguous genitalia in infants with a 46,XY karyotype and testes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/57,67,68\">",
"       57,67,68",
"      </a>",
"      ]. These patients characteristically have predominantly female external genitalia, but lack a uterus and fallopian tubes; the epididymis and vas deferens may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. Laboratory evaluation reveals low testosterone concentrations despite elevated concentration of LH, unresponsiveness to hCG (which normally acts through the LH receptor), and normal levels of testosterone precursors (produced in the adrenal glands).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     hCG stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform the hCG stimulation test in the following manner: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Basal LH, FSH, testosterone, androstenedione, and DHT are measured.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/25/33171?source=see_link\">",
"       Human chorionic gonadotropin",
"      </a>",
"      (hCG) (1500",
"      <span class=\"nowrap\">",
"       units/m2",
"      </span>",
"      SQ) is administered on day one and repeated on day three.",
"     </li>",
"     <li>",
"      Beta-hCG, androstenedione, testosterone, and DHT are measured on days three and six; measurement of beta-hCG confirms the medication has been administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A doubling of testosterone by day three and quadrupling by day six is considered a normal response. The normal ratio of testosterone:DHT after the administration of hCG is &lt;10:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/62\">",
"     62",
"    </a>",
"    ]. The normal ratio of testosterone:androstenedione following hCG stimulation is &gt;0.8 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Abnormal response to androgen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of 46,XY DSD in which androgen synthesis is normal include androgen insensitivity, MIS receptor defect, and exposure to endocrine disrupters (",
"    <a class=\"graphic graphic_algorithm graphicRef66241 \" href=\"UTD.htm?7/9/7312\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androgen insensitivity &ndash; A normal basal and hCG-stimulated androgen response in a 46,XY child with undervirilization raises the possibility of androgen insensitivity syndrome (AIS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"       \"Diagnosis and treatment of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The diagnosis of androgen receptor (AR) insensitivity (AIS) can be definitively established with AR gene sequencing or fibroblast AR kinetics. Despite the evidence that fewer than half of patients with the clinical diagnosis of partial androgen insensitivity (PAIS) show a definable mutation in the androgen receptor, and the lack of clear-cut genotype-phenotype correlations in AR mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/71\">",
"       71",
"      </a>",
"      ], 46,XY DSD patients with phenotypic and biochemical evidence of AIS should undergo gene sequencing of the androgen receptor. If no AR mutation is found, a provisional diagnosis of AIS may still be made on the basis of the clinical findings, but other causes should be considered (eg, SF-1 mutation).",
"      <br/>",
"      <br/>",
"      In infants whose clinical presentation is consistent with PAIS and whose parents strongly desire the male sex of rearing, additional diagnostic information can be gained from a trial of three monthly 50-mg depot testosterone injections. An increase in phallic length and decrease in SHBG suggests an androgenic response and demonstrates the potential for additional virilization during puberty; the absence of a response suggests complete androgen insensitivity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=see_link\">",
"       \"Diagnosis and treatment of disorders of the androgen receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MIS receptor defect &ndash; Regression of the M&uuml;llerian duct structures, which normally occurs with exposure to MIS in early gestation, does not occur in individuals with mutations in the gene coding for MIS or its type II receptor. These mutations lead to persistence of the fallopian tubes and uterus in individuals with a 46,XY karyotype and normal male external genitalia and testes, which are usually cryptorchid [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/54,72\">",
"       54,72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endocrine disrupter &ndash; Occasionally, boys with hypospadias or even more severe genital ambiguity may have histories of in utero exposure to \"endocrine\" disrupters.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       Phenytoin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      , as well as environmental exposures, have been implicated but the relationship of putative &ldquo;endocrine&rdquo; disruptors to hypospadias is still unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. These children should have normal physiologic and anatomic responses to sex steroid and gonadotropin stimuli after birth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Testing for associated adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with 17-alpha hydroxylase deficiency and 3-beta-hydroxysteroid dehydrogenase deficiency, adrenal function should be evaluated with an",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    . This test also should be performed when a defect in testosterone biosynthesis is identified. When the diagnosis of 17-beta-hydroxysteroid dehydrogenase type 3 deficiency, WT-1, or LH receptor defect (which show normal adrenal function), or CAH have been confirmed by other studies, an ACTH stimulation test is unnecessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnosis of adrenal insufficiency in children\", section on 'ACTH stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     ACTH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    in the following manner:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measure ACTH, cortisol, progesterone, pregnenolone, 17-alpha-hydroxyprogesterone, 17-alpha-hydroxypregnenolone, DHEA, and androstenedione.",
"     </li>",
"     <li>",
"      Administer ACTH (250",
"      <span class=\"nowrap\">",
"       mcg/M2",
"      </span>",
"      of synthetic ACTH) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/75\">",
"       75",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      60 minutes after administration of ACTH, measure cortisol, progesterone, pregnenolone, 17-alpha-hydroxyprogesterone, 17-alpha-hydroxypregnenolone, DHEA, and androstenedione",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal values vary depending upon the laboratory performing the testing. The laboratory should be consulted for age-appropriate normal ranges.",
"   </p>",
"   <p>",
"    Failure of any steroidogenic response suggests SF-1, DAX-1, StAR, or p450scc mutation. Mutations in SF-1 can also cause agonadism, hypogonadotropic hypogonadism, and adrenal hypoplasia. Mutations in StAR cause the lipoid hyperplasia type of CAH (",
"    <a class=\"graphic graphic_table graphicRef76865 \" href=\"UTD.htm?39/0/39949\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link\">",
"     \"Unusual causes of adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SEX CHROMOSOME DSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subtype of DSD includes many disorders that do not show genital ambiguity such as 45,X (Turner Syndrome) and 47,XXY (Klinefelter Syndrome). The category also includes some disorders that may include genital ambiguity, such as individuals with mosaic",
"    <span class=\"nowrap\">",
"     45X/46,XY",
"    </span>",
"    karyotype with reproductive asymmetry (mixed gonadal dysgenesis), or other individuals with mosaic",
"    <span class=\"nowrap\">",
"     46,XX/46,XY",
"    </span>",
"    cell lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Mixed gonadal dysgenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder is characterized by asymmetric reproductive anatomy, generally with a poorly developed testicle and Wolffian ducts on one side and a gonadal streak and incompletely developed M&uuml;llerian structures on the other. Many individuals with mixed gonadal dysgenesis have variable degrees of genital ambiguity. The presence of any external genital asymmetry, such as a single palpable gonad, should raise suspicion of this disorder. The karyotype can be quite variable, and somatic features of Turner syndrome may be noted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with mixed gonadal dysgenesis, the risk of gonadoblastoma is increased; the risk is intermediate if the gonads are in the scrotum, and high if they are in the abdomen. Management of this risk, including consideration of gonadectomy, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of the infant with ambiguous genitalia\", section on 'Gonads'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109685527\">",
"    <span class=\"h2\">",
"     Ovotesticular DSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovotesticular DSD (previously termed true hermaphroditism), is characterized by the presence of both functional ovary and testis, or ovotestis(es). In 80 percent of cases, it is associated with an XX karyotype. However, it can be seen with an XY karyotype, a mixed",
"    <span class=\"nowrap\">",
"     XX/XY",
"    </span>",
"    karyotype, or various other sex chromosome patterns. A mixed ovarian-testicular phenotype in an XY child has been associated with a small deletion in the DMRT1 gene, a sex-determining gene present in many vertebrate species [",
"    <a class=\"abstract\" href=\"UTD.htm?23/59/24506/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with a congenital discrepancy between external genitalia, and gonadal and chromosomal sex are classified as having a disorder of sex development (DSD). Some DSDs present with a genital appearance that does not permit gender declaration at birth, and this physical appearance is termed ambiguous genitalia.",
"     </li>",
"     <li>",
"      The evaluation of infants with ambiguous genitalia should be undertaken as soon as possible. This is because congenital adrenal hyperplasia, the most common cause of DSD, can be life-threatening. In addition, DSD is perceived as disturbing by most families, and calls for immediate sensitive and professional counseling and psychosocial support. (See",
"      <a class=\"local\" href=\"#H25315825\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On physical examination, key clinical features of infants with DSD can include bilaterally nonpalpable testes (",
"      <a class=\"graphic graphic_picture graphicRef73353 \" href=\"UTD.htm?24/35/25136\">",
"       picture 1",
"      </a>",
"      ), microphallus, perineal hypospadias with bifid scrotum (",
"      <a class=\"graphic graphic_picture graphicRef54419 \" href=\"UTD.htm?34/32/35329\">",
"       picture 2",
"      </a>",
"      ), clitoromegaly (",
"      <a class=\"graphic graphic_picture graphicRef64870 graphicRef76693 \" href=\"UTD.htm?15/62/16358\">",
"       picture 3A-B",
"      </a>",
"      ), posterior labial fusion (",
"      <a class=\"graphic graphic_picture graphicRef51835 \" href=\"UTD.htm?17/46/18144\">",
"       picture 4",
"      </a>",
"      ), or palpable gonad or gonads in the labioscrotal folds (",
"      <a class=\"graphic graphic_picture graphicRef78743 \" href=\"UTD.htm?18/59/19376\">",
"       picture 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial laboratory testing should include measurement of 17-hydroxyprogesterone as an initial screen for the possibility of congenital adrenal hyperplasia (CAH), and a karyotype with an immediate probe for SRY in order to direct further studies. The SRY gene is a critical factor in testicular development and usually coincides with the presence of a Y chromosome. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other studies that can be important in early evaluation include random serum electrolytes, cortisol, 11-deoxycortisol, 17-hydroxypregnenolone, dehydroepiandrosterone (DHEA), and adrenocorticotropic hormone (ACTH) to thoroughly evaluate for the possibility of congenital adrenal hyperplasia. Pelvic and abdominal ultrasonography should be performed to determine whether gonads, uterus, and vagina are present. (See &nbsp;above and &nbsp;above.)",
"     </li>",
"     <li>",
"      The results of the examination and initial laboratory testing should permit classification of the infant into one of three broad categories: 46,XX DSD, 46,XY DSD, or sex chromosome DSD. The infant can then be further evaluated to determine the nature of the underlying disorder within each of these categories. (See",
"      <a class=\"local\" href=\"#H21\">",
"       '46 XX DSD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       '46 XY DSD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Sex chromosome DSD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of these infants, which is critical and often controversial in the absence of well-defined outcome-based guidelines, requires a multidisciplinary team including specialists from pediatric endocrinology, genetics, pediatric",
"      <span class=\"nowrap\">",
"       surgery/urology,",
"      </span>",
"      and psychology or social work. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=see_link\">",
"       \"Management of the infant with ambiguous genitalia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/1\">",
"      Lee PA, Houk CP, Ahmed SF, et al. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics 2006; 118:e488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/2\">",
"      Hughes IA, Nihoul-F&eacute;k&eacute;t&eacute; C, Thomas B, Cohen-Kettenis PT. Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development. Best Pract Res Clin Endocrinol Metab 2007; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/3\">",
"      Ahmed SF, Hughes IA. The genetics of male undermasculinization. Clin Endocrinol (Oxf) 2002; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/4\">",
"      Clarkson MJ, Harley VR. Sex with two SOX on: SRY and SOX9 in testis development. Trends Endocrinol Metab 2002; 13:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/5\">",
"      Achermann JC, Meeks JJ, Jameson JL. Phenotypic spectrum of mutations in DAX-1 and SF-1. Mol Cell Endocrinol 2001; 185:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/6\">",
"      Ozisik G, Achermann JC, Meeks JJ, Jameson JL. SF1 in the development of the adrenal gland and gonads. Horm Res 2003; 59 Suppl 1:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/7\">",
"      Wada Y, Okada M, Hasegawa T, Ogata T. Association of severe micropenis with Gly146Ala polymorphism in the gene for steroidogenic factor-1. Endocr J 2005; 52:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/8\">",
"      Wada Y, Okada M, Fukami M, et al. Association of cryptorchidism with Gly146Ala polymorphism in the gene for steroidogenic factor-1. Fertil Steril 2006; 85:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/9\">",
"      Canto P, S&ouml;derlund D, Reyes E, M&eacute;ndez JP. Mutations in the desert hedgehog (DHH) gene in patients with 46,XY complete pure gonadal dysgenesis. J Clin Endocrinol Metab 2004; 89:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/10\">",
"      Little M, Wells C. A clinical overview of WT1 gene mutations. Hum Mutat 1997; 9:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/11\">",
"      Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol 2006; 21:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/12\">",
"      Klamt B, Koziell A, Poulat F, et al. Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. Hum Mol Genet 1998; 7:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/13\">",
"      Vainio S, Heikkil&auml; M, Kispert A, et al. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/14\">",
"      Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ. A WNT4 mutation associated with M&uuml;llerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004; 351:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/15\">",
"      Ross AJ, Capel B. Signaling at the crossroads of gonad development. Trends Endocrinol Metab 2005; 16:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/16\">",
"      Bagheri-Fam S, Sim H, Bernard P, et al. Loss of Fgfr2 leads to partial XY sex reversal. Dev Biol 2008; 314:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/17\">",
"      Gibbons RJ, Wada T, Fisher CA, et al. Mutations in the chromatin-associated protein ATRX. Hum Mutat 2008; 29:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/18\">",
"      Smith CA, McClive PJ, Western PS, et al. Conservation of a sex-determining gene. Nature 1999; 402:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/19\">",
"      Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996; 81:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/20\">",
"      Feldman KW, Smith DW. Fetal phallic growth and penile standards for newborn male infants. J Pediatr 1975; 86:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/21\">",
"      Davidoff F, Federman DD. Mixed gonadal dysgenesis. Pediatrics 1973; 52:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/22\">",
"      Phillip M, De Boer C, Pilpel D, et al. Clitoral and penile sizes of full term newborns in two different ethnic groups. J Pediatr Endocrinol Metab 1996; 9:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/23\">",
"      Oberfield SE, Mondok A, Shahrivar F, et al. Clitoral size in full-term infants. Am J Perinatol 1989; 6:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/24\">",
"      Riley WJ, Rosenbloom AL. Clitoral size in infancy. J Pediatr 1980; 96:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/25\">",
"      Sutphen R, Gal&aacute;n-Gom&eacute;z E, Kousseff BG. Clitoromegaly in neurofibromatosis. Am J Med Genet 1995; 55:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/26\">",
"      Sane K, Pescovitz OH. The clitoral index: a determination of clitoral size in normal girls and in girls with abnormal sexual development. J Pediatr 1992; 120:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/27\">",
"      Verkauf BS, Von Thron J, O'Brien WF. Clitoral size in normal women. Obstet Gynecol 1992; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/28\">",
"      Quigley CA, De Bellis A, Marschke KB, et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/29\">",
"      Callegari C, Everett S, Ross M, Brasel JA. Anogenital ratio: measure of fetal virilization in premature and full-term newborn infants. J Pediatr 1987; 111:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/30\">",
"      Yu H, Patel SB. Recent insights into the Smith-Lemli-Opitz syndrome. Clin Genet 2005; 68:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/31\">",
"      Sarafoglou K, Banks K, Kyllo J, et al. Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota. JAMA 2012; 307:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/32\">",
"      Eggers S, Sinclair A. Mammalian sex determination&mdash;insights from humans and mice. Chromosome Res 2012; 20:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/33\">",
"      Fl&uuml;ck CE, Miller WL. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. Curr Opin Pediatr 2006; 18:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/34\">",
"      Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84:4677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/35\">",
"      Gasca S, Canizares J, De Santa Barbara P, et al. A nuclear export signal within the high mobility group domain regulates the nucleocytoplasmic translocation of SOX9 during sexual determination. Proc Natl Acad Sci U S A 2002; 99:11199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/36\">",
"      Huang B, Wang S, Ning Y, et al. Autosomal XX sex reversal caused by duplication of SOX9. Am J Med Genet 1999; 87:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/37\">",
"      Cox JJ, Willatt L, Homfray T, Woods CG. A SOX9 duplication and familial 46,XX developmental testicular disorder. N Engl J Med 2011; 364:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/38\">",
"      Lee MM, Donahoe PK, Silverman BL, et al. Measurements of serum m&uuml;llerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med 1997; 336:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/39\">",
"      Rey RA, Belville C, Nihoul-F&eacute;k&eacute;t&eacute; C, et al. Evaluation of gonadal function in 107 intersex patients by means of serum antim&uuml;llerian hormone measurement. J Clin Endocrinol Metab 1999; 84:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/40\">",
"      Krob G, Braun A, Kuhnle U. True hermaphroditism: geographical distribution, clinical findings, chromosomes and gonadal histology. Eur J Pediatr 1994; 153:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/41\">",
"      Tomaselli S, Megiorni F, De Bernardo C, et al. Syndromic true hermaphroditism due to an R-spondin1 (RSPO1) homozygous mutation. Hum Mutat 2008; 29:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/42\">",
"      Morel Y, Rey R, Teinturier C, et al. Aetiological diagnosis of male sex ambiguity: a collaborative study. Eur J Pediatr 2002; 161:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/43\">",
"      Winter JS, Hughes IA, Reyes FI, Faiman C. Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age. J Clin Endocrinol Metab 1976; 42:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/44\">",
"      Forest MG, Sizonenko PC, Cathiard AM, Bertrand J. Hypophyso-gonadal function in humans during the first year of life. 1. Evidence for testicular activity in early infancy. J Clin Invest 1974; 53:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/45\">",
"      Kim CJ, Lin L, Huang N, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 2008; 93:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/46\">",
"      Cara JF, Moshang T Jr, Bongiovanni AM, Marx BS. Elevated 17-hydroxyprogesterone and testosterone in a newborn with 3-beta-hydroxysteroid dehydrogenase deficiency. N Engl J Med 1985; 313:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/47\">",
"      Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab 2002; 87:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/48\">",
"      Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab 2002; 87:3598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/49\">",
"      Schnitzer JJ, Donahoe PK. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/50\">",
"      Mendez JP, Schiavon R, Diaz-Cueto L, et al. A reliable endocrine test with human menopausal gonadotropins for diagnosis of true hermaphroditism in early infancy. J Clin Endocrinol Metab 1998; 83:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/51\">",
"      French S, Rodriguez L, Schlesinger A, et al. FSH Injections and Ultrasonography Determine Presence of Ovarian Components in the Evaluation of Ovotesticular Disorders of Sex Development. Int J Pediatr Endocrinol 2009; 2009:507964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/52\">",
"      Knebelmann B, Boussin L, Guerrier D, et al. Anti-M&uuml;llerian hormone Bruxelles: a nonsense mutation associated with the persistent M&uuml;llerian duct syndrome. Proc Natl Acad Sci U S A 1991; 88:3767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/53\">",
"      Imbeaud S, Carr&eacute;-Eus&egrave;be D, Rey R, et al. Molecular genetics of the persistent m&uuml;llerian duct syndrome: a study of 19 families. Hum Mol Genet 1994; 3:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/54\">",
"      Imbeaud S, Belville C, Messika-Zeitoun L, et al. A 27 base-pair deletion of the anti-m&uuml;llerian type II receptor gene is the most common cause of the persistent m&uuml;llerian duct syndrome. Hum Mol Genet 1996; 5:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/55\">",
"      Swain A, Narvaez V, Burgoyne P, et al. Dax1 antagonizes Sry action in mammalian sex determination. Nature 1998; 391:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/56\">",
"      Lalli E, Sassone-Corsi P. DAX-1, an unusual orphan receptor at the crossroads of steroidogenic function and sexual differentiation. Mol Endocrinol 2003; 17:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/57\">",
"      Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/58\">",
"      Latronico AC. Naturally occurring mutations of the luteinizing hormone receptor gene affecting reproduction. Semin Reprod Med 2000; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/59\">",
"      Givens JR, Wiser WL, Summitt RL, et al. Familial male pseudohermaphroditism without gynecomastia due to deficient testicular 17-ketosteroid reductase activity. N Engl J Med 1974; 291:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/60\">",
"      Mendonca BB, Inacio M, Arnhold IJ, et al. Male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 2000; 79:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/61\">",
"      Andersson S, Moghrabi N. Physiology and molecular genetics of 17 beta-hydroxysteroid dehydrogenases. Steroids 1997; 62:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/62\">",
"      Forest MG. Pattern of the response of testosterone and its precursors to human chorionic gonadotropin stimulation in relation to age in infants and children. J Clin Endocrinol Metab 1979; 49:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/63\">",
"      Iqbal A, Hughes IA. The testosterone:androstenedione ratio in male undermasculinization. Clin Endocrinol (Oxf) 2000; 53:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/64\">",
"      Walsh PC, Madden JD, Harrod MJ, et al. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974; 291:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/65\">",
"      Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/66\">",
"      Imperato-McGinley J, Gautier T, Pichardo M, Shackleton C. The diagnosis of 5 alpha-reductase deficiency in infancy. J Clin Endocrinol Metab 1986; 63:1313.",
"     </a>",
"    </li>",
"    <li>",
"     Luteinizing hormone/chorigonadotropin receptor. In: Online Mendelian Inheritance in Man. Johns Hopkins University, Baltimore, MD, 2003. Available at: www.ncbi.nlm.nih.gov:80/entrez/dispomim.cgi?id=152790 (Accessed on February 09, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/68\">",
"      Rousseau-Merck MF, Misrahi M, Atger M, et al. Localization of the human luteinizing hormone/choriogonadotropin receptor gene (LHCGR) to chromosome 2p21. Cytogenet Cell Genet 1990; 54:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/69\">",
"      Berthez&egrave;ne F, Forest MG, Grimaud JA, et al. Leydig-cell agenesis: a cause of male pseudohermaphroditism. N Engl J Med 1976; 295:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/70\">",
"      P&eacute;rez-Palacios G, Scaglia HE, Kofman-Alfaro S, et al. Inherited male pseudohermaphroditism due to gonadotrophin unresponsiveness. Acta Endocrinol (Copenh) 1981; 98:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/71\">",
"      Ahmed SF, Cheng A, Dovey L, et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J Clin Endocrinol Metab 2000; 85:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/72\">",
"      Jamin SP, Arango NA, Mishina Y, Behringer RR. Genetic studies of MIS signalling in sexual development. Novartis Found Symp 2002; 244:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/73\">",
"      Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, et al. Association of prenatal phenobarbital and phenytoin exposure with genital anomalies and menstrual disorders. Teratology 2001; 64:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/74\">",
"      Yiee JH, Baskin LS. Environmental factors in genitourinary development. J Urol 2010; 184:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/75\">",
"      Tordjman K, Jaffe A, Trostanetsky Y, et al. Low-dose (1 microgram) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 microgram) test. Clin Endocrinol (Oxf) 2000; 52:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/59/24506/abstract/76\">",
"      Ledig S, Hiort O, W&uuml;nsch L, Wieacker P. Partial deletion of DMRT1 causes 46,XY ovotesticular disorder of sexual development. Eur J Endocrinol 2012; 167:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5803 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24506=[""].join("\n");
var outline_f23_59_24506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL SEX DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gonads",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Genes involved in gonadal development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Internal genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      External genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Penile length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gonads",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Urethral opening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clitoral size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Virilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anogenital ratio",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25315825\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25315832\">",
"      Categorization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      46 XX DSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      46 XY DSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Abnormal testicular activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Abnormal androgen synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - hCG stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Abnormal response to androgen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Testing for associated adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - ACTH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SEX CHROMOSOME DSD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Mixed gonadal dysgenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109685527\">",
"      Ovotesticular DSD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5803|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/3/23615\" title=\"algorithm 1\">",
"      Evaluation of 46 XX infant with virilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/9/7312\" title=\"algorithm 2\">",
"      Evaluation of 46 XY infant with undervirilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5803|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/10/2214\" title=\"figure 1\">",
"      Development internal genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/56/32645\" title=\"figure 2\">",
"      Development external genitalia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7246\" title=\"figure 3\">",
"      Penile length in newborns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/15/17649\" title=\"figure 4A\">",
"      Virilization cross section view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/60/29634\" title=\"figure 4B\">",
"      Virilization external view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/59/13247\" title=\"figure 5\">",
"      Feminization scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 6\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/20/40271\" title=\"figure 7\">",
"      Testost formation metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5803|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/35/25136\" title=\"picture 1\">",
"      Bilateral cryptorchidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/32/35329\" title=\"picture 2\">",
"      Perineal hypospadias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/52/19266\" title=\"picture 3A\">",
"      Clitoromegaly1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/52/43855\" title=\"picture 3B\">",
"      Clitoromegaly2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/46/18144\" title=\"picture 4\">",
"      Posterior labial fusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/59/19376\" title=\"picture 5\">",
"      Testes in phenotypic female",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/43/33457\" title=\"picture 6A\">",
"      Mixe gonadal dysgenesis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/26/30112\" title=\"picture 6B\">",
"      Mixed gonadal dysgenesis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/11/18609\" title=\"picture 7\">",
"      Sex reversal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/7/19583\" title=\"picture 8\">",
"      Smith Lemli Opitz genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5803|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/18/303\" title=\"table 1A\">",
"      Genes involved DSD A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/31/19965\" title=\"table 1B\">",
"      Genes involved DSD B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/41/36508\" title=\"table 2\">",
"      Disorders with genital ambiguit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/0/39949\" title=\"table 3\">",
"      Different forms of CAH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15878?source=related_link\">",
"      Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31236?source=related_link\">",
"      Diagnosis and management of gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17096?source=related_link\">",
"      Diagnosis and treatment of disorders of the androgen receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24726?source=related_link\">",
"      Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35577?source=related_link\">",
"      Management of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41220?source=related_link\">",
"      Normal sexual differentiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30423?source=related_link\">",
"      Steroid 5-alpha-reductase 2 deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_59_24507="Medication effects on fracture healing";
var content_f23_59_24507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that may affect fracture healing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purported effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy",
"       </td>",
"       <td>",
"        <p>",
"         Doxorubicin",
"        </p>",
"        <p>",
"         Cyclophosphamide",
"        </p>",
"        <p>",
"         Adriamycin",
"        </p>",
"        <p>",
"         Methotrexate",
"        </p>",
"       </td>",
"       <td>",
"        Decreased callus formation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        <p>",
"         Dexamethasone",
"        </p>",
"        <p>",
"         Prednisone",
"        </p>",
"        <p>",
"         Methylprednisolone",
"        </p>",
"       </td>",
"       <td>",
"        Evidence is inconsistent; may decrease bone mineralization",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antibiotics",
"       </td>",
"       <td>",
"        <p>",
"         Fluoroquinolones (eg, Levofloxacin)",
"        </p>",
"        <p>",
"         Gentamicin",
"        </p>",
"        <p>",
"         Tetracycline",
"        </p>",
"       </td>",
"       <td>",
"        Fluoroquinolones have adverse effects upon cartilage regrowth and bone healing. Evidence concerning other antibiotics is inconsistent.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        NSAIDs",
"       </td>",
"       <td>",
"        Multiple nonspecific and COX-2 inhibitors",
"       </td>",
"       <td>",
"        Animal studies suggest decreased healing; human studies are inconsistent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24507=[""].join("\n");
var outline_f23_59_24507=null;
var title_f23_59_24508="ACC AHA ETT diagnosis CHD";
var content_f23_59_24508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise ECG testing without an imaging modality for the diagnosis of obstructive coronary heart disease (CHD)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that exercise ECG testing for the diagnosis of CHD is indicated in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An intermediate pretest probability of CHD based upon age, gender, and symptoms, including patients with complete right bundle branch block or less than 1 mm ST depression, in the absence of the exceptions listed in class IIb and class III.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of exercise ECG testing for the diagnosis of CHD in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Suspected variant (vasospastic) angina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The usefulness of exercise ECG testing for the diagnosis of CHD is less well established in patients with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; A high or low pretest probability of CHD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digoxin therapy and less then 1 mm of ST segment depression at baseline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Electrocardiographic evidence of left ventricular hypertrophy and and less then 1 mm of ST segment depression at baseline.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that exercise testing for risk assessment and prognosis in patients at intermediate or high probability of CHD is not useful in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; Patients with the following baseline ECG abnormalities:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Preexcitation (Wolff-Parkinson-White) syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Electronically paced ventricular rhythm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. More than 1 mm of ST segment depression at rest.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Complete left bundle branch block.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; An established diagnosis of CHD due to prior myocardial infarction or coronary angiography. However, testing may be warranted in such patients to assess functional capacity and prognosis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24508=[""].join("\n");
var outline_f23_59_24508=null;
var title_f23_59_24509="Patients with diabetes have worse outcomes non ST elevation ACS";
var content_f23_59_24509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diabetics with a non-ST elevation ACS have a worse outcome than nondiabetics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the OASIS registry of 8013 patients with a non-ST elevation acute coronary syndrome (unstable angina or non Q-wave myocardial infarction), 21 percent had diabetes. After a two-year follow-up, diabetic patients had a significantly higher combined event rate (cardiovascular death, new myocardial infarction, stroke, new heart failure) than nondiabetics (relative risk 1.56).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Malmberg K, Yusuf S, Gerstein HC, et al. Circulation 2000; 102:1014.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24509=[""].join("\n");
var outline_f23_59_24509=null;
var title_f23_59_24510="Dobutamine echo mortality-I";
var content_f23_59_24510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Extent of abnormality on dobutamine echocardiography predicts outcome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 365px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 3156 patients undergoing dobutamine echocardiography, survival in patients with a normal test was significantly different from those with functional abnormalities of increasing severity, ie, number of abnormal territories.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Marwick, TH, Case, C, Sawada, S, J Am Coll Cardiol 2001; 37:754.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24510=[""].join("\n");
var outline_f23_59_24510=null;
var title_f23_59_24511="Benefit of supervised exercise therapy in claudication";
var content_f23_59_24511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Benefit of supervised exercise therapy in claudication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 395px; background-image: url(data:image/gif;base64,R0lGODlhFwKLAfcAAPfTy+h0W4O9nNvs46Ol/vP59ul7Y2uwiczN/vDCdPTTm/fds/bNxPHEedvb/tPU/vGrnPLMi/359VypfURERPna0/fhu6LNtaqs/jxB+/zs6f///+BEIu66ZMLE/pGT/fjkwru8/srj1OTx6vj4/vXVofCklPb6+Jmb/bO0/uA9Grzbyez18PXEuuuCa+NSMv76+OJMK/LJhO+9arLWwfKzpfri3Ojz7Xd3d+ywTXu5lYqM/PT0/tTo3PO5rfnozP358ZPGqe+ci/Dx/v78+XS1kHl8/YGE/Vaifvn8+lemeeduU+yyUe22Wfrs1e3t/unp/v78/FFU/Ydwsvvu2eXm/klN/ZnIreZlSuVwMFKYivbZqe6VgvbarPz16Wls/cDezd/u5ojAoPvp5XJ1/eRaPPPPknCzjMbg0e20VanRukl4sTk9/eyJdO2NeWWuhZ3Lsfrq0fzw7f329Vpd/fS+suViRcuhfWJl/fTQldHn2v337UFF/eBAHvz9/P3y8OVeQfHGf0VJ/e2Rffv7/vrl4O64XkBb01VY/f308n66mPj7+V+qf7bYxP7+/WKsgfnmx67Uv/ne2Pvw3Tc7/fO2qeFIJuHh/o3CpPvx4OyvSrnax01Q/WVo/WuZsPXBtvfft21w/eGzd+uGcH1//JDEp+6Yhl5h/fXYpvzy4uiDRmJW0vD3856g/o6Q/ZaY/Wivh+qhQ+ZoTfz05s3l11mYlIWI/aao/pbHq3Z5/VCPlLa4/uRWOKXPuPzz5GellZOd7qzTvarSu+A+GzpH7V2jigAAAKOp9uupRq+w/uyvSe7u7oiIiBERETMzMyIiIru7u93d3czMzKqqqmZmZpmZmVVVVf7+/t89Gv3+/fv8+3i3k/bIvs/Q/vjX0OPk/kBAQIvBo+Lv5/bbr++gj7/A/v3478fI/o/Dpd7f/tfq32Ssg9fY/sPfz+uuSPC+f92oXvKvodXP6pGY9Jie9vC/b9DW9KWBjumUPeGoU+ezY7acb2Cki8zW7fL2+OyvTCH5BAAAAAAALAAAAAAXAosBAAj/ADcIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3btdnxvIaq7aBQl5qAqE1M/ZMmt3DiBOrlGYsGrNny6I1m7ahGbMNOJwp3sy5s0YKgK3hEEiBGeNlG6AZ88y6teuE05pF63u5LzXVgRsLBKe3t+/fwIMLH068uPHjyJMrX868ufPn0KNLn069unXhSp/VFk3atDHUuBeu/35NvnzJ8UeZNUO94XHkyZUvZ2aI3rz9+xrrE11mmaBfY4ClNlhh9OFn4IEU6ReWggg26GBBDH4V4YMUHjhhVxdWqGF5GW7V4YYgevZhViOGaCJiJV6V4oksyrViVS+2KCNbMU5V44w4mnVjVDvm6CNYPT4V5I9EajVkU0cWqSRVSS7V5JJQOvVkUlNGaSVSVR6V5ZVcCrVlUV92KSZPYQ5V5pho2nRmUGum6SZMbf4U55t0qjRnT3fWqSdJee7U556AevRnToMGaihGhd6U6KGMSrRoTY82KmmBZUU66aUHWSqTpph2ugGncHoq6qY6jmqqS6C+lOqpScmRiFqrtv8UK6tFyWGHLK+iNetKu9IalK0qqICrrqX6qhiwwQqba6XFGnsYsskq2+xYvc7YQgtjESFHBYBEG+2wZFWLkrgsttBHH9gmFUUiGhQiCQAMtFBHDRCYYAoXbbhgQABYAFLGC5YM4+3AwXJgRwCjcGFCJdx4M8YcHk7rrELmBotuTNdIIMcYknjDADd1VBKPCUJw4cYo+y5hByAvxNAHwTDH3IclMQgc882W8CJLAG2YAoEPDFSgARFCSjzxQRUnezFGRPwxhg0VAMDNJz7EAwE5priRbwBLyAIILzFYcvPY0dLMCyBYLBGAC6MMYgo5EMTjwyfcAFCBDWP8EcVAAIj/7W0MABQCQAuVmDCICwHY8QIHZMdQxhIGuCEEBHUwIIkcjphp9NEEJR0tuo6w6y688tJLjhCD5LuvLHb8a8nLZI/NQQwvAGKH2gaM4gYXQpgQTyV1cMOAN5KMIQcMHPUdbQwVMPSHDQB8UgM5briwBCAujz1MDIAs4YIb5MTzCQA2/HGNopmHyzlCnsfuvtKWvFDGrQEY4EIbXJhiAgQ11NHC8BUohAbmcL6ZKE8FMfAGRq4hh3fVIR5CcIMBllCGmo2tDy+4nQsGYYIatCBwEFMJDBC2N2qt7yAGGJvZACELtd3PDW/jnw9aULe75a2ES+kb80oSBQ1UgAE+gIAp/9pgAFmUwW8348ALsIAw/THMYRLwyAiDNYr0EUU9xqAAaf4SmAEZRjwnHEgUGDAKJA4sAMgji91kAoMxVIAbPrDXKPjFC8apUGcG6NnPgja0iEwxWaPAYVCqsZeBuEcylOnPfMC4PkcwwA0xSJa/vDUMNF5pDoXwRgtqYAIuIE5xdsTZ4yI3ucpdzoob+GO0qjgUZ9RGINyhzWlS0yFyGegaAICkzQAhBBtcAwYpTFYAiLan50Vveoe7XvZutr3uGYAXMAuklwaTRdqQ5jbjUc1sNsCb4DgLAFx4QbLKYApJFASYKqhkGjvFQBsw4IERnGAF39cGoTQDGhuQTDViWf+aWYZHIbYkjzfCaTNecEGBCAGmJdfXQ0k8MmYc4IZQrAEYRB4SPorUDCNFJQlTQDNYL+ACABoCg3WGUSCVsFm0IjqUaDgjL6PpCxcFRJgvAtRTkhBCGZL1AjcAAJUnlUhKVyrRBV3KBuToVjpj0AYGADWoFBmqClgqloDapRAmsEOyYjAKbjwVqhZJKVWrGqhrjAECWEiWJVzADUGCdSM+KKoJ9aQBCMhCrS74hEnf2hGrjsSva9FAPJZgMw4YoA5R5KtIABsSxppFDjVYAuwM64PEKvavm1vSHyoRgMkGwAfLuiyfMvujRPjAALDrQwAq8QfRpsSxH4HtVuZQBwP/2HEYS6iBHFzLK9KySAKfcMFtlwCB3fKWJbLtq49g0AIXIFEWENDAcVXl2woRgRtlTBYWTDCG6cYkuRwBL1PG2IZIBssOJiiEd2ci3vyEyJGQlCQ5bLBeSFXXPrh0gziDVQYhmLO+arqvQMOZLF6YonkAxkl7M7Jgn1TAo8EaRkgRmmBCCZgzOd0pSAcx0gqT6cKHuQZSNayCngKggB7+MLNeYwMTKBWBTf1qii28Ys9gVavBskRX3TpjPIHYLWdNa45d0AIe99gnDb5Ikjki44II9q4Fy+tej8ymH2+lekYWiBwGW9jDWpbKYLJyVtwQLBe4FbIBENgw+mAAH4QQ/8xYEvNVyJwsM29gs5212GdDC+c417gsdE7WMHZ22wDUoLV9RpKcqRJogi0hHsZNtJQWLZVB3MwAkpZKopbBafaaxQcqHRgEMs0jlzDjpXlxBg7Yg6qzgHpgwxg1qaHSJ2ngxRjOyHVe+tPqsxDWW7KeddFW4oxm4GCbG1jGY77Ta7JcwwQq6IPNYi3sUq+EGsgmyDKowerelqUOwarDq4Nd7Um7hD3QsCl1x4JLDgzDBAIJYrmtzRLVTAMHeeFLqMZig0gOYt4wcgkOIPOMZjxDo+sOixygaYAmA9xJAndGNLI4DWYn/CsSSCsW3vxweq+EGcawhjFwUPFuIzcsUf9IIS+k23EbnZua0qAGwiFCSL3g8z8BEkxNKfUVS1vCly13uUuiQXLM6Dsi1XgGQS6aSPnMHCFLfgi0+9DhoGv63NMwuURqbozL8NM74KnlVz4hsDqgmLchMILa1672clA6I/bWCCGlUZprhkebu8FOVwDgbniv9xWUCLzgA9+Kt2fEGdXgtNYdBY2v+1PsXClEJOtZX8APXvCF/7NKKt6bpzvEGnypxnqYHh/MeN4gUVeIHHYagCyL1vKXp0Tm1dcSzuvl9AwBuTGaoW+cd3HnG8WKBO5qB44rlgRV6EYIMPCKI0gh9oH/QjIQAIWze6VQiu/0d7VyjRS+gOVh5EH/Os4Rglu4ghRfQAQfoM/+y2eADmRwRTLO8Q1CRMwl0rCGM6BBgZhe3Co+91+skg1P4ADnkAKt4Aq50AlSkAHtRwkZIAV4kAs70ArJYATs9wVH0AlWAH1sgAjxdwvncAn2J3QsIRl5MQ2PsX1YAQHRxgCYQghQ8AAekAwoYAtkgAecwAYPyAeI8AVG4AoEsAvnkA5DcBCwd3mzxwMOUA6tYAtfwAkeKAWhsAMEUA7pQAKK1hI4wHvGMA0lt29W0QIC4wOAQgLfoHzMdwShQAcd+ICCQAehcASvcAsh0A2XoIUQAXursAqYpxAkkA7lQAA7EApSwIOxxwlfYAutUA7s/8ADRjEombEMXwhyi/daV+ENjON3XTIE6YAAu0AAH4B+6veAbGAFp0AGtoACGFAOD1AFJZgR6RACtCgKokCLIZAOEUEIl+ABGOAKZIAIDhh7VoAHR9AKu/AAR4hkLkFIIkcBzaBFYjgVkqcClHcYQ1AF2riN2riMG0GADuABCLgDRsCAw8h+ETiBFZgC58AOT2B9I/EDyqAMTvCNVXAOyfABZEAH5zh4fIAHpIACKdANT6BgL0ENetEM6iYrVfEHrOd6b3ENrcB+KDARMvgA5WCDOHgKVoCI7OeDX0AKHzCECGCEM1EP89gAIwEFCJACr2AEp7B+sccHdJALrzB9UP+QDdPIEtWAA8yQbc0WFTCwBCpgB3xWFxMJfRWJECRwCcp3C83XhoLwgJQQh3P4Chhwh9+ghzohj/NIjynxBA+wCyhACngwlbH3fmTwARhAf7FoEoMCDQhXDdL4f07hCC5QYt2VGBLJfh8wfqF4fuknk+zHBpyQiquYDB7wAFDwlkERBR3wlcpQDxBZEjzADiHQChv4hpf3gaHgCrfgAXm4WC2xDCXHaYR0ieMyFVygApYgCfCIlFQJfRHYCUawjufgAO/IFBIAAjLABJI5j0wQASAwZS1BAuwwiFC4g7HHBlKwiFfoAFyJKCxBib/RDCwIFfEQbXKlGCiAjj8okiT/mQ6QOBVeAAqBkAPBuZ7KkAOBAAp7cBOB6AG3UIiHCH1WoIGtEAKPCBEe8AEAGqAA2g0nYZ29wWt2uRTcIDCVwBnssAP9OHhLiRWpsAUoOY+akABmwJ7KYAb1oAlfmQBd4As7QQjfcA6/GIwRGniCAJDIqIwJ8QHsdwsosQxyqXie9hTeIDbkoBhPcAt0QJUTOhWO4AQKEJnCGQgWAAQbcKHrqZLmgJ7qOY8dUAJO4HA0kQ1VgAD5mAv8CH18cApG8AoDWZAbIKPQR6MpkX/713/ZyRRjIE6jEJtwQQgekAuIaAWusAMUORUwAAkRkAYgqgxNEAGQQEwb4JUcWo8C/wEDIBABTfCVTWAGP4CoQAEF3eCSMEmY/kgHiDCjKYGClah0O5kUf9AtS2CpcnEJr/CGbEAG5WB/GCAFtFqrtKqmTmEOFiADU6oMHaAAV2oQCcChKWkQjhAHeYCkysAEMrCkRnENQzCWZXmWVImrJtGFhASGFheUSTGUKgAIiCYXPJACnSB4iEAAZpoVs9AFCTCok4kKqQASk4AKMzComtAA4zALS3GZZACqKDGJlbitDMkUefkCexkX3XAEMskHR/AA3EcFJYCkmpADDbAA8VkSe7AADdCrM1ACVECnQYGmsWetJeGMWRSNb4oUpuCaFOYWUNAKnxp9KTCdVUEEP/9gBpE6j2lAnMZZEr0pA2nwlYaQBz9QmTshspdHsiWBkLu2kCenFDXAnW9BAiFABojICa/wDVkhAbsKnPM4tHFgtCYRBTdrCF+ZBjIAAl/2E0g7eEpbsj4JlAOLFNzwMjXgFg7gCmiZAUZwDjp5FV6gseoJoh07CToBsTOgDJowsRV7sT6BAAQQuZIbueywEtlHKkhRAWIjBGwxBBhwCoHHBnSAAd5YFfOauPNIsePgBUDhBeOQAL1aD6iQCVVWmv+Raik7FHGqAi4AsmCRDedgBMMoCK5QuVYRBchqtsLZrGsbFEDQtUKrAHGApZjLErp3e7kbFImAqj0LFt+AAlL/SAlsEAoh4JhR0ZuBKqmUqqpHQQSQgLNna6jdm70nAXLSgKP06xNREAAqUAbhOhYksAtfIHhS0ApQYBV7IKVfWaVO4LtIcQ1GqqzuaQGOSxODwh/3q32lChSjsD3qRRYPYAsLewQIYBUV6qQZ2gX6mhW+YKH2KqIkmqPViWq4u8E+IQRT1bJf8QQEELOUgAfJUJ5SUaRH+pVMoKTmABZRmp4LrABUQL2j1RLXW8MJ2hOVkE7p8hV2arWBxwkfcAlU4b6QKqmGyr5g4ajpO4+TWqlz+3HGkMGqiYlCwQAvEw9gkQ4f4Kq54AHm2xS6yqtNHKxrcazJasTMaydDp5D4/2vDOiEJYmMKXsEDyYAHgkcHt5CuUOEL7Oqusku7c3G6X3mv+XoSg2J7VMytPKEB4oRpW3ENCEAKw8gHO+CwUXENiPuVFGuxihG4G/uVhRvFLGHKuJa/NzEHWiUL8wsVVdAKzye+X7ALNMsUNgu/OsuzrfGzXqsMQ1u0IIF9l0vMNbG//RtpVUG1oUDAKFAF5+ub2bzNUJwYZGsGyqsMO6u2yqV5OtEGCPTBVfGgMpkBpIAADlwUvOyuv+wgt5y6gbAArMtgLIFtB7FtcQzMO0EOU1V1UvGjQRp4eIABQtwUpzuoOZAAqxsi69quX9nJSsYSxXZsA6FseDHRmMUTPv+QTp8wFVFwp4goCB/gAE+BvHkwz8zqrDLyvL+JoYYArO8MISxha6mma7v3Sk+rEwzAOOTmFKzqqrDax0eBxkGrxutbJGKcs4QqvxAxKKdGTaom0xR9E46sAlwAFeNaroF3rpi8E0CQxAyRwExMpVY60DNCxBI7wXotHslcEhrMyDGhAQy31D+RsAtrCw8A2DRRAgqgECccyjD8JpmNoZudEPuwBfg8E3OQVrLQvEbxss1MCV8ws0MBBEzABIUtEIKNoYQdKHw9pZrAwNbnBTmQBofNE6pRG75HUwQSfDSxv8PAC+RsFIRQtVebtUZRAvN42RvgvtRc1pAQ3G7i1er/y8YbkAfzKNpGIQ2DcRmkl1E8VxNkFgP0hRR5u7d9+7dFAdvCuQBHTaXS69h1AtRCLQPjMKXAXRT6pB0b4HjM9k/dBBw3AW0cgNFD4bmgG3ijW7rTzZ4q7SwhvZ7kvRj6x3/+9xDRYOAGXne2cXe6cVM1AW4qUAdFcQ3BO7w74NNKsQdb4K6K2wUVzDlegAo4PuChSk0qSKo05xvMgOBht94xwXcqAAGUXRPfG77jGwLRTBRAAAoNgONfad0nJd7B2eEnga1fGIYUYeDp7XRK/hL9pgJuIBQBPMCBV8AHnBRc29cTu56yfVK+vZ5AHubOQIkqKLARYeAyBSC/d9wq/x4TC6cCAcDfLxHC/0zCT64TdT6lFGsBCsChXO4VrKAHCEELBRAWXs7hKWGy0FiXqMwSGacCG+cTPOzDnRDE3eqbul2xTGrf7JnnXnECRTABImAQaKAE25AEX7Hn7NnnJsG0u+e03vYSjqBy4OcSGMAJ1F7t1F54W5ynX5wU7pvfGboAs03dxLrpXHEBSuDrBBHsSiAMYDHq7AnmJTENPckMPwnOJuFz7w0TBMB+tpDHobvHXA0UYpzN9TAOOy4QoDAOCr/wDA8KYWHu6L4B6s7uYLEADH/x42ABKEFIxI17cuwSLsgBMCgT+/6AlnzXQ0G2aTyZXdDQdgHxIjDxZ/8hiRaHb2w90y1BdsNghjNR8mk5y0hxrGbw1cowA1uwwoph7kqw9BRveBeBb18kcjdPmi3B5JxI8n55FIRM1h2ACjGsGIugB72gCEu/9IqgBj1A7LRXb4SBA89o7yFRjdfY8x74AUQBwXnA9SXgyYmRBD2gBmRf9oJf9hNw9uqgDUblEsqukHD/EavH6GKbEj5/eXYfFFSgAPP8q4abGH4wAMEgABMg+NsgBkyv9OFQBII/AQJAAwPgBxgCE/Mut1ONEsNXlMYnExjYnJXfE5OA+dFLBZw/AJEgBqFf9kUAByJwAjK/ATBfACIAB6hf9owgBjQQBq6PFZu2yFUsEt3/J2HRPhMp0H67nxOZELFCmweMahfZEAaNIAaMIPjHjwahLhDLLxAwPxCsgAZXcAaCDxCMwjUSd23DQYQJFS5k2NDhQ4gRGRqTWNFiwmUUjG005uzix4sUQY5EeI2LCkuSSK6smIwSpVdQZM6EwoPlzYipUHVQ1rNJnjgGcQ4lWtTiNXGNMD1S0lTJmSvtWC08sU6JsIUXlMBKspBVO1wHnCp5hG7TCKNph4pUW5EZx40e235kO3chhGF9GNhlieHlLb5pfW2Z0VNZEzM/hAZm3LjhiE2lrDo9gAsMC4gDaDQMJg4iCzBBxDp9U2rFDcepN9RVffAttGWxWztkHbjF/zAVPmZLJPASw26QXrrUM5wmwo8owJUbvbEiyJuxsIKswNy6eSlY0YOAQb28aG3V0ZpJi73MO0Lwc71xUEHuPMPelJK9f+hlHPGeTCJASk7ff0XQcMnOKVhM6+48yNCBjjJc2qnuv5CWmwaujt5LL61rxohBhVEgPAgFSthIwUOE9lggAcOYkAESIkh0MSEW2rlitKbWweSsFzdIKhymnIIKjQdzVOjCxiaESy7viCzqjzJUCAAGD18JcRcSzQGlAU16ykEGEFoU0kNW0IDjjLEeGSiMLxW6JgwaxOixqSLgEGGqNJVkrDzZLGRMgiVUACQRDz8IMQQIgbAASy0Dsf8AyjT9Y0UEOIoYixExaAhjsUYZykYzARgZq4gLRCggRzsDmwYHVHFgRk++rnFBhRfG8NAVSjIoxz8JLAgkh0QtkCDT9wqg5YJtJhUgkgH8APYiP9SJRIAJxtrmAlpO8LBUu6ShEMnlsF3JFJQqgDCbHWr14D0YQJCBV2VyaAAUIJZd7gRaeinWqQkECEYdZeVdSRt1hFEkWqd06EWPRejztq23NMKBAmpYnasGFfrgZtwj2MjgHO/SXbcnTRJYIF5/Z1tEDzV0GGsCRdToQZuSjUoCZUXGUqLlHhJWbmG1cHAGGmOkmYYCidXiBrdKICTkiFoRUI4ISGRgwjCR94j/WbUkehDYZoMRvpqvk+1dWV91YG6N57R8XsYYa6wxxrwk56rAEhWEUJoUSvjoZjeoI5haE03qGceLrxsDOBhope2FFp0Ld4xeYsdGtl/G0DZqQmncNobo8yyHKMMXOFQ6l7wfaM2RHyJIw7B6tiDccbv8GOBZguGk1lrYlSsAUkmdopSGZPnyvCjzlmGGGbjjTusPQFRYoj/6CCGDEkFMd8yROMxowrAZUJkl97ayYVMMT52KU1Tw/wtzzEnPxJSo4dNPKH6GougTkD/+I2F6QdhpzBEn5GF7PekAKlIhv6KsqRE8GsuP6IRAEn3lCmRyyiMwQZD3rYR+N4EGkqrB/znlFeVVscqgckgQCkpYwQGBuYYTFNCELCmjAyWYBASHkqA3KeEAUQmSDYUUIBopoTQrQAtLNriSZUyoPNV4W+eMIoRw+ecaJPhCCtPBFyoowBCG6YACaii/bDQkjBUZwQpKsaCmHGA7PfThspoThAE1RTqnscgYV5MQO96JQhtpRtFuQrFhXMw/POgEJThxiZFkwgkQmUQJDBFDQyiACjZcgSJwl5ATKGITD7lBaOK4lekcqI2wK+MZx1KZyzyEBgLoyh0PUgAdtMMxa6NQM1blxKFwow8qqMF/eIAHQ36DJDJoQEMyUQKeKEMTP3FCCXO3CLFYEpM1O0DjDgLEsf+8wSxFHKUPxbEJTEymKVBxkEIKAB1WurIAxTqD2e4EjWfEZhrSUNhQ5qYCU/xnCKeghBSqQJJM9GSRCPEFKgrjEzPEwRHd3MANoom7TOqwO2GaYJku6BmGZnQDCmSgj+CABjqNAJ1JoMg6n8JGvgDtVBuphh9HMobQucCZuxkCHdggBSisRAY9KeYsCFOcxCxUow19aEQPMAAx9a4plGrEpYb6VIQ4QjPk+5Sc1IFOY5j0DCjlCw7i+YxmPINbO7tJIpq3BEa95wl0oAQicgpQw8iwOMeBHlQdejOVMYKCSxUDsoQKVcAqRHa0a6CnBMBOrnbVGdHYnBJxSRIYBED/BWXI33uu8QREUIIOT1gJDFAUV/2wKLAKEUcOlZCvYARvtKttSLMQV7txJpYvb3EbDhwbwpGMQgUxGMNMWwOFzNJhCCAhQhxKkIAYxjUOrD3INXoQhNoxohdlY251IZK1C5QvnbNZRjM2Ig1qjBU4wyOHCjjgDf9UQQqUOMVwK0IEJ6CiAeyKa1yLuVoWRGKvZHmodf3rEK2OdDfRsO0GcNDSx37EByoYRgv88w1OUAIP7n1IFKiwhQZMDWQzyMM4khvXgT5VG2gQA4HEcoAb3FWa/2XxK9mJA5EqYbuqwVPycGsRBvRhGBDwzyUi3AmbNMQRk+hCIDSszA7kAQQk/9tpfXn61DBcoEcTQIcIqNkdFV+yxdXVKgsoEuMZB8YZzjASR8S7G7RJgm5c8E86rECJLwQ5IdfIxDhksDoumgEE5lBIQJ1smBC3sQCbuJcSttGIAiziyglRsTW3PNoTINaVYKYcX8Zc5riM5C0buaVGjBGxDUDDu8+gJ0R4poEXDMMAvlWNA94cChIkJBULuLNhNGGICFjAag1p8p+VcV8bZkMPpSDYI+CApubCAcULcegVWP1ohmYjCFs9CFtEeoHU1DhPK1EiM+IpnmlswJYGPvOQLjIHO6hAFr96jwMEQQlYb2AWoIjAAHuCawu8DiJ74He//c1vG95ADXEUAP8a3FmSByqEFc+GdrQfWJeEi3mPFVqJtzdgDRwchALM0JZ5gBYRb0VBsmWQA33Y8W5S0HuLhjGEDEDxPWgvAgwC8FEkZNtwnJt7N86YeLkjwlhjQGMDG9c4NT4eamNE4yDgmPhGLNKG3RaCPvKYwj3g4Q53+EQGCzggzgdwhfIxIgg9yHnZK3JEkiyDieXBOEu0FY22D53jTTz6Q0p1DROYFwDe2QMIzKAPd/yjJ2kIxDi+iHNW0GCvOliBls3++IagnSQ4CNpBqNFHkFBA6Jjz9jLALe5V+QzkEvHBMIbxCeCYAwR5OGhP8nGHLlCB4cz1gwjCQaBecBPyu4/8ct7/8gwcXB7zH9m0MTq9EVCL2hikHj1EGMAeHqsGCJBQQOuVwQRRTGEVR8hjw8VxATSGgxaV5n35da4cT3PapQqxAd0G4RgJ/EAB9Uiuu1DhBA9kgA22+Cu0T7AClYETGog48ytA9DiPakAVoVs/hNAAXlABA+g/tYCBHygB+jOMHEiAEogDLymHDKAEV8A554KupYKDATBAFJwIFruQOcACFcACdkuL4jou+sqBeiiBH/AShAiBD/yAhruBYKARAWiHVkpBIzzA/0oPR5AsXii5ooAv+aKvwFGAH0irOQsBNoCJR0sCNKC5NBIGUTpCMZS83EkPN9gtGxiKKHACDDsy/02YAQWAhBhsiF14CRTYsgGAgykLAj2YPTHkPTKEHfDIOw7Yu5VwBCoosiNTBg6DBJKJiGTIwlZgMVZoBKXahk1wvD/cxEAECW1zqTpQARWog5G4hkkYh0DAMwLSMz67CAzIQgLwLz+gBUxwinW4AIzaRF2cHwnZIwqwMTRTCADggGEwgY/IBFpTxVszA10jiVvwDesagV6IIzEQAfLbxV3sxIvANI4AofFKCBvYEDeoCF8ABRmwN2XAN30jifj4Ddb6v5oZpwHERno8v91Qoth4BmbQCGBsDRyQug2QA14YhgCoq4WYtwhYOZ+IgJcjilZ4iRFZLXXAhbC7AnWoR/+M5EXloDyl24Axo7x+TI1EUAVVGAMJkIUXnAOG8AILSMjkaoKt84W0ABE22AU/lJ/82itFAANHy8h61EaL+D0ccBsKAEngSAQsiAVkKAMm1ICE6DszSKbB27pMmAspYQNCgaoRKzE5UoMw9MmMBEqL4Dk+mgZqALXZQMoswLos6ANLsIFrUL08kEplIDzDu0mQEBQ2uBUok7KmoDJawEuwNEKxDEpV6cijdMFY6Al3sIQsiADrY4IGiD0JnItyyYBz0ahBK7RDG5XB/EwkXA48UQ6kVIG1zDplcAfAcQf7cwKDbBVbMJeMEjZiawpjQzbQzE1XAo6MOBLgMABRXMz/uMKHLFgCHUyNa2CajWEogRNCg9NN6NzN3Si+TNuNQniB04yrLIgBb6jMwCAEvOEDp2kjmfPCpwiGm4tOjCzMiHiN8lgOGxDOuHIHBvBOviAEI8ibvfGhryufCRg7wVRPTlwO8SCPbdsNUPC1EmgNQiAdPrAeBEo8pWI8TRRQ3WRPiOBGnwsMR1DI+mKCR2SM/aEe/5Gf2ru9pniD3LNQFq22XvRNBPW1nljQxjgh6lmh9Pm+8Bu/Fu1RDIWIGlOOLTADIs2DQHgHIiVSBQjQj6CiFMJR2Pm/AFSCIpjHHr3SH32IIGVAvuCBKrKCK3KcESQYRriCE7xSNJVO1bi0/23h0rkgJENCJBKJshJSg4uEkSB0iiHsycFsOj/9U0ANVEEdVEItVEM9VLg4O+BgUxi9scAYAmCSAmEiEW3IDmdTiF4gC2vhQvM8ADC00CxtOGwJVYbQtgV0VLvYp376pxfpgWi51IPIVCUQgTycslLowxYl1UcbVQmhhuKxhg1NjSxdq7Z6qxxxVSW4VFm9gkvcBM/0UVBVVOWYEGeohmdgGzctCmJFBM5KE2S9Aq0Yi1vMRTTV1S3j1eWgBj66pQSbC+DSrG5tFGQdi2o8uDQ11xZD190oD2awpZAMRr6AgvUSrkwRBzXYK0awuTRVQQHV19YgyzZt17RQL/aisP8cGYFg2K/TSlYmBU18XUFpnQ2IbdRusQsIkzA5c5EboIFCe4TeEYFv7dg+jVaJ+NgN0LZ/nQ2gvIQ3A7IXuYFGaFlcGJamEIGDiNmF1Uj1dNjWwNl6Ugs3g7NY8xAWaIR4VAKxEwGYkVWjRQikTVo1vdCQfdiey9aRcDV4m1pH2YSrZYRSEIEi1Iaa6dqEcNVtqFBobdixXdOyldibODlKIAO1PQ9WWAHznABMQAM+XQSyY4gBeNakpZ8/sIMOKUCmpbFPNNuLeAA+YAMyIIRgAQOuPC0xaAe8BdsIWYnJxQZsqFx/IbqSrVnvOJVUYdfYxYlr4FxKMALQnZd2QNH/phADMDhd1KUL1bUD1mVd140IaSDLak2LupMI2MWI5UOIZdAcY8i4a90Ia0DMkbhc1dAWkiWroegGPqAEUujd3VgENMCE2hGAFYDc4sUJz1nd5FXeinCGjNsAZkBL4JhehGAGZ2iGBRwzj/OIZ2ipaKCAeNKgvW2NhsleiBmJavAuY0AwT0u+USs1u8NdBPjAI1Bf1VgEEajNptAkApxf+h0J+71f/I0IZ/BGxhI6a+VfsOoI89AcZzCejdsca9A4HPi4ClY/Hc5hjrDdg9DHs9yAjlOIBEaIZgg3kgDf1PAZoBEab7SIA+PfPuq8zxs30TM1nDiHD7SF7mMMbaCF/yAon5tphBRW4bV4iD4RRTpWARe+Y9at4zq2m4MAr42gAGmY4Q2o4c5bBn0UYPNwhuN5BqEDmmh4u48rygDeYY9cZKXbOKBLOqBZBlHj5GdYiCfWOCRO3eYDDrVhG7fJ2YiYhj6Ku41r4ujtPZbIP0rYAZn9iFmkSKfYBhpITzg2IjnWY1HE4zsWZgbjY4UIL0EmZM6BGHXlCGrYR4TYuOBDulDjOUB+ZuRbYrlLZriohrdzYgQTNyn+3gdWDczRnCy+iGh4hnCDXYg5OkdeOj9liXLIwhBsDD/Qgyt4E17+yl9WC8tpYRdOGhhGMGogmgseuk+WZvGoBkQOYBCqYP8CtmaEsIZopmTXiCdDtt3ukmIB9sjFuuYNeOIF/mQHlt19VbriOR5VfghpaAYEc+W58zg7GR4spAQfDIxs6AE4EKciCAaADui2qF/kLeiKoLy4ULpNc4aG5ogfvjiOgGhvfAbOieSNYD7srYZl4Lmwst0KRgjGCmRPawbtheqXFmOVng1qDeKb8DYO9uIoBj1yK+WP2IUsfIVWUQc4QKMiUAPdI+rKOd77NWiikGaGomLGABqOaAZMHontZamhQ76DUD7mU+uPSAE2YIM7nIsBuIA4OgM1wE3BFlaWsF/DPux1tiHFvpNTgdhgdQy0cQlKmES1CINeoJED6IUzLW3/nb2JyU1tQDzn8KgGa/Cu2G4MnvELSgAMowiDgyWQC+ht3wbYpSXuO9lHM2OGU71diXhGSnDHGxKGvYIFOFCHW67uFdbbtW4NI7ElDtbcjYqP+cCJEYgEpXqDK+iBM1Zv647O1k6p7W0Gaxhnv2WIhxSRm1jZlr0CPbhG/ybf627v2YAGahjw/UXVhaBJKiGJqp1SsePRCP8Pm/WvAG8MC0dus/2Azc7Kj6jatn1bex3xp51wu6Yxn7Hg5ctw72YIWtnLj2CFTTjcKuNTGq9xAMduU+lG7vaPC7mGy8xMiSgAw8WXcFDcIxeSEreuE58LC5+GtP5thriG2FzOiDgB/9HFF+El3ix3cpq9ceYCj2xQTgTwrRP43doRg8Zr80zZ8vcA4P/u4CRcCPDMm/FkCPZ1Xz2NXz5fFstBgJeIdEn/Aolo3rgw8KGIZYgAdOpcleLrXm3+mZvo8qFiDfzUT4ZIghKuHRRudH95dEmPdUqH4f3tX+/gdJQ+CK+ipwW2cFBT1/gGCVIfpcapC38gAzZ4UIVI4zUumEbwZVd3EViP9UifdYiI4YRY5oa+YUou4n1smKguSiG24FUpYqlWv4SwOCguZ8tDy7ibYiXPqEY4gOpgCxaohTXoH4TIZX/u5Wj/mmmndjir9GcGZG234Xw8HkpWZG9r5KSDZIqQZP/XWHhLlrtMjgbqXA3v3QBu5t/VtohhtyE/UJliAAYUOHkUmIdaUAItsIcN2Od+3uVIGOp/d/SHqCKBz3mdfwnOZghlDrpBbuhmPku4iGYQouaI+bgO2hw/hmZuxvWEkOlkdnceF/Z4Z6gT+AWWJ4aXyABdYPl+8Gm/DobArvmrIRKc33m1j/XO9kiEVuiWYmCP34CHjmjXmOhmqOjoxWi7R/iOVgh113VGpnvN42Z13XjjpfDAOoav1wJi8HqW94TQVgNyNXvHCXhqt/aHUOqOYOq4eGruPYitRuwkvuqIz2p62uquNoavBvxctzxojoZQD3arV3zAesXG1wKb2e3/yrd8QRwJSM95zWcJ0h+lkLeha/ALyHcKLfAE6vb99MF8WVftjDp+G1L+r1cCJDgEEIR+1gZ+nR/+srN+CLoFyNeCxieGfPZ++fHzOL96hmL8rT//HbBP9j/7N8fs0SoArQcILcQoUcqgS0kxFhsWMmzo8CHEiBInUqxo8SLGjBo3cuzo8SNFYyBHkixpsqNIiylPsmwJ0Y8OJfyAtULRqhW9X0oOFHDp8yfQoEKHklxJ9CjSoheNJm06sdEZhRtWntBxwSnWrFq3HmXK9atTrxHFgk26iKHRs2XXsm3blqzbuCXhOqQrN6jdu3r38vWYty/gsUsDE/1L+DBivYYT/wM2vJjxxseQJ1NOKrmyW8eYT17e7PnzyM4OZcQB3ZACM7yDTX8Uzfo1bIiuF8ZRZkgj6oXRjEVDCu1xbofLjD1juMyaseQ4NjxLbsxab4maY0embv06xtkbZihTNi5j8N3R4wZvyMxZM2gLnTlbtgGaM+bVNkSj8My9YJXYs+/v7x/tR+N0p0waEmAUHm/MPNNce8tQkFwzu6lXTXEKNmNMexsgh+EyzKBmTDXNLHTebxuEmFxqG2a4oTGpOfQMM9RQs4E0xuDH0DPzLdTMNNKt9p+PQApJHV0JaDIgkkkquWR3qDCEYDQKRrNMM9X8hp+EJlZ43zIwnueeM8woqP8elfNVWSIFy42YYZhSboDabslFcyU0zSwDTXEv6vimi7L9OGRdgApqWpFMGnqoMk4uFFyNHVKwUI4b4GBMM8xkSeEGHi4qo3PGUKPpiBRMU1yJ8BlDgTTUdCrjjHw6pKpz1dQ4HqR78hhkRdoROiivm4nmxZIJXITDM71RU+Gj8jE0K4hvIktflV8yBCp9xKVWIkPWfJrhiFzC2BCVPWYaH3u9wadsfXnml2uvALb7bmKiJcAkJBY5mJwz0mSabI6/JTcjM/hW6Jw1C7FYDbUbUGPneyI9SJy+By/jDKXfMhQiQ7tJUx+EyzWXnDU3+qnfu7rCe7JlHEFi6G1DJTz/2XSUhfnkvwvVCTG7KOu8V2eGHKpoUC9DFjNj/rqo4DLR3FqppPGFtDPUcpkcdc5VTxacNWqi1mjDVlP99VZTg73u05UFdzY12P4WHTiduj023FmJHXdDREOGtdbMcI3tRHPT/XfZgM/1591H36d0j0zj4HTfgjv+k99/242Yv8QtWvN7Fz6jb+CPez74560RPmjkoQNeetyTC4q66am3jtLoq78+u0asj606oLbTHrXuX+M+ZO+769xZGJic8FAYV31Wnk+/Cxm88Cd3doAS2xzPUBiPKAFGRVD6BlyfI3aaWsAgRwMrhuo1TnK70EdfMkfZV3+9/LhY5L1czGeq/66km9NHATRktBBVcY5s62vf+xIYqPhpz3r1uwiUFMSgZdyLUpfa0oVWhC9HBQxj4yrRiVqkoQ2OEEUOUVBDbtUQARpMTQbEVa/cp0DSeUR+29Ce/SDoIvFIqUxX0o0xJrQlCnqJTWJ6BpmqtIEzOcyF0mpTsfgUpwR1aiq0Ulir9nXAzvFKhjPM3UQEoIQxkrGMZjwjGoPxJBc1ClSRmlSlLqjFN3HKOZ9K1r5G1TVToQp9nmKh/lDIECWuMItZ2yIiafjFBNJFjGh8JCTJqMaFEMtYz1LWQpg1H/toUWkI49Ycq/UtvmloWzdCWpfCt7+GEEs99Qlgq1R1xQV6Tf+Ri4yea+SHiQZeryIVzNcc+2XHTAmMmCAzWKwStjD3oCk5/pMYxZphsWnxT2F2PJ9zgJnIF8rulrjsyANt2Mug4ZEyzgOSF73pH+LhEHu8dFk5YRY7MKpzd50RYw7dqYRGuI59MaynPTlygkk6JHl0O+d/0gnQ6ygUXghd50Jn11D4+bOLEX3dRBFYUVte9HMZ/edGu9lRj170of356Eg9g1KObpOeKX3cSkXKRZa+VHIlnSfwagrTm4bUpTq1aURNup+Y/jRePK2lTIsKN7cxtalOfSpUoyrVqVK1qla9ahV7mlOlctVzRC3LV7sq1sOE9StlHStaeebQtLLVd2v/bStch/fWuNJVo3atK159atG88vV5c+0rYLFz1rAFtrAM/athEwuawWqFsYp9rF8QC9nJMsaxWLEsZTM706RqtrN8wexP2obV0ZK2tKY9LWpTq9rVsra1rn0tbGMLW8lSVK47A21jaXtX6UENt3LTLUhtK1yU+bYrvT3ubZG7W+Dudbi8rS1xlRvd5EL3uc5lLk05W13sane5ggIH1MC7M/HqjLwoM69n06ve9bK3ve59L3wlEg2KNQte5RPhyZhxoXjyCk+U2hOvlKa+EAL4P9Yo2DRspLMEi4xX1ajvyZj2Q16VT304mI9+AaXCIOpMkO+aGcqG4yIVxlB9DJmG/4iApz4ItytOJm7fhU6VXwgZQ1wlbkg0nmFjIG34xe+aFbzSA60Ct6tGBeyiiaVByCEdeAMMhhcAnWyMI/NKW9DacYudwd/VqU9BVAbSfJND5EHdV5UBpq8L2/Xg5zQYUPed0cfEHN8507nOdr4znvOs5z3zuc9+/jOgAy3oQRO60IY+NKITrehFM7rRjn40pCMt6UlTutJ3TnCKP1K+NFu60xS5EMOo9JyMDGfKUs50R3aD6g2U+ssRqdGqG4IcM3tazzFeDqwKhpFWnxokCWbcQnhd62EvEUM8otSojwOh+ZQaBxcqWIwxhGlYpUbZx2yINB6Wr1Inp4DRdsa0a/88qWXTiFKSwtCDmhGxFjX72eJDdqyJ3dkLnegZkyoYxVJDsWmUmt8XggavMb0MTI+Q08G+0MaaYSeCg6vbUnaOjf0VDVifOz6TetSs+y1qaCT4PgyXt3ovNI1JMePecerNpKjBa5EH3Nw1shGs0iSyB+eJYtX4eLAd/nFpsGjKFL83MeOTcYeLPOW9BnnIa8wQk8vp3Coneo1bLqKXuwcHD+MfzdcDIpyzWufm3hG7u/3zUQdM6GE3ddE9dXSke1bkSx91vjew75Ur/d+9pvrFLGcchCtt4V9PIYcZXmpo+EsaYy9Y2UfIDLpP48HxCVi82Q5Zt1My2RtSIuONCW5UlydnYs5BlUOyjS99cV3zHy8ffQ1vbqAnfuhoV/q4KVZNydOeK6rSde1zj5Voh0z3vv898IMv/OETv/jGPz7yk6/85TO/+c5/PvSjL/3pU7/6SA8IADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACD: absolute claudication distance; FCD: functional claudication distance.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Nicolai, SP, Teijink, JA, Prins, MH, et al. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg 2010; 52:348.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_59_24511=[""].join("\n");
var outline_f23_59_24511=null;
